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Abstract
Background: There have been substantial improvements in the management of chronic pancreatitis, leading to the pub-
lication of several national guidelines during recent years. In collaboration with United European Gastroenterology, the
working group on ‘Harmonizing diagnosis and treatment of chronic pancreatitis across Europe’ (HaPanEU) developed these
European guidelines using an evidence-based approach.
Methods: Twelve multidisciplinary review groups performed systematic literature reviews to answer 101 predefined clinical
questions. Recommendations were graded using the Grading of Recommendations Assessment, Development and
Evaluation system and the answers were assessed by the entire group in a Delphi process online. The review groups
presented their recommendations during the 2015 annual meeting of United European Gastroenterology. At this one-day,
interactive conference, relevant remarks were voiced and overall agreement on each recommendation was quantified using
plenary voting (Test and Evaluation Directorate). After a final round of adjustments based on these comments, a draft
version was sent out to external reviewers.
Results: The 101 recommendations covered 12 topics related to the clinical management of chronic pancreatitis: aetiology
(working party (WP)1), diagnosis of chronic pancreatitis with imaging (WP2 and WP3), diagnosis of pancreatic exocrine
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insufficiency (WP4), surgery in chronic pancreatitis (WP5), medical therapy (WP6), endoscopic therapy (WP7), treatment of
pancreatic pseudocysts (WP8), pancreatic pain (WP9), nutrition and malnutrition (WP10), diabetes mellitus (WP11) and the
natural course of the disease and quality of life (WP12). Using the Grading of Recommendations Assessment, Development
and Evaluation system, 70 of the 101 (70%) recommendations were rated as ‘strong’ and plenary voting revealed ‘strong
agreement’ for 99 (98%) recommendations.
Conclusions: The2016HaPanEU/UnitedEuropeanGastroenterologyguidelinesprovideevidence-basedrecommendationsconcerning
key aspects of the medical and surgical management of chronic pancreatitis based on current available evidence. These recommen-
dations should serve as a reference standard for existing management of the disease and as a guide for future clinical research.
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Introduction
Chronic pancreatitis (CP) is a serious disorder which
can have a severe impact on the quality of life in add-
ition to life-threatening long-term sequelae. As well as
pain, pancreatic exocrine insufficiency (PEI) can result
in malnutrition – in a population apt to neglect their
nutrition. Long-term complications include diabetes
mellitus and pancreatic cancer. The incidence in
European countries ranges from 5 to 10 per 100,000
inhabitants. With a median survival of 20 years, the
calculated prevalence is around 120/100,000
inhabitants.1
While understanding of this illness is improving,
establishing the formal diagnosis is far from being a
well-known routine. While many patients with CP
enter the healthcare system via a gastroenterologist or
surgeon due to an acute manifestation of acute pan-
creatitis or pain, much of their long-term care is con-
ducted in the community by general practitioners or
diabetologists.
As a consequence, the Harmonizing diagnosis and
treatment of chronic Pancreatitis across Europe
(HaPanEU) initiative of United European
Gastroenterology (UEG) aims to provide the commu-
nity with evidence-based, state-of-the-art clinical guide-
lines to help in the management of these patients.
The statements are based on the recent guidelines
and recommendations published by the Australian,2
Belgian,3 German,4 Hungarian,5 Italian,6 Romanian7
and Spanish8,9 Societies of Gastroenterology and
Pancreatology, and a Cochrane report10 as well as per-
tinent new literature, which have been included in the
study. A list of abbreviations which are defined on first
use in the text is also included in the Supplementary
Material.
Methods
Scope and purpose
The overall objective of these guidelines is to provide
evidence-based recommendations for the diagnosis and
medical, endoscopic and surgical management of CP,
with particular emphasis on the diagnosis and treat-
ment of PEI as the major symptom. One particular
aim is to revisit the following diagnostic tests for pan-
creatic function: the faecal elastase-1 (FE-1) test, the
mixed-triglyceride breath test (MTG-BT), and the
secretin-stimulated magnetic resonance cholangiopan-
creatography (s-MRCP) test. Finally, malnutrition as
a consequence of PEI and the resulting pancreatic
enzyme replacement therapy (PERT) has been another
focus of these guidelines.
Stakeholder involvement
Individuals from all relevant professional groups
involved with CP and PEI have been included. Target
users of the guidelines are clinicians involved in the care
of patients with CP.
General outline of the process
First phase: drafting the work plan. The HaPanEU consor-
tium was formed as a consequence of an open call from
the UEG National Societies Committee. The consor-
tium received endorsements and funding from the
UEG via a LINK award to the Swedish and German
societies of Gastroenterology.11
Second phase: systematic literature reviews. The work was
ordered into 12 working parties (WPs), which are listed
at the end of the document. At the beginning of the
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process, each WP identified the most important clinical
questions in their field and then the entire group
decided on the final set of questions for each of the
areas under discussion.
Systematic review guidelines
A systematic search for relevant articles was performed
using the PubMed, Embase, and Cochrane databases.
Inclusion criteria were: (a) randomised or observational
cohort studies, including systematic reviews, on
patients with CP, that focused on the speciEc study
questions; (b) studies published in the English language;
and (c) studies available in full text. If review groups
were capable of translating non-English publications
they were encouraged to do so.
Exclusion criteria were: (a) non-randomised studies
with less than 20 patients because of the likelihood of
selection bias; (b) studies on patients with ‘acute-on-
chronic pancreatitis’; and (c) non-randomised studies
prior to 2004. Randomised controlled trials (RCTs)
prior to 2004 could only be excluded if the reviewers
felt that they were not relevant to current practice.
Grading of the evidence
The recommendations format comprised the question,
the statement, its level of evidence and strength of rec-
ommendation, and the percentage agreement of the
global consensus group with the Enal version. In the
present document the statements are followed by qual-
ifying comments, written by each working party and
reviewed by the entire scientiEc board (executive com-
mittee). Relevant comments and suggestions made by
the global consensus group (expert readers) have also
been taken into account. Statements and their comments
should be read together. In certain areas, the evidence
level is low, reFecting paucity of randomised trials and of
good quality diagnostic studies. For some topics, expert
opinion represented the highest level of evidence.
The Grading of Recommendations Assessment,
Development and Evaluation (GRADE) system12,13
(Supplementary Material, Table S1) was applied in line
with the International Association of Pancreatology/
American Pancreatic Association (IAP/APA) guidelines
on acute pancreatitis.14 All reviewers were advised to
take a GRADE system tutorial (link on UpToDate:
http://www.uptodate.com/home/grading-tutorial).
Outcome reporting
The Enal outcomes of the systematic reviews were dis-
cussed amongst the members of the review group (WP).
The review groups provided the following for each clin-
ical question:
1. Recommendation: the GRADE strength of recom-
mendation (1¼ strong, 2¼weak) and the quality of
evidence (A¼ high, B¼moderate, C¼ low),
together with the strength of agreement (strong/
weak)12,13 during plenary voting (see
Supplementary Material, Table S1). Initially, the
GRADE recommendation also included a quality
of evidence level D; however, this was combined
with level C (see Supplementary Material,
Appendix). In the absence of studies speciEcally
addressing a particular question, this had to be
stated and the recommendation was then based on
related studies or expert opinion.
2. Comments: these remarks could discuss any relevant
aspect regarding the recommendation, such as
important exceptions/contra-indications, availabil-
ity, lack of evidence, risks and costs.
Third phase: UEG/European Pancreas Club (EPC) joint meet-
ing, Delphi process. After a meeting during the 47th EPC
(2015) in Toledo, Spain, the questions were answered
and distributed amongst the entire expert group. The
questions and answers that had been agreed upon,
including related comments, were then uploaded to
the Delphi platform and voted upon. Voting participa-
tion was 100% of the expert group. All questions with
less than 80% agreement were discussed at a meeting
during the UEG week (2015) in Barcelona, Spain, with
Test and Evaluation Directorate (TED) voting. The
comments to all questions, and particularly those with
less than 80% agreement during the TED voting, were
returned to the working parties for a final round of
discussion.
Fourth phase: drafting the manuscript. Following the con-
sensus reached after the UEG week (2015) and a final
round of adjustments, a first draft of the manuscript
was issued and agreed upon by the expert group. This
was then sent out to external readers and finalised
according to the comments received. In addition to
this written version, an interactive smartphone app,
Guideline on Chronic Pancreatitis, has been developed
that can be downloaded for free (HaPanEU).
Future aspects
These guidelines reflect current, state-of-the-art proced-
ures and will be updated by the UEG association when
they believe there is a need to do so, but no longer than
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10 years after their publication.15 As sometimes occurs
during literature reviews, when looking for evidence,
the group identified several areas where studies are
lacking and this has been stated.
Results
The 12 main topics are presented consecutively, incor-
porating a total of 101 questions and their respective
answers. The GRADE strength of recommendation (1/
2) and quality of evidence (A, B, or C) is provided12,13
along with the strength of agreement during plenary
voting. For each recommendation the comments from
the reviewers and attendees at the meeting are listed.
Definition
Q0: What is the definition of CP (regardless of the aetiology)?
Statement. CP is a disease of the pancreas in which
recurrent inflammatory episodes result in replacement
of the pancreatic parenchyma by fibrous connective
tissue. This fibrotic reorganisation of the pancreas
leads to progressive exocrine and endocrine pancreatic
insufficiency.4 Diagnosis is established via high quality
imaging modalities, which allow identification of the
following signs: increased density of the parenchyma,
atrophy of the gland, calcification, pseudocysts and
irregularities of the main pancreatic duct and its side
branches. Diagnosis should be based on imaging per-
formed in symptomatic patients presenting with indica-
tors suggestive of pancreatic disease. The diagnostic
criteria have been reviewed elsewhere.4 Complications
of CP encompass strictures of the pancreatic duct and/
or the biliary ducts, pseudocysts, pancreaticolithiasis,
duodenal stenosis, malnutrition, vascular complications
and recurrent or persisting pain. (Strong agreement)
Comments. As pathognomonic symptoms do not
exist for this disease, the diagnosis has to be based on
objective criteria such as cross-sectional imaging.
Minimal suggested imaging requirements are detailed
for both computed tomography (CT) and magnetic res-
onance imaging (MRI) in the Italian guidelines6 and are
specified below. There is a disease continuum from
acute to chronic pancreatitis16 and a significant percent-
age do progress to CP.17
Aetiology of CP (WP1)
Q1-1: What needs to be done to define the aetiology of CP
in adult patients?
Statement 1-1. It is recommended that a comprehen-
sive medical history, laboratory evaluation and imaging
studies are performed in patients with CP. (GRADE
2C, strong agreement)
Comments. CP is a continuing inflammatory disorder
of the pancreas, which leads to replacement of pancre-
atic tissue by fibrotic tissue. As a consequence, endo-
crine and/or exocrine insufficiency can develop.18 In CP
patients the risk of developing pancreatic carcinoma is
elevated.19 CP incidence ranges from between 1.6–23
per 100,000 and an increase in prevalence has been
noted.20
The most common risk factor for CP is alcohol
abuse, with a logarithmic risk increase, although the
type of alcohol consumed is irrelevant.21–27 The
amount and duration of alcohol consumption required
to develop CP has not been unequivocally defined.
Some authors suggest at least 80 g/day for a period of
at least six years. Smoking is most probably an inde-
pendent risk factor. Since smoking leads to the progres-
sion of CP, all patients should be advised to stop
smoking.28
Genetic factors also contribute to CP development.
The most important genetic risk factors are variants in
cationic trypsinogen (PRSS1), serine protease inhibitor
Kazal-type 1 (SPINK1) and carboxypeptidase A1
(CPA1). Further genetic susceptibility genes are cystic
fibrosis transmembrane conductance regulator (CFTR),
chymotrypsinogen C (CTRC) and carboxyesterlipase
(CEL).29–34 Additionally, autoimmune processes can
lead to the development of CP.
To diagnose CP, a complete medical history and
clinical investigations, including imaging technologies
and function tests, need to be applied. The aetiology
of CP is defined after a thorough patient investigation
considering all known risk factors, including alcohol
consumption (for example using the AUDIT question-
naire) and smoking, as well as laboratory values (trigly-
ceride-levels; Ca2þ-levels for ruling out elevated
primary hyperparathyroidism (PHPT); carbohydrate
deficient transferrin (CDT)/phosphatidylethanol
levels), and family medical history.
Autoimmune pancreatitis (AIP) should be ruled out
following current consensus guidelines and when no
other aetiology can be found in patients. AIP signs
include elevated immunoglobulin (Ig)G4 serum levels,
the presence of lactoferrin and carbonic anhydrase
auto-antibodies, and imaging showing a typical ‘sau-
sage-like’ configuration of the pancreas.35
Cholecystolithiasis and/or choledocholithiasis alone
are not considered risk factors for the development of
CP. Protective environmental factors have not been
described. Whether anatomic anomalies such as pan-
creas divisum increase the CP risk is still a matter of
debate; however, with additional risk factors, pancreas
divisum might lead to CP development. If no
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aetiological factor can be identified, genetic screening
for predisposing variants can be offered.
In recent guidelines, CP has been classified into dif-
ferent forms (calcifying, obstructive, autoimmune and
groove). These classifications are based on clinical fea-
tures, morphological characteristics and response to
treatment. In calcifying CP, for example, perilobular
fibrosis and acinar destruction with infiltration of
acute and chronic inflammatory cells are present.
Obstructive CP develops as a secondary complication
due to an area of obstruction with dilatation of the
pancreatic duct proximal to the stenosis, atrophy of
acinar cells and fibrosis. Characteristics of AIP are dis-
cussed in detail in Q1-4. Finally, groove pancreatitis
affects the groove between the pancreatic head, duode-
num and the bile duct (see Q4-1.9–Q4-1.11).
Q1-2: What aetiological factors should be investigated in
paediatric patients with recurrent acute pancreatitis or CP?
Statement 1-2. Cystic fibrosis needs to be ruled out
by chloride iontophoresis, while genetic causes seem to
be much more important in children than in adults.
Laboratory evaluation needs to include Ca2þ and tri-
glyceride levels. Recommended imaging modalities are
abdominal ultrasound or magnetic resonance cholan-
giopancreatography (MRCP). (GRADE 2C, strong
agreement)
Comments. The incidence of CP in children has been
reported at 4–13 in 100,000.36–38 As such it is of great
importance that pediatricians are aware of the differen-
tial diagnosis of CP in children with abdominal pain
and they should attempt to define the aetiology follow-
ing a diagnosis of CP.
Until the first genetic associations were identified,
the aetiology of CP in children was idiopathic in up
to 70% of patients. Inherited CP is characterised by
early onset of the disease (in most cases before 20
years of age) and some patients show a positive
family history. In patients with a positive family his-
tory, dominant PRSS1 mutations (p.N29I and
p.R122H) are frequently found.29 Genetic variants in
SPINK1, CPA1, CTRC, CEL, CFTR and PRSS1
(mainly p.A16V) can be found both in patients with a
positive and negative family history of CP.29–34 In con-
trast, a protective variant, p.G191R, has been identified
in the anionic trypsinogen (PRSS2) gene.39
Patientswith inheritedCPcandevelop their first symp-
toms as early as their first year. In paediatric patients,
genetic variants can be tested after informed consent
and genetic counselling according to country-specific
national guidelines. Genetic testing should be offered to
patients with a positive family history as well as to paedi-
atric patients without an identified aetiological factor.
Testing should include PRSS1 (sequencing of exon 2
and 3 to cover mainly p.A16V, p.N29I and p.R122H),
SPINK1 (all four exons, mainly p.N34S and
IVS3þ 2T>C in exon 3 and intron 3), CPA1 (several
variants, mainly in exons 7, 8 and 10), CTRC (espe-
cially exon 7), CEL (hybrid allele only) and may include
screening for variants in CFTR.
In every paediatric patient, cystic fibrosis has to be
ruled out, since 10–15% of cystic fibrosis patients with
pancreatic sufficiency (comprising 1–2% of all patients
with cystic fibrosis) present clinically with recurrent
attacks of acute pancreatitis.40–42 Other aetiologies
including parasites, hypertriglyceridaemia, hypercalcae-
mia, and anatomic anomalies are rare, but should be
investigated.
Q1-3: In which CP patients should we rule out cystic fibrosis?
Statement 1-3. A diagnosis of cystic fibrosis needs to
be ruled out in all patients with CP onset before the age
of 20 years as well as in patients with so-called ‘idio-
pathic’ CP (regardless of the age of onset). (GRADE
1B, strong agreement)
Comments. The recommended investigations for
ruling out a diagnosis of cystic fibrosis should follow
national and international guidelines.43 Note, this does
not imply a complete sequencing of the CFTR gene but
only of known hotspot variants. Moreover, if no fur-
ther clinical signs of cystic fibrosis are present (for
example, no pulmonary symptoms, no male infertility)
the diagnostic workup should be restricted to sweat
chloride iontophoresis.
The first description of an association between
CFTR variants and CP was published in 1998.31
Several association studies investigated the role of
CFTR variants in CP and concluded that the associ-
ation is not as strong as previously suspected with
odds ratios of around 3–5.44,45
CFTR variants range from severe to mild and
include polymorphisms. CP patients carrying CFTR
variants harbour at least one mild variant allele giving
them residual CFTR function. In many patients, CP is a
complex genetic disease and these patients simultan-
eously carry variants in several different genes (for
example, SPINK1, CTRC, CFTR). The interpretation
of these complex genotypes is difficult and should be
performed in specialised centres in the appropriate
European county. Testing for rare CFTR variants
with, in most cases, unknown functional consequences
should only be performed in a research setting. Certain
complex genotypes with variants in genes such as
SPINK1 and CFTR are associated with CP develop-
ment, while others represent the expected finding of
concomitant variants.
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Q1-4: Should the diagnosis of AIP be ruled out in all pancrea-
titis patients?
Statement 1-4. If no other aetiology of CP can be
identified in a patient then a diagnosis of AIP should
be ruled out. (GRADE 2C, strong agreement)
Comments. AIP is a rare but important differential
diagnosis in patients with acute and chronic pancrea-
titis. As such, the screening for aetiological factors
should include the information needed to diagnose
AIP. AIP was described for the first time in 1961 by
Henri Sarles346 and studies have demonstrated that
males suffer more often from AIP (ratio 2:1).
Approximately 5% of patients with CP also have
AIP. Note, up to 5% of patients with suspected pan-
creatic adenocarcinoma are finally diagnosed as
having AIP.
Symptoms include recurrent attacks of abdominal
pain and jaundice in up to 50% of patients.
Morphological characteristics in up to 40% of cases
comprise a ‘sausage’-like configuration of the pancreas,
and an irregular stenosis of the pancreatic duct without
prestenotic dilatation. In contrast, calcifications are
rare.46–51 AIP can be divided into type 1 and type 2
categories. In type 1 AIP, IgG4 serum levels are ele-
vated in most cases and histological findings are in
accordance with lymphoplasmocytic sclerosing pan-
creatitis (LPSP). Obliterative phlebitis and periductular
fibrosis are also common features of type 1 AIP. In type
2 AIP, IgG4 levels are within the reference level. A
typical histological change is idiopathic duct centric
pancreatitis (IDCP) and granulocytic epithelial lesions
(GELs). While type 1 AIP is associated with the IgG4-
related disease spectrum, type 2 AIP can be accompa-
nied by ulcerative colitis.
Type 1 AIP represents a systemic disease that may
affect various organs.46,49,52,53 The disease is unique
since both pancreatic morphological changes and pan-
creatic insufficiency respond very well to immunosup-
pressive therapy.46–51 Several reports have
demonstrated the normalisation of exocrine and endo-
crine insufficiency under immunosuppressive medica-
tion.46,51,54 However, the diagnosis of AIP remains
challenging since patients with this disease may have
atypical presentations.35,52,55 Thus, AIP may underlie
any inflammation of the pancreas and a complex
workup needs to be performed. Therefore, clinical
and radiological (first choice – MRCP, second – endo-
scopic ultrasonography (EUS)) as well as serological
and immunohistochemical investigations (only in
patients with other signs of AIP or with focal segmental
lesions) are necessary. Some diagnostic autoantibodies
have been described,56,57 however, they are not com-
mercially available.
Q1-5: Is there a recommended classification system that
should be used when defining the aetiology?
Statement 1-5. There is no preferred classification
system for defining the aetiology of CP since the avail-
able classification systems need to be evaluated in ran-
domised prospective trials with endpoints of morbidity
and mortality. Only in this way can a recommendation
be made on which system to use in the future. (GRADE
2C, strong agreement)
Comments. Distinct classification systems have been
developed for CP patients, but only the Toxic/meta-
bolic, Idiopathic, Genetic, Autoimmune, Recurrent
acute pancreatitis, and Obstructive (TIGAR-O) and
the M-ANNHEIM classification systems take the aeti-
ology of CP into account.
Classification systems are of great importance for
guiding management strategies, since treatment strate-
gies cannot rely solely on the type and degree of mor-
phological changes in the pancreas, but need to include
clinical, functional and imaging findings. So far no glo-
bally accepted classification system has been estab-
lished. Classification systems currently in use are:
1. Manchester classification
2. ABC classification
3. M-ANNHEIM
4. TIGAR-O
5. Rosemont classification
TheManchester classification system uses imaging mod-
alities and clinical signs of CP.58 The degree of severity is
mostly influenced by the presence of exocrine and/or endo-
crine insufficiency or the presence of complications, while
imaging findings are of minor importance. The ABC clas-
sification recommends similar findings to the Manchester
classification system.59,60 The Rosemont classification was
developed to diagnose CP using EUS and is described in
the comments for Q2-9.61 In the M-ANNHEIM system,
the stage, severity and clinical findings of CP are inte-
grated.62 The M-ANNHEIM system is the only one offer-
ing a severity index and is used accordingly.63–65 Finally,
after a complex procedure, a score of between 0–25, rep-
resenting the severity of CP, is calculated.66 Different guide-
lines recommend using the TIGAR-O classification.
This system comprises six aetiologic groups: toxic/meta-
bolic, idiopathic, genetic, autoimmune, recurrent acute
pancreatitis, and obstructive groups.67
Q1-6: Are there different courses of the disease?
Statement 1-6. Depending on the aetiology, CP has
different disease courses and long-term complications.
(GRADE 1B, strong agreement)
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Comments. Categorising patients according to the
underlying aetiology is clinically important. The
course of the disease and the risk of developing pancre-
atic cancer vary considerably between different aetiolo-
gies.68,69 For example, epidemiological studies have
shown that calcifications, and exocrine and endocrine
insufficiency, develop after a shorter time period in
alcoholic CP patients compared to other aetiologies.
Although causal treatment options for alcoholic CP
are currently not available, cessation of alcohol con-
sumption may reduce the rate of progression, decrease
pancreatic pain, and partly restore pancreatic exocrine
function (see WP12).70 Smoking has been recognised as
an independent risk factor for the development of CP
and pancreatic calcifications.28,71
In patients with early onset CP, especially hereditary
(<20 years), the risk of pancreatic cancer is increased
considerably, and cessation of smoking may reduce the
risk in this group.72 In addition, patients with different
genetic mutations demonstrate a different clinical pres-
entation (for example later development of diabetes
mellitus, and calcifications) than patients with other
aetiologies.68,69 In patients with genetic predispositions,
the age of onset is generally earlier, and exocrine and
endocrine insufficiency are more prevalent compared to
other aetiologies.68 Patients with inherited CP seem to
have a higher risk of developing pancreatic adenocar-
cinoma: a meta-analysis calculated a 69-fold risk
increase for these patients while other aetiologies had
a 13-fold risk increase.73 This assumption has been
challenged by recent studies that demonstrated that
the risk of developing a pancreatic adenocarcinoma is
unrelated to the genotype.68 Most likely, the early onset
of the disease in these patients and the longer disease
course are the main reasons for an increased risk of
developing pancreatic cancer. According to a recent
epidemiological study, the risk of cancer development
in CP is actually lower than stated in previous
reports.74 Unfortunately, early screening of these
patients for cancer or premalignant lesions is difficult.
To date, no convincing strategy has been recommended
and hopefully further studies will address these issues.
The clinician should strongly advise his patients to stop
smoking and to reduce, or eliminate entirely, the
amount of alcohol consumed.
Finally, recent studies have demonstrated that the
interaction of different genetic risk factors with each
other or the interaction of other risk factors, such as
pancreas divisum, with genetic variations75 might
increase the risk of developing CP. Thus it is essential
for clinicians to determine the aetiology of the disease
correctly.
Q1-7: In which CP patients should genetic screening be
performed and which genes should be investigated?
Statement 1-7. All patients with a family history or
early onset disease (<20 years) should be offered gen-
etic testing for associated variants. (GRADE 2C, strong
agreement)
Comments. Genetic screening for every CP patient
cannot be recommended since alcohol abuse is the pre-
dominant cause of the disease in up to 60% of adult
cases. In patients with early onset CP, genetic screening
can be offered after informed consent (see Statement
1-2). Note, the genetic test results will neither change
the medical treatment offered to the patient nor alter
the disease course. However, it might enable some
patients to understand their disease better and might
even impact family planning. In patients with alcoholic
CP, routine genetic testing cannot be recommended.
Variants in SPINK1 and CTRC, and to a lesser
extent, common single-nucleotide polymorphisms
(SNPs) in the PRSS1 and CLDN2-MORC4 loci, are
associated with alcoholic CP.
Diagnosing CP (WP2 and WP3)
Evaluation of the various cross-imaging modalities
such as MRI and computed tomography (CT) as well
as EUS, contrast-enhanced ultrasound (CEUS) and
even endoscopic retrograde cholangiopancreatography
(ERCP) for diagnosing CP relies heavily on a recent
review and meta-analysis performed by several mem-
bers of the consortium, applying both the Quality
Assessment of Diagnostic Accuracy Studies
(QUADAS-2) and GRADE criteria.76 The results are
summarised in Supplementary Material, Table S2.
Q2-1: What is the best overall imaging modality for
establishing a diagnosis of CP?
Statement 2-1. EUS, MRI, and CT are the best ima-
ging methods for establishing a diagnosis of CP.
(GRADE 1C, strong agreement)
Comments. Imaging modalities are indispensable for
the management of CP. The most frequently used ima-
ging modalities are ERCP, abdominal ultrasonography
(US), EUS, MRI and CT; however, summary estimates
of their accuracy are lacking. The aim of a meta-ana-
lysis76 was to obtain summary estimates of the sensitiv-
ity and specificity of the various imaging modalities
employed for CP assessment. In addition to GRADE,
the QUADAS-2 tool was used to assess the quality of
the methods used in the studies. A bivariate random-
effects model was used to obtain summary estimates of
sensitivity and specificity. Full text was retrieved from
268 studies of which 42 studies evaluating 3392 patients
fulfilled the inclusion criteria. The risk of bias was low
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in only 29% of studies according to QUADAS-2 and
the quality of evidence was very low according to
GRADE. Estimates of sensitivity and specificity are
presented in Supplementary Material, Table S2. A sum-
mary of results from 14 studies with head-to-head com-
parisons of various modalities confirmed the overall
summary estimates (Supplementary Material, Table
S3). EUS, ERCP, MRI and CT all have comparable
high diagnostic accuracy in the initial diagnosis of CP.
EUS and ERCP outperform the other imaging tech-
niques and US is the least accurate. ERCP is no
longer considered to be a diagnostic test for CP. The
choice of imaging modality can therefore be made
based on invasiveness, local availability, experience
and costs.76 Although less complete, the German S3
guidelines came to a similar conclusion.4
Q2-2: Which method is most appropriate for the identification
of pancreatic calcifications?
Statement 2-2. CT examination is the most appropri-
ate method for identifying pancreatic calcifications,
while for very small calcifications non-enhanced CT is
preferred. (GRADE 2C, strong agreement)
Comments. Pancreatic calcifications are common in
patients with CP. It is estimated that up to 90% of
patients will develop calcifications during long-term
follow-up, particularly in those patients with alcohol-
induced CP.77 In the appropriate clinical context, the
presence of pancreatic ductal calcifications is pathogno-
monic for CP and their visualisation using portal phase
contrast-enhanced CT was reported to have moderate
sensitivity and very high specificity (close to 100%).78
However, very small calcifications may be obscured by
pancreatic parenchymal contrast enhancement; there-
fore, a non-contrast-enhanced phase CTmay be a neces-
sary add-on to portal phase contrast-enhanced CT in
order to depict previously undetected calcifications in
the latter phase.
Q2-3: Is the use of MRI/MRCP examination for the assessment
of irregularities in the main pancreatic duct, abnormal side
branches, strictures and dilatations sufficient to diagnose CP?
Statement 2-3. The presence of typical imaging find-
ings for CP with MRI/MRCP is sufficient for diagnosis;
however, a normal MRI/MRCP result cannot exclude
the presence of mild forms of the disease. (GRADE 1C,
strong agreement)
Comments. MRCP is based on heavily T2-weighted
images and has been used in clinical imaging for more
than 18 years in order to evaluate biliary and pancreatic
duct abnormalities. MRCP depicts the pancreatic ductal
system in CP and demonstrates narrowing, dilatation
and filling defects with moderate to high accuracy.79
One of the early studies80 demonstrated very good cor-
relation between ERCP and MRCP findings in patients
with pancreatitis and concluded thatMRCPmayobviate
the need for ERCP. One of the challenges of MRCP in
the diagnostic evaluation of CP is its relatively low sen-
sitivity in mild CP, since subtle changes in the main pan-
creatic duct and the side-branches cannot be identified as
easily with MRCP as with ERCP.
Q2-4: What advantage does intravenous (IV) secretin
administration provide during the MRCP examination for the
evaluation of CP?
Statement 2-4. The use of IV secretin increases the
diagnostic potential of MRCP in the evaluation of
patients with known/suspected CP. (GRADE 1C,
strong agreement)
Comments. The use of IV secretin stimulates pancre-
atic exocrine function and increases fluid excretion via
the main pancreatic duct. It is useful in the evaluation
of CP with MRCP as:
1. It enhances visualisation of the main pancreatic duct
and abnormal side-branches compared to non-s-
MRCP. In a study reviewing a cohort of 95 patients
(both normal individuals and patients with CP), the
overall sensitivity for the detection of CP increased
from 77% to 89% after the use of secretin.81
2. It reveals strictures or abnormal dilatations. In a
study performed in a paediatric population with a
diagnosis of idiopathic CP, the use of secretin
improved the overall sensitivity.82
3. It may quantify exocrine function.83–86
Quantification of exocrine function has been
reviewed in many studies and the results correlate
well with the severity of pancreatitis.83,84
Theoretically, s-MRCP could be helpful in the dif-
ferential diagnosis of intraductal papillary mucinous
neoplasm (IPMN) of the pancreas; however, the only
small study performed was inconclusive.87
Q2-5: Does duodenal filling (DF) during s-MRCP have a
diagnostic value in grading the severity of CP?
Statement 2-5. DF during s-MRCP does not help to
evaluate the grade of severity of CP. (GRADE 2C, mod-
erate agreement)
Comments. It is expected that with increasing sever-
ity of CP there will be a decrease in the amount of
acinar cells and fluid output, which can be detected
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with s-MRCP. However, limited data exist in the litera-
ture on this specific subject. Two studies have evaluated
the potential use of DF score during s-MRCP described
by Matos et al.88 in grading the severity of CP.’’ As it
stands in the text now, it appears that it is Matos et al.
who state that there are two studies that have evaluated
the potential use of DF etc, which is not true. It was
actually Matos et al. that described the DF score during
s-MRCP. The standard of reference in the first study89
was the Cambridge classification of ERCP,90 while in
the second study85 it was MRCP. Both studies agreed
that the grade of CP severity cannot be evaluated on
the basis of DF. This is due to the fact that a substantial
number of patients with severe CP may still have
normal DF (grade 3) and patients with mild changes
may show reduced DF (grade 1 or 2). However, DF has
been shown to correlate well with other methods for
assessing the exocrine pancreatic reserve (see WP4 for
the evaluation of pancreatic function).
Q2-6: What is the role of abdominal ultrasound in
suspected CP?
Statement 2-6. Abdominal US can only be used to
diagnose CP at an advanced stage. (GRADE 1A,
strong agreement)
Comments. Abdominal US is frequently the first line
imaging modality used in patients with abdominal pain
and the suspicion of CP.91,92 US is readily available in
most facilities and can easily be repeated without the
inherent risks of radiation and contrast media of other
techniques. US technology has improved substantially in
the last decade but studies that aim to compare US with
other imaging modalities are still limited. A recent meta-
analysis analysed the diagnostic performance of different
imaging modalities with the inclusion of 10 US studies.
Sensitivity and specificity rates for US (67%/98%) were
lower when compared to CT (75%/91%) and EUS
(82%/91%), respectively. The limitations of US include
operator-dependency and obscured visualisation of the
pancreas, for example, due to obesity or intestinal gas.93
The presence of pancreatic and/or intraductal calcifi-
cations is pathognomonic for CP.94–96 Calcifications are
found in roughly 40%of patients with advancedCP.94 In
US imaging, calcifications exceeding a diameter of 2mm
are visualised as hyperechoic foci with posterior shadow-
ing.Theuse of colourDoppler can facilitate the detection
of small pancreatic calcifications, which can be identified
by the presence of twinkling artifacts.97,98 Other typical
sonographic signs of CP are duct calibre abnormalities,
i.e. a dilated and irregular pancreatic duct.91 Alterations
in the size of the pancreas are nonspecific since a small
atrophic glandwith focal alterations can also be found in
healthy elderly subjects and localised tumour-like lesions
can be present inmalignancy orAIP.99,100 Inmoderate to
severe CP, the pancreatic echotexture is frequently het-
erogeneous during the course of the disease.91,101 In early
CP, there are no (or only subtle) morphological changes
that cannot be detected by conventional US.
Q2-7: What is the role of abdominal US in recognised CP?
Statement 2-7. US can be applied in patients with sus-
pectedCP complications. (GRADE2C, strong agreement)
Comments. US can be used to visualise CP compli-
cations such as fluid collections, pseudocysts, acute CP
flare-ups and pseudoaneurysms.91,94,102 Unfortunately,
prospective randomised studies that compare US with
other imaging techniques are lacking. Pseudocysts and
fluid collections are typically anechoic, while pseudoa-
neurysms can be visualised with colour Doppler.98
Apart from the diagnostic evaluation, US can be
used for US-guided diagnostic and therapeutic pancre-
atic interventions such as biopsies and drainages.103
Q2-8: What are the indications for CEUS?
Statement 2-8. CEUS can increase diagnostic accur-
acy in CP patients with cystic and solid pancreatic
lesions. (GRADE 1C, strong agreement)
Comments. CEUS improves accuracy when charac-
terising pancreatic focal lesions. Note, prospective con-
trolled studies in patients that define the role of CEUS
in CP are lacking. US contrast agents are injected intra-
venously, are confined to the blood pool and allow real-
time characterisation of pancreatic perfusion. Repeated
administration can be performed in the same session if
needed. CEUS has been used extensively in the charac-
terisation of focal liver lesions, whereas CEUS of the
pancreas is less widely used.104–108 Sonovue, approved
for echocardiography and for the differentiation of liver
tumours, is the most widely used contrast agent.
Conventional B-mode US is limited in its ability to
differentiate mass-forming pancreatitis from pancreatic
cancer. When applying CEUS, a ductal adenocarcin-
oma is typically hypoechoic in the arterial phase due
to its low vascularisation, whereas focal CP usually
shows contrast enhancement similar to the surrounding
pancreatic parenchyma.109–111 In advanced CP, hetero-
geneous hypovascularisation due to fibrosis may be
present, making the differential diagnosis of pancreatic
cancer very difficult.107,112
CEUS can also be used to differentiate between neu-
roendocrine tumours that are highly vascularised and
demonstrate a hyperenhancing pattern.105 New algo-
rithms are used to characterise the perfusion pattern
in order to discriminate between normal pancreatic
Lo¨hr et al. 161
perfusion and patterns of tumour perfusion.113 Finally,
CEUS is also useful in differentiating between avascular
debris and vascularised nodules in cystic lesions.
Q2-9: What is the role of EUS in patients with suspected CP?
Statement 2-9. EUS is the most sensitive imaging
technique for the diagnosis of CP, mainly during the
early stages of the disease, and its specificity increases
with increasing diagnostic criteria. (GRADE 1B, strong
agreement)
Comments. EUS is considered to be the most sensi-
tive method for diagnosing CP.114,115 Certain criteria
characterising the disease have been defined and are
divided into parenchymal and ductal criteria116,117 To
date, there is no EUS optimal cut-off for establishing a
diagnosis of CP. However, a cut-off of 3–4 criteria is
often used. With the assumption that not all criteria are
equally important, the Rosemont classification defines
the EUS criteria for CP and their specific validity.61
However, this classification does not improve the diag-
nostic value of the standard criteria.118 Another prob-
lem for the validation of EUS has been the gold
standard: when comparing EUS with ERCP and the
secretin test, the agreement is 100% for severe forms
of CP (>5 criteria), 50% for moderate forms (3–5 cri-
teria) and 13% for mild forms of the disease (0–2 cri-
teria). In fact, close to 25% of patients with normal
secretin-cerulein tests show EUS abnormalities suggest-
ive of CP. When the applied gold standard includes the
sum of the ERCP findings, the secretin test and the
clinical characteristics of the patient, EUS shows a
diagnostic sensitivity >84% and a specificity approach-
ing 100%.119 When compared with histology as the
gold standard, the sensitivity of EUS for the diagnosis
of CP exceeds 80%, with a specificity of 100%.120
Moreover, there is an excellent correlation between
the number of EUS criteria present and CP severity
with respect to the histology.121
Q2-10: What is the role of EUS in the follow-up of patients
with known CP, for the (early) detection of malignancy?
Statement 2-10. EUS has a potential role in the
follow-up of patients with CP in the detection of com-
plications, mainly due to its ability in detecting pancre-
atic malignancy. (GRADE 2B, strong agreement)
Comments. There is a lack of data regarding the role
of EUS in the follow-up of patients with known CP.
However, due to the accuracy of EUS in evaluating
both the pancreatic parenchyma and the ductal
system, this method is very useful for the detection of
complications related to CP,122 such as pancreatic
cancer. EUS was recommended as a screening program
for patients in the high risk group, i.e. those with her-
editary CP.123,124 Although there is no clear consensus
on whether and how to conduct pancreatic cancer
screening, many centres recommend the use of EUS,
based on its ability to identify pancreatic masses smaller
than 1 cm,125 although this ability is reduced in the
presence of CP. In fact, the differential diagnosis
between inflammatory and malignant masses and the
early detection of malignancy in patients with known
CP remains a difficult task for all diagnostic imaging
techniques.122,126
Q2-11: What is the role of EUS (plus elastography,
contrast enhancement, and fine needle biopsy) in the
differential diagnosis of solid pancreatic masses
(mass-forming CP vs pancreatic cancer)?
Statement 2-11. EUS is an essential tool in the differ-
ential diagnosis of CP with other pancreatic masses or
cystic lesions. EUS-guided fine needle biopsy can be con-
sidered as the most reliable procedure for detecting
malignancy. EUS-guided elastography and contrast
enhancement may provide useful information, but
their role in this setting needs to be assessed further in
future clinical trials. (GRADE 2C, strong disagreement)
Comments. Differentiation between mass-forming
CP and other pancreatic lesions remains a chal-
lenge.122,127 Although EUS produces high-resolution
images, this procedure cannot reliably differentiate
between malignant and inflammatory lesions due to
the similar EUS appearance of adenocarcinoma and
focal pancreatitis. In case of doubt, EUS-guided
tissue acquisition can be helpful. In a general setting,
the diagnostic yield of EUS-guided tissue acquisition
for the diagnosis of solid pancreatic masses ranges
from 80–95%.128–133 However, in case of an underlying
CP, the sensitivity of this method can decrease to
between 50–75%.134–138 An especially challenging task
is to differentiate AIP from cancer.139,140 Histological
criteria have been proposed to establish the diagnosis
from EUS-guided biopsies.141 The probability of false
negatives is reported to be between 5–10%, so that
given operable findings on images and a suspected
tumour, surgery is recommended even without prior
cytological confirmation.
Based on imaging techniques, a sensitivity of 84%
and a specificity of 97% have been reported for MRI
combined with MRCP. A sensitivity of 93% and a spe-
cificity of 75% have been calculated for differentiating
between CP and pancreatic carcinoma.76,142 However,
this does not apply when a carcinoma develops in the
presence of CP. In this case, even after exhausting all
diagnostic techniques, the sensitivity for detecting a
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tumour is 67%, with a specificity of 45% – inferior to
that documented for EUS-guided tissue acquisition.
New EUS imaging techniques, such as elastography
and contrast-enhanced harmonic EUS (CEH-EUS)
have been proposed to increase the diagnostic yield
for this condition.127 Several studies aiming to deter-
mine the role of these techniques in the differential diag-
nosis of solid pancreatic masses have been published.
EUS-guided elastography has shown high levels of
accuracy in establishing malignancy in solid pancreatic
lesions, and has been demonstrated as being specifically
useful for distinguishing between mass-forming CP
including AIP and pancreatic cancer, with sensitivities
ranging from 80–95% and specificity from
40–90%.143–152 In fact, the technique may add informa-
tion to EUS-guided tissue acquisition.153 Recent
meta-analyses have demonstrated the ability of EUS
elastography in the characterisation of solid pancreatic
masses, and the detection of malignancy.154–157
CEH-EUS has also demonstrated its usefulness in
differentiating between the vascularisation patterns of
pancreatic lesions, as hypovascular lesions are strong
indicators of malignancy,127,158–160 and this has been
proved in recent studies.159,160 A new development
has been the ability to measure the contrast agent,
and by quantifying the peak of enhancement, the sen-
sitivity and specificity in differentiating between mass-
forming CP and pancreatic cancer reaches
85–95%.161,162 Another advantage of CEH-EUS, as
previously documented for elastography, is its role in
directing EUS-guided tissue acquisition, thus increasing
diagnostic yield.163,164 Although EUS-guided elastogra-
phy and contrast enhancement may deliver accurate
information, their role in this setting needs to be
assessed further in future clinical trials.
In general, it must be clearly stated that all of the
US-based techniques require a great deal of experience
and are very much investigator-related in their diagnos-
tic accuracy; variability is only low in the hands of
experienced investigators.165
Diagnosing PEI (WP4)
Q3-1: How is PEI defined?
Statement 3-1. PEI refers to an insufficient secretion
of pancreatic enzymes (acinar function) and/or sodium
bicarbonate (ductal function). (GRADE 1A, strong
agreement)
Q3-2: What are the clinical consequences of the different
grades of insufficiency?
Statement 3-2. Due to the large reserve capacity of
the pancreas, ‘mild’ to ‘moderate’ exocrine insufficiency
can be compensated, and overt steatorrhoea is not
expected unless the secretion of pancreatic lipase is
reduced to <10% of normal (‘severe’/’decompensated’
insufficiency). However, patients with ‘compensated’
PEI also have an increased risk of nutritional deficien-
cies (in particular, of lipid-soluble vitamins with
respective clinical consequences). (GRADE 1B, strong
agreement)
Comments 3-1 and 3-2. Mild PEI is defined as the
reduced secretion of one or more enzymes with
normal bicarbonate concentration in duodenal juice
and normal faecal fat excretion; moderate PEI is
defined as having a reduced enzyme output and bicar-
bonate concentration but normal faecal fat excretion;
while severe PEI has a reduced enzyme output and
bicarbonate concentration plus steatorrhoea.166
Steatorrhoea and azotorrhoea in severe PEI result
when exocrine (mainly lipase and trypsin) pancreatic
function is reduced by >90%.167,168 Patients with stea-
torrhoea typically report weight loss and an increase in
daily bowel movements, with fatty, bulky stools that
are difficult to flush away; this occurs mainly after
high-fat-containing meals. As steatorrhoea occurs
after meals, it is typically observed 2–3 times a day in
individuals with a normal lipid-content diet.6,169
Clinical symptoms and signs of micronutrient deficien-
cies due to impaired absorption of lipid soluble vita-
mins include: vitamin K deficiency – ecchymoses due
to clotting; vitamin E deficiency – ataxia, peripheral
neuropathy; vitamin A deficiency – impaired night
vision, xerophthalmia; vitamin D deficiency – contrac-
tion or muscle spasms, osteomalacia and osteoporosis.
Further clinical consequences of PEI can include hyper-
oxaluria, urinary oxalate stones, renal insufficiency,
impairment of cognitive functioning and thus working
ability (with resulting financial strain) and reduced
overall quality of life (QoL).3,4,6,9,169
Although it is commonly held that steatorrhoea is
the most important clinical manifestation of PEI, some
studies have shown reduced absorption of fat-soluble
vitamins even in patients with mild to moderate exo-
crine insufficiency.170–173 Importantly, after excluding
patients with steatorrhoea (i.e. severe PEI), it was
found that significantly reduced faecal elastase levels
correlate well with low vitamin D3 levels in patients
with an osteoporotic fracture.174 Accordingly, mild to
moderate exocrine insufficiency also appears to be of
clinical relevance.
Q3-3: What are the main causes of PEI?
Statement 3-3. The main causes of PEI are loss of the
pancreatic parenchyma, obstruction of the main pan-
creatic duct, decreased stimulation of the exocrine
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pancreas and inactivation of pancreatic enzymes.
(GRADE 1B, strong agreement)
Comments. PEI results from a loss of functioning
pancreatic tissue and is seen in patients with CP and
other diseases including severe acute pancreatitis, pan-
creatic carcinoma, cystic fibrosis and partial or total
surgical resection of the pancreas (primary PEI).175
Further potential causes of PEI are obstruction of the
main pancreatic duct, decreased stimulation of the pan-
creas or inhibition of exocrine function by endocrine
tumours or pharmacological treatment (secondary
PEI).175 In CP, PEI results from a progressive loss of
functioning pancreatic tissue, which leads to insufficient
secretion of digestive enzymes into the duodenum.176
CP is the most frequent cause of PEI and, in an unse-
lected group of patients with CP, pancreatic exocrine
function was reduced by about 50–80% compared with
healthy volunteers.177 Other relatively common condi-
tions in which PEI occurs due to a loss of functioning
parenchyma include pancreatic carcinoma and previous
pancreatic resection in adults178 or cystic fibrosis in
children.179 Nearly 90% of patients recovering from
necrotising acute pancreatitis also had PEI, the devel-
opment of exocrine insufficiency strongly correlating
with the extent of pancreatic necrosis.180 However,
PEI has also been reported during the early recovery
phase of acute pancreatitis; in particular, pathological
values for FE-1 were found in 12% of patients with
either mild or severe acute pancreatitis and were signifi-
cantly related to the aetiology of the disease.181
Even in patients with normal secretory capacity of
the pancreas, PEI can be caused by obstruction of the
main pancreatic duct due to benign or malignant dis-
eases.6,169 Reduced endogenous stimulation can cause
or contribute to PEI in coeliac disease, diabetes melli-
tus, inflammatory bowel disease and after gastrointes-
tinal surgery.169,182 PEI has been demonstrated in
approximately 50% of patients with insulin-dependent
diabetes mellitus (IDDM), and in 30–50% of patients
with non-insulin-dependent diabetes (NIDDM),183–188
based on exocrine atrophy.189 Studies using unselected
patients from registries and less sensitive techniques for
pancreatic function testing suggest lower frequencies of
PEI, that is 26% in IDDM and 12% in NIDDM.190–192
Impaired pancreatic function is frequently observed
after partial or total gastrectomy193–196 and results
from various causes, such as a deficient grinding of
nutrients, altered gastric emptying, alteration of pan-
creatic innervation and post-cibal asynchrony.197,198
PEI is also present in patients with marked protein defi-
ciency. Rare causes of PEI include Shwachman-
Diamond syndrome, Johanson-Blizzard syndrome and
congenital enzyme deficiency, such as trypsinogen or
enteropeptidase (enterokinase), as well as isolated
amylase, lipase or other protease deficiencies.178 While
patients with HIV may have PEI,199 association with
other conditions such as irritable bowel syndrome (IBS)
is less clear.200 Somatostatinoma201 and somatostatin
administration202–204 may inhibit exocrine secretion
and thereby cause secondary PEI.175 Furthermore,
insufficient amounts of active enzymes in the intestinal
lumen can be due to their inactivation despite normal
secretory activity of the pancreas, as in
hyperchlorhydria.
Q3-4: When does PEI develop during the course of CP?
Statement 3-4. CP is a progressive disease and exo-
crine function gradually decreases during the course of
the disease. (GRADE 1B, strong agreement)
Comments. The development and timing of the clin-
ical manifestation of PEI in CP depends on the cause of
the disease, among other factors. In patients with alco-
holic CP, severe PEI with steatorrhoea usually appears
about 10–15 years after diagnosis. In patients with early
onset idiopathic CP or an hereditary form of the dis-
ease, exocrine insufficiency often does not manifest
until even later,4,205 despite the destruction of pancre-
atic tissue in the early stages of the disease. This late
onset is due to the large functional reserve capacity of
the pancreas.167,206 However, as shown in a large retro-
spective cohort study, about 10% of patients present
with steatorrhoea at the time of diagnosis.205
Q3-5: Can PEI be diagnosed or excluded using imaging
techniques (morphological tests)?
Statement 3-5.1. Signs of CP (morphological alter-
ations) and functional impairment usually develop in
parallel, but this is not always the case. (GRADE 1B,
strong agreement)
Comments. It is well substantiated that in the major-
ity of patients with CP, a correlation exists between the
extent of the morphological and functional changes.
However, discordant findings with varying degrees of
morphological and functional changes are found in
about 25% of patients.206–208 Even when EUS is used
as the most sensitive technique for the detection of mor-
phological alterations, normal morphological findings
are not always equivalent to normal pancreatic func-
tion.207,209 For example, despite normal morphology,
PEI is often found in patients with the ‘small duct dis-
ease’ type of CP.207 In an important study, in which
EUS and secretin test results were compared with histo-
logical findings as a reference, the sensitivity of EUS for
a diagnosis of ‘CP’ was 84%, and that of the secretin
test was 86%, while a combination of the two methods
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produced a sensitivity level of 100%.210 This implies
that either morphological or functional impairment
can be the only sign of CP.
Statement 3-5.2. The s-MRCP technique reveals
ductal morphological alterations and simultaneously
gives semi-quantitative information on functional
changes.211 (GRADE 1C, agreement)
Comments. Given the statement above, s-MRCP is
probably the most appropriate morphological test for
the assessment of pancreatic exocrine function.211 The
extent of pancreatic fluid secretion can be classified
using the DF score described by Matos et al.88 (grade
0: no fluid signal in the duodenum; grade 1: fluid lim-
ited to the duodenal bulb; grade 2: fluid filling up to the
genu inferius; grade 3: DF beyond the genu inferius).
Pancreatic exocrine function is considered reduced
when the DF score is less than grade 3. The examin-
ation requires about 45 min. The assessment of exo-
crine pancreatic function using the s-MRCP test
correlates with the results of FE-1 measurements, the
pancreolauryl test and the Lundh test,212–215 which can
be utilised in patients with CP as well as in those with
other benign or malignant pancreatic diseases,216
including cystic fibrosis.217 However, minor degrees of
DF are equivocal and require further diagnostic
evaluation.
Q3-6: Which test is clinically indicated for diagnosing exocrine
pancreatic insufficiency?
Statement 3-6. In a clinical setting, a non-invasive
pancreatic function test (PFT) should be performed.
The FE-1 test is feasible and widely available and is
therefore most frequently used in this setting, while
the 13C mixed triglyceride breath test (13C-MTG-BT)
offers an alternative. The s-MRCP test may also be
used as an indicator of PEI but provides only semi-
quantitative data. (Grade 1B, agreement)
Comments. FE-1 is a very simple test for the indirect
and non-invasive evaluation of pancreatic secre-
tion.166,218,219 This test is widely available and only
requires a small stool sample for analysis. It is widely
accepted that the lower the FE-1 concentration, the
higher the probability of PEI. However, guidelines
agree that the FE-1 test is not capable of excluding
mild to moderate PEI,175 and there is no consensus
regarding the cut-off for PEI in patients with CP: fig-
ures of <15, 50, 100 and 200 mg/g have been pro-
posed,168,169,220 and a threshold of 200 mg/g has been
used most frequently in accordance with the intended
use label of the test.175 Very low FE-1 values are most
probably associated with PEI, whereas high values
(>500 mg/g) allow the clinician to exclude that compli-
cation. The probability of false positive results due to
stool dilution should be considered in patients with
diarrhoea.221 Finally, the more specific monoclonal
FE-1 test (rather than the polyclonal FE-1 test) is
most appropriate for use in clinical practice.222
The coefficient of fat absorption (CFA) is generally
accepted as the gold standard for the diagnosis of stea-
torrhoea, which is characteristic of severe PEI.
Currently, it is the only test accepted by the American
Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) for the indication
and monitoring of PERT in clinical trials. The CFA
requires patients to maintain a strict diet containing
100 g of fat per day over five days, and to collect the
total amount of faeces excreted over the last three days
of this five-day period. A CFA< 93% is considered
pathological.167 Apart from detecting only severe PEI,
the test has limitations in terms of specificity (false posi-
tive results in non-pancreatic fat malabsorption), avail-
ability, patients’ compliance and handling of faecal
samples in the laboratory. Therefore, it is no longer
used in some European countries.
The 13C-MTG-BT is an appropriate alternative to
the CFA, both for the diagnosis of PEI and for evalu-
ating the efficacy of PERT in clinical practice.223–225
Modifications of the test may allow the detection of
mild to moderate PEI.226,227 However, the test also
has limitations in terms of specificity (false positive
results in non-pancreatic fat malabsorption),227 and it
is not yet widely available and is only commercialised in
some European countries.
Pancreatic secretion volume can be evaluated semi-
quantitatively by s-MRCP. Pancreatic secretion evalu-
ated by this technique correlates with FE-1 test results;
however, its sensitivity for PEI is as low as 69%.228,229
In addition, there is very limited evidence supporting
this technique for the diagnosis of PEI in clinical
practice.
Only direct tests that require the collection of duo-
denal juice in response to a hormonal stimulus, such as
secretin and/or a cholecystokinin (CCK) analogue (or a
meal), allow the quantification of pancreatic exocrine
secretion and the reliable detection of mild to moderate
exocrine insufficiency.230 Therefore, they have been
accepted as the reference standard.4,175,230
Conventionally, these tests have been performed via
the insertion of a naso-duodenal tube, but endoscopic
variations have also been developed, are currently
favoured in the USA,210 and are increasingly used in
some European countries. However, independent of the
precise method of duodenal juice collection, the exam-
ination is invasive, labour-intensive and expensive.
Therefore, such tests are confined to specialist centres.
On the other hand, SPT and CFA are still required for
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the evaluation of new tests if those are meant to detect
not only severe exocrine insufficiency with overt malab-
sorption but also more gradual changes in pancreatic
function.
Q3-7: Is a pancreatic function test required for the diagnosis
of CP?
Statement 3-7. A function test is required for the
diagnosis of CP. (Grade 2B, strong agreement)
Comments. The morphological grading systems have
pitfalls regarding both sensitivity and specifi-
city,61,208,210,231–233 and it has been shown that either
morphological or functional impairment can be the
only sign of histologically proven CP.210 Thus, a diag-
nosis of CP depends on a combination of clinical, histo-
logical, imaging and functional criteria. Proof of
impaired exocrine function using function testing is
particularly required for diagnosis in CP patients with
inconclusive morphological findings. Moreover, several
diagnostic and classification systems take exocrine
function into account.58–60,62,205,234 However, these
are more important for clinical studies.
Q3-8: Should a pancreatic function test be performed at the
time of diagnosis?
Statement 3-8. Every patient with a new diagnosis of
CP should be screened for PEI. (Grade 1A, strong
agreement)
Comments. The recommendation is based on the fol-
lowing aspects: as explained above, the initial pancre-
atic function test may provide a basis for the diagnosis
of CP in a subset of patients. Moreover, the detection
and treatment of exocrine failure has implications for
patient outcome and follow-up.4,9,10,235 However, exo-
crine failure may be present even when morphological
findings are absent or minimal206,207,209,210,236,237 so
that morphological investigations alone do not allow
for the assessment of exocrine function. In addition,
even with unequivocal morphological findings of CP,
clinical symptoms of exocrine failure are not always
evident at the time of diagnosis and a lack of symptoms
does not allow for the reliable exclusion of exocrine
insufficiency, even if it is severe and associated with
steatorrhoea.167,205,238,239 By contrast, all available
function tests detect these severe forms of the disease.
Q3-9: Should a pancreatic function test be performed during
follow-up, if symptoms of malabsorption occur/deteriorate?
Statement 3-9. In order to detect maldigestion prior
to the occurrence of overt clinical symptoms, the
presence of PEI should be evaluated annually in
patients with CP. Apart from this, function tests
should be repeated if previously normal when symp-
toms occur or deteriorate and can be attributable to
PEI. (Grade 1B, strong agreement)
Comments. It is well substantiated that the state of
exocrine function will deteriorate over time in the
majority of patients due to disease progression.205,238
FE-1, as the most frequently used test, has only
54–75% sensitivity in mild to moderate
PEI218,219,230,240,241 and may therefore have to be
repeated to diagnose progressive PEI. The absence of
severe PEI with steatorrhoea170,171,174,242 or its normal-
isation following PERT223 does not exclude the possi-
bility that PEI complications, such as loss of bone
density and malabsorption of fat-soluble vitamins,
may develop; thus more sensitive tests may be required.
Q3-10: Should a pancreatic function test be performed to
monitor enzyme treatment?
Statement 3-10. To evaluate the efficacy of enzyme
replacement therapy, it is sufficient in most cases to
verify the normalisation of nutritional parameters and
symptomatic improvement. When symptoms of exo-
crine insufficiency persist in spite of adequate PERT,
function tests (13C-MTG-BT, acid steatocrit, and quan-
titative faecal fat) are recommended in order to evalu-
ate treatment efficacy. (Grade 2B, strong agreement)
Comments. In general, a rapid improvement of clin-
ical symptoms and increase in weight and BMI can be
noted once patients with PEI are put on PERT. The
response can be verified by measuring the said nutri-
tional parameters in the serum.243 The latter is import-
ant as a lack of symptoms does not exclude residual
PEI.223
Q3-11: Are there special recommendations for specific patient
groups?
Statement 3-11. Specific attention is required when
screening for PEI in patients with CP and diabetes
mellitus, pancreatic carcinoma, or following pancreatic
resections or gastric resections. (Grade 1B, strong
agreement)
Comments. Diabetes mellitus, pancreatic carcinoma
and pancreatic resections are potential complications
of CP.3,4,9,169,182 On the other hand, even in the absence
of CP, these diseases and conditions can be associated
with PEI. Therefore, the likelihood of PEI is further
increased in patients with both CP and one of these
conditions. Following gastric resections, postcibal
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asynchrony may cause further deterioration of nutrient
digestion and absorption without directly affecting pan-
creatic secretory capacity.177
Q3-12: What are the blood parameters for measuring
malnutrition?
Statement 3-12. Established blood parameters of
malnutrition such as prealbumin, retinol-binding pro-
tein, 25-OH cholecalciferol (vitamin D), and minerals/
trace elements (including serum iron, zinc and magne-
sium) should be measured.173,244,245 (GRADE 2C,
strong agreement)
Comments. The malnutrition resulting from PEI is
no different from malnutrition due to other aetiologies.
Accordingly, the same parameters can be measured.
Treatment for CP
Surgery in CP (WP 5)
Q4-1.1: In patients with symptoms of CP, should endoscopy or
surgery be performed?
Statement 4-1.1. Surgery is superior to endoscopy in
terms of mid-term and long-term pain relief in patients
with painful CP. (GRADE 2B, agreement)
Comments. Physicians face a choice between endos-
copy and surgery in the treatment of patients with CP
and a dilated pancreatic duct (obstructive CP), without
a clear consensus of opinion for this group of patients.
Therefore, we assessed and compared the effects and
complications of surgical and endoscopic interventions
in the management of pain for obstructive CP and
included relevant trials irrespective of blinding, the
number of participants randomised, and the language
of the article.246–250
We identified three eligible trials.246–248 Two trials
compared endoscopic intervention with surgical inter-
vention and included a total of 111 participants: 55 in
the endoscopic group and 56 in the surgical group.
Compared with the endoscopic group, the surgical
group had a higher proportion of participants with
pain relief, both at mid/long-term follow-up (2–5
years: risk ratio (RR) 1.62, 95% confidence interval
(CI) 1.22–2.15) and long-term follow-up (5 years,
RR 1.56, 95% CI 1.18–2.05). Surgical intervention
resulted in improved QoL and improved preservation
of exocrine pancreatic function at mid/long-term
follow-up, but not thereafter. However, there were no
sham-controlled studies and without this one must be
careful with the conclusions. There is certainly an effect
of invasive procedures, but in RCTs the placebo effect
may be up to 25% and the surgical and endoscopical
studies were not blinded. No differences were found in
terms of major post-interventional complications or
mortality, although the number of participants did
not allow for this to be evaluated reliably.
The third trial, with 32 participants, compared sur-
gical intervention (17 patients) with conservative treat-
ment (15 patients). Surgical intervention resulted in a
higher percentage of participants with pain relief and
better preservation of pancreatic function; however, the
trial had methodological limitations, and the number of
participants was relatively small.
For patients with obstructive CP and a dilated pan-
creatic duct, we find that surgery is superior to endos-
copy in terms of pain relief. Morbidity and mortality
seem not to differ between the two intervention mod-
alities, but the trials identified do not provide sufficient
power to detect the small differences expected in this
outcome.
Q4-1.2: What is the optimal timing for surgical therapy in CP?
Statement 4-1.2a. To achieve optimal long-term pain
relief in patients suffering from CP, early surgery is
favoured over surgery at a more advanced stage of
the disease.251 (GRADE 2B, weak agreement)
Statement 4-1.2b. The risk of developing PEI is lower
after early surgery for CP than after surgery performed
at an advanced disease stage. Pancreatic resection tech-
niques have a higher risk of PEI than drainage tech-
niques. (GRADE 2C, weak agreement)
Statement 4-1.2c. No recommendation can be drawn
from the evidence regarding the effect of early surgery
on developing endocrine pancreatic function during
follow-up since few studies exist and those that do are
contradictory. (GRADE 2C, strong agreement)
Statement 4-1.2d. Long-term QoL is improved after
early surgery (<3 years from onset) compared to sur-
gery at a more advanced stage of disease. (GRADE 2C,
agreement)
Comments. Information was extracted from several
studies.246–250,252,253 Multivariable analysis identified
preoperative opioid use as an independent risk factor
for a lower physical composed score (coefficient 4.81
(7.36 to 2.28), p< 0.001). For the mental compo-
nent score (MCS), preoperative opioid use was also
independently associated with diminished QoL (coeffi-
cient 5.34 (8.01 to 2.70), p< 0.001).251
Since QoL data, including assessment of pain relief,
are scarce in the long-term setting, a multicentre trial
evaluated these patient-oriented outcomes by
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comparing early surgery to a step-up approach, includ-
ing endoscopy. Accrual has been completed but results,
including follow-up, will only be available in late 2017
(ESCAPE trial, ISRCTN 45877994; http://www.
pancreatitis.nl).
Q4-1.3: What operative technique should be used for patients
with CP and an enlarged pancreatic head?
Statement 4-1.3a. Duodenum-preserving pancreatic
head resection (DPPHR) was compared to conven-
tional pancreaticoduodenectomy (PD). The available
data show that the DPPHR and PD procedures are
equally effective in relieving postoperative pain.
Endocrine and exocrine insufficiency are comparable
after both strategies at the short-term assessment.
QoL is significantly improved after DPPHR compared
to PD. (GRADE 1B, agreement)
Statement 4-1.3b. Modifications of DPPHR – the
Beger and Berne procedures – are equal in terms of
pain relief, postoperative morbidity and mortality;
however, the operating time and length of hospital
stay is significantly shorter for the Berne procedure
than for the Beger. (GRADE 1B, strong agreement)
Statement 4-1.3c. DPPHR was compared to conven-
tional PD for long-term follow-up (up to 15 years). The
available long-term data show continued pain relief in
the majority of patients, with no differences between
surgical procedures for pain and QoL outcomes.
Occupational rehabilitation remains significantly
better with DPPHR compared to PD. Endocrine and
exocrine insufficiency were comparable after both stra-
tegies on long-term assessment. (GRADE 2B, strong
agreement)
Statement 4-1.3d. There is a non-significant trend
towards improved long-term mortality with DPPHR.
(GRADE 2B, strong agreement)
Statement 4-1.3e. Long-term follow-up of DPPHR
modifications. There are no differences in long-term
outcomes between the Beger, Berne and Frey proced-
ures. (GRADE 1B, strong agreement)
Comments. Pancreatic head resection represents the
surgical treatment of choice for CP with pancreatic
enlargement. PD and all available DPPHR modifica-
tions are potential surgical alternatives, all aiming at
the relief of intractable pain and the decompression of
adjacent organs.254
In order to evaluate short- and long-term outcomes
of DPPHR versus PD in the surgical treatment of CP
with pancreatic head enlargement, a systematic
literature search was performed to identify available
systematic reviews (SRs) and RCTs. A total of 2192
citations were retrieved, one SR254 and 12 publications
relating to seven RCTs were included.255–266 The crit-
ical appraisal revealed trials with heterogeneous meth-
odological qualities. The summarised results comparing
PD versus DPPHR for the surgical treatment of CP
were extracted from the RCT publications and the SR
with meta-analysis. Two RCTs comparing DPPHR
modifications with each other (Beger vs Bern, Beger
vs Frey) were included without meta-analysis (which
was not feasible due to a low sample size). For the
remarks section, surgical aspects were also backed
with non-randomised evidence as necessary.
Statement 4-1.3f. Neither DPPHR nor PD succeed in
interrupting the progression of CP toward endocrine
and exocrine failure. (GRADE 1B, strong agreement)
Comments. Since QoL data, including the assessment
of pain relief, are scarce in the long-term setting, a
multicentre trial evaluated these patient-oriented out-
comes comparing PD versus all modifications of
DPPHR. Results will be available later in 2017
(ChroPac trial, ISRCTN 38973832; http://www.chro-
pac-trial.eu/).
Q4-1.4: What is the definition of an enlarged pancreatic head?
Statement 4-1.4. A normal pancreatic head varies
considerably in size, although a diameter of >4 cm on
CT or MRI imaging is usually considered as enlarged.
(GRADE 1C, agreement)
Comments. The definition of an enlarged pancreatic
head is relatively homogeneous in the literature. A
diameter >35 mm267–269 or 40 mm247,270 is widely
adopted. This diameter should be measured in the
anteroposterior direction on cross-sectional imaging.267
However, some authors do not give data regarding pan-
creatic head size in their series and thus do not modify
the surgical treatment according to this criter-
ion.264,271–273 With a dilated main pancreatic duct
(MPD) and a normal sized pancreatic head the differ-
ential diagnosis of a main-duct IPMN must be
entertained.
Q4-1.5: What is the definition of a dilated main duct?
Statement 4-1.5. In adult patients, a main duct diam-
eter of 5mm in the pancreatic body seems amenable
to ductal drainage for the majority of pancreatic sur-
geons. This threshold of 5mm is therefore proposed as
the definition of a ‘dilated main duct’. (GRADE: 1C,
agreement)
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Comments. The definition of a dilated main duct is
less consensual than that for an enlarged pancreatic
head, since ducts >3–8mm in diameter are considered
as dilated. Regarding dilated pancreatic ducts, all
authors consider only the maximum diameter and
never provide the length and the location (cephalic vs
distal) of dilated segments or the parenchymal thick-
ness. In children with CP, a 5mm diameter is con-
sidered sufficient to indicate surgery.274
Q4-1.6: When should a total pancreatectomy be considered
in CP?
Statement 4-1.6. A total pancreatectomy should be
considered in patients without duct system dilatation,
who are resistant to conventional medical, endoscopic
and previous surgical treatment and who have severe
pain. (GRADE 1C, agreement)
Comments. The group of patients with the features
described above, although small, has a very high
level of suffering and a total pancreatectomy can
be considered in these patients. If available, an
effort should be made to combine the total pancrea-
tectomy with islet autotransplantation (TPIAT);
however, experience of this procedure is rather lim-
ited. This alternative is of particular importance in
patients with an increased risk of developing pancre-
atic cancer (smokers; patients with hereditary
pancreatitis).275
Q4-1.7: How to operate on a patient with painful CP, a dilated
main pancreatic duct and a normal-sized pancreatic head?
Statement 4-1.7a. For these patients, a lateral pan-
creaticojejunostomy with a Roux-en-Y loop and
Frey’s procedure provide comparable pain control
(low quality of evidence). However, no recommenda-
tion can be made for the preferred surgical technique in
these patients. (GRADE 2B, strong agreement)
Statement 4-1.7b. Both a lateral pancreaticojejunost-
omy with a Roux-en-Y loop and Frey’s procedure seem
to provide equivalent pain control in patients with main
duct dilatation and a normal size pancreatic head.
(GRADE 2B, strong agreement)
Comments. In the literature, patients with a docu-
mented normal-size pancreatic head and dilated MPD
were historically treated by Roux-en-Y pancreaticoje-
junostomy according to Partington and Rochelle.
Beger’s procedure was evaluated in this setting in only
one retrospective study.276 Findings were evaluated
according to head size: a good result (opiates with-
drawn) was observed in three out of 11 (27%) patients
without head enlargement and 13 out of 16 patients
(81%) with head enlargement (p¼ 0.018).276 In some
recent series, patients received a pancreaticojejunost-
omy and/or Frey’s procedure according to the sur-
geon‘s preference or the study period. Study
characteristics and the results of Roux-en-Y pancreati-
cojejunostomy and Frey’s procedure are given in
Supplementary Material, Table S4 (those series that
included patients with a so-called ‘cephalic inflamma-
tory mass’ were excluded).277
There is great heterogeneity in patients included in
these series due to the variable prevalence of other
potentially painful conditions (pseudocysts, biliary
obstruction) and persisting alcohol consumption,
which makes the comparison of results difficult. In
one series,277 wide opening of ductal system (MPD)
including in the head was adopted. In another
series,278 extension of drainage by a ductal opening in
the pancreatic head, with or without parenchymal
resection was associated with significantly better pain
control.
Q4-1.8: Is there a volume-outcome relationship in CP surgery?
If so, what should be the minimal annual volume (potentially
based on cancer surgery?
Statement 4-1.8. An experienced high volume pancre-
atic centre is recommended for the surgical treatment of
CP. (GRADE 2C, strong agreement)
Comments. A systematic search in PubMed, Embase,
and Cochrane revealed no publications on the impact
of hospital or surgical volume in CP surgery. Therefore
an experienced high volume centre is recommended for
the surgical treatment of CP. For pancreatic resection
(for pancreatic cancer) several publications were identi-
fied that indicated an advantage (concerning mortality)
for high volume centres.279–283
The cut off (low vs high volume centre) was defined
as between 10–20 cases per year per hospital. The sur-
gical treatment of CP is commonly located in experi-
enced pancreatic centres, as the number of CP patients
is much lower than the number of pancreatic cancer
patients. As resection for CP is technically similar to
that for pancreatic cancer, the total number of pan-
creatic resections is more important than the fre-
quency of surgery for CP. As in resectable
pancreatic cancer, the decision for surgery in CP
should be made by an interdisciplinary expert panel
that includes an endoscopist and gastroenterologist.284
This allows for an individual therapeutic concept so
that each patient may consider non-surgical thera-
peutic options. In CP, improving QoL/pain is the
dominant outcome parameter, while mortality is a sec-
ondary outcome parameter.
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Q4-1.9: What is the role and outcome of surgery in groove
(paraduodenal) pancreatitis?
Statement 4-1.9. Surgery should be performed when
medical and endoscopic options have failed. Surgery
should be aimed at pain relief and/or complete pain reso-
lution, and should solve the patient’s malnutrition status
(body weight gain), on condition that the patient stops
alcohol and drug abuse. (GRADE 2C, strong agreement)
Comments. Groove pancreatitis is a rare yet well-
defined form of CP that may constitute a painful con-
dition in affected patients.285 It presents a diagnostic
challenge.286
Q4-1.10: What is the best timing for surgery in patients suffer-
ing from groove pancreatitis?
Statement 4-1.10. The initial treatment of groove
pancreatitis should involve medical treatment and occa-
sionally, endoscopic drainage procedures may be help-
ful. If these approaches fail, the patient should be
referred for surgery. (GRADE 2C, strong agreement)
Q4-1.11: Which is the most appropriate surgical procedure for
groove pancreatitis?
Statement 4-1.11. In expert hands, pancreaticoduode-
nectomy is the most suitable surgical option for
patients with groove pancreatitis (Supplementary
Material, Table S5). (GRADE 2C, strong agreement)
Comments. There were no RCTs on this topic hence
all of the studies considered are observational cohort
studies or retrospective analyses. The quality of the evi-
dence is predictably low and influenced by selection
bias and we found no study comparing the results of
medical, endoscopic and surgical treatments. Notably,
there are no studies comparing pancreas-preserving vs
pancreas-sparing procedures. Pancreas-sparing proced-
ures have been described as surgical options when only
the duodenum is involved and pancreatic involvement
can be definitely ruled out. An additional argument in
favour of pancreaticoduodenectomy is that there is a
small, but unquantifiable, risk of pancreatic cancer in
patients with presumed groove pancreatitis.287
Medical therapy for exocrine pancreatic
insufficiency (WP6)
Q4-2.1: What are the indications for pancreatic enzyme repla-
cement therapy (PERT) in CP?
Statement 4-2.1. PERT is indicated for patients with
CP and PEI in the presence of clinical symptoms or
laboratory signs of malabsorption. An appropriate
nutritional evaluation is recommended to detect signs
of malabsorption. (GRADE 1A, strong agreement)
Comments. PEI in CP is consistently associated with
biochemical signs of malnutrition.288 The indication for
pancreatic enzyme replacement is classically established
for steatorrhoea with faecal fat excretion of >15 g/day.
Since the quantitative measurement of faecal fats is
often omitted, the indication for enzyme replacement
is also present with a pathological pancreatic function
test in combination with clinical signs of malabsorp-
tion, or anthropometric and/or biochemical signs of
malnutrition.244,289–292 Symptoms include weight loss,
diarrhoea, severe meteorism and flatulence, and
abdominal pain with dyspepsia. Abnormally low nutri-
tional markers associated with PEI and indicating
PERT include fat-soluble vitamins, prealbumin, reti-
nol-binding protein and magnesium, amongst
others.244 Therapy with oral pancreatic enzymes
purely as a trial for 4–6 weeks may also be beneficial
if symptoms are unclear.
Q4-2.2: What are the enzyme preparations of choice?
Statement 4-2.2. Enteric-coated microspheres or
mini-microspheres of <2mm in size are the prepar-
ations of choice for PEI. Micro- or mini-tablets of
2.2–2.5mm in size may be also effective, although sci-
entific evidence in the context of CP is more limited.
Comparative clinical trials of different enzyme prepar-
ations are lacking. (GRADE 1B, strong agreement)
Comments. The efficacy of pancreatic enzyme prep-
arations depends on a number of factors: (a) mixture
with meal; (b) gastric emptying with meal; (c) mixing
with the duodenal chyme and bile acids; (d) rapid
release of enzymes in duodenum.
Pancreatic enzyme preparations are formulated as
pH-sensitive, enteric-coated, mini-microspheres that
protect the enzymes from gastric acidity and allow
them to disintegrate rapidly at pH 5.5 in the duodenum
to release the enzymes.293,294 The efficacy of pH-sensi-
tive, enteric-coated, mini-microspheres in patients with
CP has been demonstrated in several recent stu-
dies.295–298 Enteric-coated preparations have been
demonstrated to be more effective than conventional
uncoated preparations.299 A recent Cochrane review
on the efficacy of pancreatic enzyme preparations in
patients with pancreatic insufficiency secondary to
cystic fibrosis demonstrated a higher efficacy for
enteric-coated microspheres compared to enteric
coated tablets.300 It has been shown that mini-
microspheres of 1.0–1.2mm in diameter are emptied
simultaneously with the meal and are associated with
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higher therapeutic efficacy compared to 1.82.0mm
microspheres that still work satisfactory.301
Q4-2.3: How should pancreatic enzymes be administered?
Statement 4-2.3. Oral pancreatic enzymes should be
distributed along with meals and snacks. (GRADE 1A,
strong agreement)
Comments. The effectiveness of pancreatic enzyme
supplements presupposes the mixing of enzymes and
chyme. Thus, enzyme preparations should be taken
with meals. If more than one capsule/tablet per meal
must be taken, it may be beneficial to take one part of
the dose at the beginning with the rest being distributed
during the meal.302,303
Q4-2.4: What is the optimal dose of pancreatic enzymes for
exocrine pancreatic insufficiency in CP?
Statement 4-2.4. A minimum lipase dose of 40,000–
50,000 PhU is recommended with main meals, and half
that dose with snacks. (GRADE 1A, strong agreement)
Comments. Although enzyme preparations include a
large variety of pancreatic enzymes for digestion, the
PERT dosage is based on lipase activity. The recom-
mended initial dose is about 10% of the physiologically
secreted dose of lipase into the duodenum after a
normal meal.177 That means that a minimum activity
of 30,000 IU of lipase is required for the digestion of a
normal meal. Since 1 IU of lipase equals 3 PhU, the
minimum amount of lipase needed for digestion of a
normal meal is 90,000 PhU (endogenous enzyme secre-
tion and the orally administered enzymes taken
together).
Clinical trials have evaluated different enzyme prep-
arations given at different doses. Enzyme activity is
shown in different commercially available products in
accordance with procedures specified by the Fe´de´ration
Internationale Pharmaceutique (FIP), the European
Pharmacopoeia (PhEur) or the United States
Pharmacopeia (USP). The equivalence among different
units is as follows: for lipase, 1 FIP/PhEur unit¼ 1 USP
unit; for amylase, 1 FIP/PhEur unit¼ 4.15 USP units;
and for protease, 1 FIP/PhEur unit¼ 62.5 USP
units.304 Thus, since FIP, PhEur and USP are equiva-
lent for lipase, clinical trials evaluating the efficacy of
different preparations and doses on fat digestion can be
compared directly.
The most recent and well-designed RCTs have
shown the efficacy of PERT with enteric-coated mini-
microspheres at a dose ranging from 40,000–80,000
PhU of lipase per main meal, and half that dose per
snack.297,298,303,305–307 Studies evaluating enteric-coated
microspheres have shown a similar efficacy for doses
ranging from 10,000–40,000 PhU of lipase per meal,
indicating the lack of a dose-response relationship
with these preparations.308–310
Q4-2.5: How should be the efficacy of PERT be evaluated?
Statement 4-2.5. The efficacy of PERT can be evalu-
ated adequately by the relief of maldigestion-related
symptoms (e.g. steatorrhoea, weight loss, flatulence)
and the normalisation of the nutritional status of the
patients. In non-responder patients, the use of pancre-
atic function tests (CFA or 13C-MTG-BT) with oral
enzymes may be of help. (GRADE 1B, strong
agreement)
Comments. Although the disappearance of the clin-
ical signs of malabsorption is classically considered as
the most important criterion for the success of PERT,
which is associated with an improvement of the QoL,311
more recent studies have demonstrated that symptom
relief is not consistently associated with normalisation
of the nutritional status.223 A recent review of reported
data supports the concept of normalisation of nutri-
tional parameters (both anthropometric as well as bio-
chemical) as the optimal way to evaluate the efficacy of
PERT.243
If the symptoms do not respond, or respond only
partially, this may be due to other mechanisms.
Several studies have shown that breath tests with 13C-
labelled lipids provide a good measure of fat digestion
and faecal fat excretion and are therefore suitable for
monitoring the effectiveness of enzyme replacement
therapy.223,288,312 The success of replacement therapy
cannot be assessed by measuring the faecal concentra-
tion of elastase, because only the natural human
enzyme, and not the therapeutically administered
enzyme contained in pancreatin, is measured. Faecal
chymotrypsin excretion provides no information
about the effect of enzyme replacement therapy on
nutrient digestion and nutrient absorption; however,
it can be used to test for compliance (low values cor-
respond to inconsistent intake).4
Q4-2.6: What should be done in cases of unsatisfactory clinical
response?
Statement 4-2.6. In cases of unsatisfactory clinical
response, the enzyme dose should be increased
(doubled or tripled) or a proton pump inhibitor (PPI)
should be used. If these strategies fail, another cause for
maldigestion should be sought. (GRADE 2B, strong
agreement)
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Comments. The recommended initial dose of 10% of
the cumulatively secreted lipase activity into the duode-
num after a normal meal (see above) should suffice to
prevent malabsorption and steatorrhoea in more than
half of patients treated. Although solid scientific evi-
dence is lacking, clinical experience shows that a dou-
bling or tripling of this dose is necessary and helpful in
some patients. The inhibition of gastric acid secretion
either by H2-blockers or PPIs is of help in patients with
an insufficient response to the initial enzyme
dose.290,313,314 Whether increasing the oral enzyme
dose is more effective than the addition of a PPI in
these patients is unknown, and both strategies
should be considered as appropriate. If the secretion
of gastric acid is suppressed, then uncoated pancreli-
pase could be used in cases of insufficient clinical
response.
Patients with CP frequently have abnormal bacterial
gut colonisation.315 This may be considered as a pos-
sible cause of persistent symptoms and other disturb-
ances if the above-mentioned measures are
unsuccessful.
Q4-2.7: Should PPIs be added to pancreatic enzyme
supplementation in the treatment of PEI in CP?
Statement 4-2.7. The addition of a PPI to oral pan-
creatic enzymes is of help in patients with an unsatis-
factory response to PERT. (GRADE 1B, strong
agreement)
Comments. Several RCTs have shown that add-
itional acid suppression can improve the effect of
PERT compared with pancreatin alone.290,316–318
However, only very few patients with varying PEI
aetiologies were included in these studies. Moreover,
variable pancreatin preparations and variable drugs
for acid suppression (different H2-antagonists and/or
PPIs) have been investigated. Therefore, the recom-
mendation to add a PPI to oral pancreatic enzymes
in patients with an unsatisfactory response to PERT
is based on data of only moderate quality.
Subgroup analyses suggest that the addition of a
PPI leads to a significant improvement and even
normalisation of fat digestion in patients with PEI
and an incomplete response to enzyme substitution
therapy.313 By contrast, patients with an adequate
response to enzyme substitution therapy did not
profit from an additional PPI313,319 (Supplementary
Material, Table S6). This probably explains why a
recent retrospective analysis of a large patient data-
base did not show superior effects of PERT on fat
absorption in patients who received acid-suppressing
therapy for other indications throughout the
study.319
Endoscopic therapy (ET) (WP7)
Q4-3.1a: To which patients should ET be proposed?
Statement 4-3.1a. In patients with uncomplicated
painful CP and a dilated MPD, we recommend ET as
the first-line treatment after failed medical therapy fol-
lowing discussions by a multidisciplinary team (MDT).
The clinical response should be evaluated at 6–8 weeks;
if it appears unsatisfactory, the patient’s case should be
discussed again by a multidisciplinary team of endos-
copists, surgeons and radiologists, and surgical options
should be considered, in particular for patients with a
predicted poor outcome following ET. The manage-
ment of CP-related complications is discussed below.
(GRADE 2B, agreement)
Q4-3.1b: Is there a role for ET in asymptomatic CP?
Statement 4-3.1b. ET has no role in asymptomatic
and uncomplicated CP. (GRADE 2B, agreement)
Comments. In patients with uncomplicated painless
CP, no study has demonstrated any benefit for ET,
including for the treatment of exocrine or endocrine
pancreatic insufficiency.320–322 Nevertheless, certain
CP complications may indicate treatment even if they
are asymptomatic; for example, some biliary strictures
and pancreatic pseudocysts (PPCs), as discussed below.
Q4-3.1c: How does ET compare with surgery with respect to
timing, efficacy and cost?
Statement 4-3.1c. ET is performed first in most cases,
with surgery reserved to the minority of patients whose
painful symptoms do not respond well to ET. The effi-
cacy of ET has been found to be lower compared with
surgery in a single randomised trial but this included a
small number of highly selected patients at the later
stages of the disease. (GRADE 2B, agreement)
Comments. In an RCT that compared endoscopic
EUS-guided drainage vs surgery for uncomplicated
PPC in 40 patients, endoscopic drainage was significantly
better than surgery in terms of cost, length of hospital
stay andQoL up to threemonths post-procedure.323 At a
median follow-up of 18 months, clinical outcomes and
QoL were similar for both groups. The total mean cost
was lower for patients managed by endoscopy compared
to surgery ($7011 vs $15,052). Moreover, a large review
of a non-comparative historical series of endoscopic and
surgical treatments that included 787 patients showed
similar morbidity (13.3% vs 16.0%, respectively) and
long-term PPC recurrence (10.7% vs 9.8%, respectively)
but lower mortality with the endoscopic method (0.2%
vs 2.5%, respectively).324 Finally, ET does not
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significantly affect subsequent surgical therapy if it
becomes necessary.
Q4-3.1d: Which patients respond best to ET?
Statement 4-3.1d. Pre-treatment factors useful to
identify the best responders to ET are the location of
obstructing stones in the head of the pancreas, the
absence of MPD stricture, a short disease duration
and a low frequency of pain attacks before ET.
(GRADE 2B, agreement)
Comments. Factors independently associated with
long-term (2 years) pain relief following ET for CP
include the location of obstructive calcifications in the
head of the pancreas (the most robust predictor of good
outcome, identified in an RCT),325 a short disease dur-
ation and a low frequency of pain attacks before ET,
complete MPD stone clearance and an absence of MPD
stricture at initial ET, as well as the discontinuation of
alcohol and tobacco during follow-up.321,326–328 Disease
duration before ET was assessed using the dates of the
first pain attack and most studies reported better clinical
results in patients with a shorter disease duration.
Q4-3.2a: What are the indications for extracorporeal shock
wave lithotripsy (ESWL)?
Statement 4-3.2a. ESWL can be considered as first-
step treatment for larger, radiopaque stones (5mm)
obstructing the MPD, and is usually followed by the
endoscopic extraction of stone fragments; although, in
centres with expertise, ESWL alone may be a more
cost-effective option (strong recommendation, moder-
ate quality evidence). We suggest performing non-con-
trast enhanced computed tomography (NCCT) before
ESWL to determine the location, size, number and
density of stones (weak recommendation, low quality
evidence). (GRADE 2C, agreement)
Comments. ESWL is the gold standard for non-sur-
gical MPD stone removal. A meta-analysis of 17 stu-
dies (a total of 491 patients) showed that ESWL is
useful for clearing MPD stones and for decreasing
CP-related pain.329 ESWL is highly effective at frag-
menting radiopaque pancreatic stones: a systematic
review of 11 series found that ESWL successfully frag-
mented stones in 89% of 1149 patients.330 However, in
an RCT with long-term follow-up, comparing surgery
with endoscopy plus ESWL, surgery was more effective
than the combination of endoscopy and ESWL for
larger stones.247,248
In general, stone extraction using a Dormia basket
without prior lithotripsy should not be attempted as
this technique fails in a majority of patients (83% and
91% in two series of 46 and 125 patients, respect-
ively);327,331 moreover, it carries a relatively high
morbidity.332
Q4-3.2b: Should some stones be preferentially selected for
treatment (stone size and location)?
Statement 4-3.2b. ESWL should target stones with a
minimal diameter of 2–5mm, starting in the head of the
pancreas and progressing to the head to permit elimin-
ation of stone fragments. (GRADE 2C, agreement)
Comments. In the majority of series, stones targeted
by ESWL were mostly radiopaque stones obstructing
the MPD with a minimal diameter of 2–
5mm.320,325–328,333–337 Endoscopic clearance of MPD
stones targeted by ESWL is more frequently obtained
in the case of single stones and stones confined to the
head of the pancreas.321,325,326,333,338 Other factors
associated with complete stone clearance from the
MPD that require confirmation include: (a) a stone
density <820 Hounsfield units (prospective study,
128 patients),338 (b) intravenous injection of secretin
during ESWL (retrospective study, 233 patients),339
and (c) ERCP performed >2 days as compared with
2 days following ESWL (retrospective study, 30
patients).340
Q4-3.2c: What are the potential indications for treatment by
ESWL alone?
Statement 4-3.2c. ESWL alone may be the most cost-
effective option but it should be reserved to centres with
expertise in this technique. (GRADE 2C, agreement)
Comments. ESWL without subsequent ERCP may
also be used to treat painful uncomplicated CP: two
uncontrolled series reported spontaneous MPD stone
clearance in 70–88% of 350 patients and pain relief
was achieved at 44 months in 78% of the patients.335,341
In an RCT that compared ESWL alone vs ESWL fol-
lowed by ERCP in 55 patients,325 the only significant
differences between groups were a longer hospital stay
and a higher treatment cost in the ESWL plus ERCP
group.
Q4-3.2d: What are the post-ESWL complications?
Statement 4-3.2d. Pancreatitis is the most frequent
complication of ESWL. (GRADE 2C, agreement)
Comments. In a prospective series of 634 patients
with a treatment protocol that helped to distinguish
between ESWL-related and ERCP-related complica-
tions (ERCP was performed after the last ESWL
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session), 99 complications were attributed to ESWL
(15.6% of patients, 6.7% of ESWL sessions), 16 of
these being classified as moderate to severe (2.5% of
patients). Post-ESWL pancreatitis accounted for two-
thirds of the complications.342 Other adverse events
attributed to ESWL in large series include pancreatitis,
skin erythema, haematuria, gastrointestinal bleeding,
‘steinstrasse’ (acute stone incarceration in the papilla
responsible for MPD dilatation), hepatic subcapsular
haematoma and perforation.320,321,335,337,342
Q4-3.2e: What is the frequency of long-term pain recurrence
after ESWL alone or when combined with endoscopic stone
extraction?
Statement 4-3.2e. At long-term, pain relapses requir-
ing analgesics or more invasive treatment has been
reported in 5–45% of patients. (GRADE 2B,
agreement)
Comments. Long-term, complete or partial pain
relief following ESWL associated with ERCP has
been reported in 70–96% of the patients included in
five retrospective studies (Supplementary Material,
Table S7).320–322,343 In the above-mentioned RCT that
compared ESWL alone vs ESWL followed by ERCP in
55 patients,325 at the end of follow-up (51 months) 31
patients (56%) had no pain relapse with no difference
between the two treatment groups.
Q4-3.3a: How is a dominant pancreatic stricture defined? What
are the long-term results of stricture dilation, temporary single
plastic stenting, temporary multiple plastic stenting?
Statement 4-3.3a. Dominant MPD strictures in the
head of the pancreas are defined as strictures with an
upstream MPD dilation 6mm in diameter or stric-
tures that prevent the outflow of contrast medium.
Stricture dilation alone has yielded disappointing
results while satisfactory long-term results have been
reported in more than two-thirds of patients with tem-
porary plastic stenting. (GRADE 1C, agreement)
Comments. The abovementioned definition is usually
accepted.344,345 Stricture dilation alone is not a stand-
ard treatment option for MPD strictures.347 The same
is true for single plastic stenting for a short period (six
months) even if associated with repeated balloon dila-
tion of the stricture.348
In five retrospective case series with long-term (24
months) follow-up and a total of 348 patients,349–352
pain improvement was reported in 62–83% of patients
with a mean follow-up of 24–69 months after single
plastic stent removal. In the largest study,350 after a
median stenting duration of 23 months, 62% of
patients maintained satisfactory pain control without
pancreatic stent replacement during a median time of
27 months. The majority of pain recurrence, requiring a
new period of pancreatic stenting, occurred during the
first year following stent removal (79%), with almost all
(97%) having relapsed by 24 months.350 Consequently,
if a patient remains stable during the first year after
stent removal, subsequent relapse and need for re-stent-
ing are less likely.
Results of multiple plastic stenting were reported in
a single study that included 19 patients.353 A median
number of three simultaneous stents (8.5–11.5 Fr) were
left in place for seven months. At a mean follow-up of
38 months following stent removal, 84% (16/19) of the
patients remained pain-free (Supplementary Material,
Table S8).
Q4-3.3b: With temporary plastic stenting, which is the most
appropriate stent design, length and diameter?
Statement 4-3.3b. We recommend using a straight
polyethylene (8.5–10 Fr) pancreatic stent with the
shortest possible length, tailored to the location of the
MPD stricture. (GRADE 1C, agreement)
Comments. The choice of stents is influenced by the
stricture severity (limiting the maximal stent diameter
that might cross the stricture), its location (affecting the
stent’s length) and the shape of the MPD (i.e. difficult
anatomy such as ansa pancreatica).
Although a bench study suggested that stent occlu-
sion is associated with a stent diameter >8.5 Fr,354 a
larger clinical study found that patients with stents
8.5 Fr (n¼ 129, 79%) were three times more likely
to be hospitalised for abdominal pain than those with
10 Fr stents (n¼ 34, 21%).355 In 2006, a new S-type 10
Fr stent was proposed to prevent stent migration,356
but despite good results in a small study it is not cur-
rently used.
Q4-3.3c: What is the most appropriate stent exchange
schedule?
Statement 4-3.3c. Stent exchange may be performed
either at regular intervals (for example, three months)
or ‘on-demand’ in patients with a recurrence of pain
and MPD dilatation. (GRADE 1B, agreement)
Comments. ‘On-demand’ stent exchange is the pre-
ferred strategy, as the duration of the stent’s clinical
effect is unpredictable and is not correlated with stent
clogging.357 With an ‘on-demand’ strategy, stent
replacement was reported to be required after a mean
period of 8–12 months.350 Criteria used during ERCP
for terminating MPD stenting include: adequate
174 United European Gastroenterology Journal 5(2)
outflow of contrast medium 1–2min after ductal filling
upstream from the stricture location after stent
removal, easy passage of a 6 Fr catheter through the
stricture location, and decreased focal narrowing.349–351
Note, complete stricture resolution is not needed for
pain relief.351,358
Q4-3.3d: What are the indications of stenting for MPD stric-
tures? What are the criteria for not replacing a temporary stent
after removal?
Statement 4-3.3d. We recommend treating domin-
ant MPD strictures located in the head of the pan-
creas and associated with pain by single plastic
stenting for at least 12 months with at least one
planned stent exchange within one year. Criteria
used for not replacing a temporary plastic stent
after removal are adequate contrast medium outflow
in the duodenum and easy passage of a 6 Fr cath-
eter through the residual dilated stricture. (GRADE
1B, agreement)
Comments. Satisfactory results reported in Table 4.3-
2 were obtained using the abovementioned treatment
modality. Multiple plastic stenting is another option
but it is technically more complex and it has not been
compared with single plastic stenting.359 Criteria used
during ERCP for terminating MPD stenting include:
adequate outflow of contrast medium 1–2min after
ductal filling upstream from the stricture location
after stent removal, easy passage of a 6 Fr catheter
through the stricture location, and decreased focal nar-
rowing.360–362 Note, complete stricture resolution is not
needed for pain relief.348,362
Q4-3.3e: How are refractory MPD strictures defined and how to
treat them?
Statement 4-3.3e. Refractory MPD strictures are
defined as persistent symptomatic dominant strictures
after one year of single stent placement. We recommend
multiple pancreatic duct stenting for treating a refrac-
tory MPD stricture or a trial of 3–6 months with a fully
covered self-expandable metallic stent (FC-SEMS) or
surgical pancreaticojejunostomy. (GRADE 2C,
agreement)
Comments. The above-mentioned definition is usu-
ally accepted.345,363 For refractory MPD strictures,
besides the insertion of multiple plastic stents, the tem-
porary insertion of a FC-SEMS is an option, although
uncovered and partially covered self-expandable metal-
lic stents (SEMSs) have provided disappointing
results.364 Five recent studies have reported encoura-
ging results with a FC-SEMS in a total of 61 patients;
however, the follow-up after stent removal for
this group was short (Table 4.3-2).363,365,366
Pain improvement was reported in 40/48 patients
(83%). The optimal duration of treatment with FC-
SEMS should probably be around 3–6
months.363,365,366 Furthermore, a recent systematic
review suggested that both FC-SEMS and multiple
plastic stents produce similarly good results.367
Q4-3.3f: How do temporary single plastic stenting, temporary
multiple plastic stenting, temporary SEMS placement and bal-
loon dilatation compare in terms of indications, long-term
results and complications?
Statement 4-3.3f. Polyethylene 10 Fr pancreatic
stents tailored to the shape of the MPD and length of
the stricture are most commonly used. Occlusion of
MPD stents usually occurs within 2–3 months while
symptoms of CP usually recur between 6–12 months.
Thinner MPD stents (8.5 Fr) are associated with more
frequent hospitalisations for abdominal pain than 10 Fr
stents. Placement of a single pancreatic plastic stent
achieves MPD stricture resolution in nearly 60% of
cases while simultaneous placement of multiple pancre-
atic stents was reported to be of additional benefit in a
single study. Complications related to MPD stenting
are usually mild and managed conservatively. The
European Society of Gastrointestinal Endoscopy
(ESGE) recommends treating dominant MPD stricture
by inserting a single 10 Fr plastic stent, with stent
exchange planned within one year even in asymptom-
atic patients to prevent complications related to long-
standing pancreatic stent occlusion. Simultaneous
placement of multiple, side-by-side, pancreatic stents
could be applied more extensively, particularly in
patients with MPD strictures persisting after 12
months of single plastic stenting. (GRADE 1C,
agreement)
Comments. Stricture dilatation alone is not a stand-
ard treatment option for MPD strictures.330,345 The
same is true for single plastic stenting for a short
period (six months) even if associated with repeated
balloon dilatation of the stricture.358
Q4-3.3 g: What are the adverse events related to pancreatic
stenting in CP?
Statement 4-3.3 g. Adverse events include stent occlu-
sion and stent migration. (GRADE 1B, agreement)
Comments. Pancreatic duct stenting is associated
with complications such as stent occlusion (may
induce the formation of pseudocysts in rare cases),
stent migration, including distal migration to the
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duodenum with the risk of impaction on the opposite
duodenal wall and risk of duodenal perforation, and
proximal migration into the pancreatic duct, with
technical challenges for stent removal. Distal and prox-
imal migration of the pancreatic stent were reported in
1.5–7.5% and 0.8–5.2% of patients in two
studies.368,369
Spontaneous stent migration has been reported in
8% of patients with FC-SEMS, but with large differ-
ences between studies, from 0% in one study363 to 39%
in another study.370 Moreover, adverse events such as
cholestatic liver dysfunction developed in four patients
(without a history of previous endoscopic biliary
sphincterotomy) and may be associated with compres-
sion of the bile duct orifice due to expansion of the FC-
SEMS.363,370
Q4-3.4a: How does ET with temporary single plastic stenting,
temporary multiple plastic stenting, and temporary SEMS pla-
cement compare with surgery for biliary stricture (BS) treat-
ment in terms of long-term efficacy, cost and complications?
How to select patients for ET?
Statement 4-3.4a. Temporary stenting of common
bile duct (CBD) strictures with multiple simultaneous
plastic stents or covered SEMS provide long-term suc-
cess in 90% of cases. This compares with stricture
resolution in a minority of patients only following
temporary stenting with a single plastic stent. No
valid study comparing ET vs surgery was found. We
recommend treating CBD strictures responsible for
symptomatic (recurrent acute cholangitis, obstructive
jaundice) or persistent (>1 month) cholestasis. We
suggest electing ET for patients deemed to comply
with repeat ERCPs and who are at high surgical
risk, present with portal hypertension or have local
abdominal conditions contraindicating surgery.
Multiple side-by-side plastic stents or FC-SEMS, not
single plastic stents, should be used. (GRADE 2C,
agreement)
Comments. We recommend treating CBD strictures
responsible for symptomatic (recurrent acute cholan-
gitis, obstructive jaundice) or persistent (>1 month)
cholestasis (strong recommendation, low quality evi-
dence). We suggest electing ET for patients deemed to
comply with repeat ERCPs and who are at high surgi-
cal risk, present with portal hypertension or have local
abdominal conditions contraindicating surgery. An
effectual recall system should be established in order
to avoid septic complications (weak recommendation,
low quality evidence). Resective surgery should be con-
sidered in other patients as well as those with an inflam-
matory mass of the head of the pancreas or suspected
neoplasia.
Q4-3.4b: What is the indication for biliary stenting in biliary
strictures in CP?
Statement 4-3.4b. CBD strictures responsible for
symptomatic (recurrent acute cholangitis, obstructive
jaundice) or persistent (>1 month) cholestasis are indi-
cation for stenting. We suggest electing ET in patients
deemed to comply with repeat ERCPs and who are at
high surgical risk, present portal hypertension or local
abdominal conditions contraindicating surgery. An
effectual recall system should be established in order
to avoid septic complications. Resective surgery
should be considered in other patients as well as
those with an inflammatory mass of the head of the
pancreas or suspected neoplasia. (GRADE 2A, strong
agreement)
Comments. The indications for the treatment stated
above are generally accepted, with persistent cholestasis
defined as alkaline phosphatase (ALP) levels >2–3
times the upper limit of normal values lasting for
more than one month.371–373
Temporary biliary stenting, usually for one year with
regular stent exchange in the case of plastic stents, is the
mainstay of treatment. In the long-term following stent
removal, stricture resolution persists in 10–38% and
44–92% of patients following single vs multiple plastic
stenting, respectively.330 Treatment with single plastic
stents has been abandoned for this indication345 and
removable covered SEMSs have been proposed as an
alternative to multiple plastic stents, with the advantage
of requiring theoretically only two ERCP proced-
ures.374–378 The use of uncovered SEMSs for this indi-
cation should be banned because of the unavoidable
hyperplastic tissue reaction, which usually impedes
their removal.379,380
An RCT that compared six-month stenting using
multiple plastic biliary stents vs covered SEMSs for
treating CP-related biliary strictures in 60 patients
found similar results with both stent models, including
stent-related morbidity (23% vs 29%, respectively) and
success rates two years after stent removal (90% vs
92%, respectively).381 A meta-analysis of non-com-
parative studies in patients with CP-related biliary stric-
tures found higher success rates at one-year follow-up
with FC-SEMSs vs plastic stents (77% vs 33%,
p¼ 0.06) but these results should not be taken into
account as patients with single and multiple plastic
stenting were grouped, although treatment with single
plastic stents is no longer current practice.382 Economic
evaluations comparing the different treatment options
are unavailable in this setting. With the FC-SEMS, a
multicentre prospective study (127 patients with
CP-related biliary strictures) found that the stricture
had resolved in 90.5% of patients who underwent
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scheduled FC-SEMS removal, with stricture recurrence
observed in 10.5% of patients at 18-months follow-
up.383 Unfortunately, no ‘intention-to-treat’ analysis
was provided.
In patients with CP and alcohol abuse, compliance
with stent exchange may be problematic: in two series
involving 43 patients, 70% of patients had stent-related
complications (fatal in 5% of cases) because they did
not present for scheduled stent exchanges.384,385
A single comparative, retrospective study of endo-
scopic vs surgical treatment for CP-related biliary stric-
tures was identified:386 33 patients had primary ET
(35% covered SEMS and 65% multiple plastic stents,
for a mean stenting duration of 11 months) while six
patients underwent surgery. The success rate at two
years was 12% vs 65% for endoscopic and surgical
treatment, respectively. The success rate reported after
ET is highly discordant from those reported in an RCT
(12% vs 90%)381 and the authors suggested that these
extremely poor results might be related to their defin-
ition of failure that included asymptomatic ALP eleva-
tion about the upper limit of normal values.
Q4-3.5: For children, in which conditions is ET recommended?
Statement 4-3.5. In children with uncomplicated
painful CP and an obstructed MPD, we recommend
ET as the first-line treatment after failed medical ther-
apy. (GRADE 1C, agreement)
Comments. In children, CP usually presents as epi-
sodes of moderate abdominal pain.387 Compared with
adults, paediatric patients have a lower prevalence of
complications including PPC and CBD strictures.388
Three large retrospective series reported that ET
(whether or not combined with ESWL) decreases CP-
related pain in children (Supplementary Material,
Table S9).389–391 In a retrospective study that included
37 children with CP, the recurrence of a flare-up of CP
was more frequent in patients who had ERCP vs sur-
gery; however one-third of patients in the ERCP group
had diagnostic ERCP only.392 Therefore, a therapeutic
step-up strategy similar to that proposed in adults (con-
servative measures/ET/surgery) seems appropriate. The
outcome of this strategy was reported in a prospective
study that included 12 children and 32 months after
treatment (ERCP, n¼ 8; surgery, n¼ 2), all children
were free from a recurrence of pancreatitis without
impairment of everyday activities.393
With respect to procedure-related morbidity, highly
different rates have been reported in paediatric series
(the reader is referred to Oracz et al.391 for a review
of morbidity rates); however, importantly, two large
studies have suggested that morbidity rates are similar
in children compared with adults.388,394
In a common guideline issued by the ESGE and the
European Society for Paediatric Gastroenterology,
Hepatology and Nutrition, therapeutic ERCP is
strongly recommended in paediatric patients (>1
year old) for diseases amenable to endotherapy,
including CP.
Treatment of PPCs (WP8)
The decision in whom, when, and by which procedure
PPCs should be treated has been very controversial in
the past. PPCs develop as a frequent complication of
acute or CP. The prevalence of PPCs in CP lies between
20–40%.395 PPCs occur most often in patients with
alcoholic CP (70–78%),396 while the second most
common cause is idiopathic CP (6–16%). Within the
first six weeks after an acute bout of pancreatitis,
40% of pseudocysts resolve spontaneously, whilst com-
plications occur in 20% of cases indicating the need for
intervention. The spontaneous remission of pseudo-
cysts after 12 weeks is very rare, and complications
are observed in up to two-thirds of cases. An increase
in pseudocyst size to >5 cm is associated with the devel-
opment of complications. If pseudocyst formation
becomes symptomatic, then surgery, percutaneous or
endoscopic drainage can be performed. All of these
procedures demonstrate comparable results regarding
technical success and recurrence rate.396
Q4-4.1: Should pseudocysts be treated?
Statement 4-4.1. We recommend ET for those
patients with uncomplicated chronic PPCs for which
treatment is indicated and that are within endoscopic
reach. Transpapillary (TP) drainage is preferred over
transmural (TM) drainage for small (<6 cm) PPCs
communicating with the MPD in the head or body
of the pancreas, or if TM drainage is contraindicated
or not feasible. If TM pseudocyst drainage is elected:
(a) it should be performed under echoendoscopic guid-
ance if there is no luminal bulging and (b) several
double-pigtail plastic stents (not self-expandable
metal stents) should be inserted to drain the PPC
into the digestive lumen until cyst resolution with a
minimum of two months of stenting. (Grade 2A,
strong agreement)
Comments. Universally accepted indications for PPC
treatment include the presence of symptoms, complica-
tions (infection, bleeding, or rupture), or compression
of surrounding organs (gastric, duodenal or biliary
obstruction).397 Treatment of asymptomatic and
uncomplicated PPCs is not indicated, regardless of
size.398 Note, the duration and size of PPCs do not
accurately predict the probability of spontaneous
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resolution (less than 10% in a CP setting) or the devel-
opment of complications.399,400
Chronic PPCs may be drained by endoscopic, per-
cutaneous or surgical means. Percutaneous drainage
should not be performed in chronic PPCs, except in
patients who are not candidates for other
procedures.401
Q4-4.2: Which treatment modality is recommended for a
chronic pseudocyst?
Statement 4-4.2. ET is recommended for chronic
PPCs whenever possible. If TM pseudocyst drainage
is elected: (a) it should be performed under echoendo-
scopic guidance and (b) several double-pigtail plastic
stents, or self-expandable metal stents if solid debris
(walled-off pancreatic necrosis (WOPN)) is found in
the cavity, should be inserted to drain the PPC into
the digestive lumen until cyst resolution, with a min-
imum of two months of stenting. (Grade 2C, strong
agreement)
Comments. Surgical procedures for treating pseudo-
cysts tend to have higher success rates, but also have a
somewhat higher mortality than endoscopic pseudocyst
drainage into the duodenum or stomach and an inter-
disciplinary therapeutic concept is recommended.396,402
Percutaneous drainage should not be performed in
chronic PPCs, except in patients who are not candi-
dates for other procedures.401
Two endoscopic approaches have been described for
draining PPCs into the gastrointestinal lumen: TP and
TM drainage. TP drainage is feasible only in the case of
direct communication between the PPC and the MPD,
which occurs in 40–66% of all PPCs.402–404 TP and TM
drainage of PPC were compared in three non-rando-
mised studies that included 173 patients (CP was diag-
nosed in 40–92% of patients).402,405,406 Compared with
TM drainage, TP drainage was used for smaller PPCs,
was associated with lower morbidity (1.8% vs 15.4%),
and had similar long-term success.345
With respect to TM drainage, two RCTs compared
X-ray guidance alone vs X-ray guidance combined with
EUS407,408 and found a higher rate of technical success
when EUS guidance was used because it can be per-
formed even in the absence of intraluminal PPC bul-
ging, which is observed in approximately half of
cases.406 Following TM drainage, early stent removal
is associated with more PPC recurrences compared with
stent maintenance, according to an RCT (28 patients)
and a retrospective study (92 patients) that identified a
stenting duration >6 weeks and the insertion of mul-
tiple double-pigtail stents as independent predictors of
a favourable outcome.401,409 SEMS should not be used
to drain PPCs as it is more expensive and has no
advantage over plastic stents, according to a systematic
review that included 17 non-comparative studies.410
Some associated lesions may affect the strategy of
PPC treatment: If extrahepatic portal hypertension is
present, EUS-guided PPC drainage has been recom-
mended to decrease the risk of bleeding.411 This strat-
egy has not been compared with conventional TM
drainage but it has been reported to be safe in a small
series of patients.412
The success rate in a published study of 1126
patients with TM drainage of a PPC was reported as
79.2%, with more recent studies reporting success rates
significantly over 85%, which corresponds to surgical
results. The mortality rate in a series involving over 30
patients was 0.2%, the recurrence rate was reported as
7.6% and the complication rate was 12.8%.396
Q4-4.3: Is EUS guidance needed for TM drainage of
a pseudocyst?
Statement 4-4.3. TM drainage should preferably be
done under EUS guidance. (GRADE 1B, strong
agreement)
Comment. EUS is a procedure that can best assess
the appearance of the pseudocyst wall, its content, loca-
tion and relationship to adjacent blood vessels.
Therefore, endoscopic TM drainage should be per-
formed under EUS guidance to reduce the rate of
failed puncture attempts and complications.408 A
direct comparison of the complication rate for TM
needle drainage without ultrasound guidance is not
available. With respect to TM drainage, when two
RCTs compared X-ray guidance alone vs X-ray guid-
ance combined with EUS,407 they found a higher rate
of technical success when EUS guidance was used
because this can be performed even in the absence of
intraluminal PPC bulging, which is observed in
approximately half of the cases.408 If extrahepatic
portal hypertension is present, EUS-guided PPC drain-
age has been recommended to decrease the risk of
bleeding;411 this strategy has not been compared with
conventional TM drainage but it has been reported to
be safe in a small series of patients.412
Q4-4.4: When is TP drainage preferred over TM drainage
in PPCs?
Statement 4-4.4. We recommend ET for those
patients with uncomplicated chronic PPCs for which
treatment is indicated and that are within endoscopic
reach. TP drainage is preferred over TM drainage for
small (<6 cm) PPCs communicating with the MPD in
the head or body of the pancreas, or if TM drainage is
contraindicated or not feasible. If TM pseudocyst
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drainage is elected: (a) it should be performed under
echoendoscopic guidance if there is no luminal bulging
and (b) several double-pigtail plastic stents (not self-
expandable metal stents) should be inserted to drain
the PPC into the digestive lumen until cyst resolution
with a minimum of two months of stenting. (GRADE
2B, strong agreement)
Comments. Universally accepted indications for PPC
treatment include the presence of symptoms, complica-
tions (infection, bleeding or rupture), or compression of
surrounding organs (gastric, duodenal or biliary
obstruction).397 Treatment of asymptomatic and
uncomplicated PPC is not indicated, regardless of
size.398 Note, the duration and size of PPCs do not
accurately predict the probability of spontaneous reso-
lution (less than 10% in a CP setting) or the develop-
ment of complications.399,400
Chronic PPCs may be drained by endoscopic, percu-
taneous or surgical means. Percutaneous drainage
should not be performed in chronic PPC, except in
patients who are not candidates for other procedures.401
Q4-4.5: When should asymptomatic pseudocysts be treated?
Statement 4-4.5. Asymptomatic PPCs, which have
reached a size of >5 cm in diameter and which do not
resolve within 3–6 months, should be treated. (GRADE
2C, strong agreement)
Comments. PPCs which are shown to be enclosed by
a fibrous wall of >5mm on imaging, are particularly
suited for endoscopic or surgical drainage. Gouyon
et al. were able to show, in a multivariate analysis,
that a pseudocyst size <4 cm is the only prognostically
favourable factor for spontaneous resolution,413 while
untreated cysts >5 cm result in complications (rupture,
infection, jaundice or haemorrhage) in 41% of cases.414
This was confirmed in a prospective case series in which
up to 67% of patients with a PPC still present six
months after the diagnosis of PPC suffered from
nausea, vomiting and intense pain.415
With respect to the timing of PPC drainage, no com-
parative study is available and we suggest the following:
if no recent episode of acute pancreatitis has been iden-
tified, PPC that are thought to be the main cause of
pain or complications should be drained promptly as
the spontaneous resolution of PPC is uncommon and is
observed mostly for small (<3 cm) intrapancreatic col-
lections with a long follow-up;413 if a recent episode of
acute pancreatitis has been identified, or if the PPC was
not detected on prior examination, the PPC should be
observed for up to six weeks to allow for either spon-
taneous resolution or maturation of the cyst wall;416
MRI and/or EUS should be performed to distinguish
between an acute effusion or collection (with or without
necrosis) and a previously undiagnosed chronic
collection.
Q4-4.6: What is the role of fine needle aspiration of cystic
lesions?
Statement 4-4.6. Diagnostic needle aspiration of a
cyst may be performed for suspected infected cystic
contents or for suspected neoplasm. (GRADE 2C,
strong agreement)
Comments. If diagnostic needle aspiration of the cyst
confirms an infection of the contents, then drainage of
the pseudocyst is indicated. Surgical resection should be
carried out if malignancy is detected. In summary: If
EUS-guided needle aspiration of a cyst reveals a carci-
noembryonic antigen (CEA) level >400 ng/ml, a vari-
ably increased or low amylase (lipase) level, high
viscosity, mucin or epithelial cells in the cyst contents,
then the presence of a mucinous neoplasm must be
assumed. It is then usually a mucinous cystic neoplasm
(MCN), which is more prevalent in women aged
between 30–50 years of age, is located usually in the
pancreatic tail and demonstrates mural nodules on ima-
ging. In this situation, the so-called eggshell pattern of
calcification is typical. Prognosis after surgery is good
in the presence of non-invasive growth. If, however,
invasive growth is confirmed, then the average survival
is 45 months.417
Aspiration biopsy of an MCN differs very little
from an IPMN; which is regarded as a precancerous
lesion. Its malignant potential depends on its location
(main duct or side branch duct) and the size of the
lesion as well as its solid parts. An IPMN originating
from the main pancreatic duct should always be
resected because in 52–92% of cases a carcinoma
will develop from this lesion within a period of eight
years. For lesions of the side branch duct this amounts
to 6–46%.417 Those lesions <1 cm on MRI or EUS
and originating from a side branch duct may be fol-
lowed-up by imaging after one year. Side-branch
lesions, which are between 1–3 cm in size and exhibit
no solid components, should be followed up after six
months. On the other hand, lesions that are >3 cm or
exhibit mural nodules or cytology with higher-grade
dysplasia must be resected. Serous cystadenoma is
diagnosed as pancreatitis in 30% of cystic lesions
and virtually never turns malignant. In this case,
aspiration of the cyst is negative for mucin, CEA
and amylase and the cytology reveals glycogen-rich
epithelium. Direct SpyGlass pancreatoscopy with
related techniques (biopsy, confocal laser microscopy)
may increase diagnostic accuracy in selected cases to
determine small or focal dysplasias.418,419
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Q4-4.7: What is the indication for surgery of cystic lesions?
Statement 4-4.7. A surgical approach should be
chosen for a suspected malignant cystic lesion.
(GRADE 1C, strong agreement)
Comments. In 2–3% of all CT scans of the abdomen,
a cystic lesion of the pancreas is discovered as an inci-
dental finding,420 while with MRI, it can be up to 10%.
More than two-thirds of these lesions are dysontoge-
netic cysts or PPCs. The prevalence of PPCs in CP lies
between 20–40%, and of the cystic lesions which are
not PPCs but genuine cystic neoplasms, 30% are
benign serous cystadenomas, 45% of the resected
lesions are MCNs and 25% are IPMNs. Solid pseudo-
papillary tumours or cystic acinic cell carcinoma are
less frequently encountered. For a classification of the
differential diagnosis of cystic tumours in asymptom-
atic patients, the question of connection to the pancre-
atic duct (IPMN and PPC) and the size of the cystic
lesion (indication for resection in the case of IPMN or
therapeutic indication for pseudocysts) is essential.421 A
short MR protocol may be used.422 Diagnostic needle
aspiration of a pseudocyst with the aid of EUS helps in
differentiating between premalignant cystic neoplasms,
cystic malignancies and pseudocysts. There is an urgent
indication for surgery if malignancy is suspected, given
that healing can be achieved in this situation with a five-
year survival rate of 63% after resection of a malignant
tumour.396,423,424
Q4-4.8: What is the role of non-invasive duct visualisation
for PPC?
Statement 4-4.8. Visualisation of the pancreatic duct
can be performed before endoscopic or surgical drain-
age of the pseudocyst. (GRADE 2B, strong agreement)
Comments. Whether an attempt to drain the pseudo-
cyst via the papilla should be performed using ERCP
before transgastric or transduodenal pseudocyst drain-
age is still a matter of controversy. On the one hand,
drainage of the pseudocyst via a stent in the pancreatic
duct is the ‘most physiological’ form of drainage.
Depending on the study, 22–57% of PPC have a con-
nection with the pancreatic ductal system.425 Based on
current data, endoscopic retrograde pancreatography
(ERP) can precede endoscopic TM drainage in order
to detect a connection with the duct or to exclude rup-
ture of the pancreatic duct (8% after acute necrotising
pancreatitis). If a complete MPD rupture is present, TP
stent placement upstream from the rupture should be
attempted.426,427 This has been shown to improve the
success of TM PPC drainage in a retrospective series.428
If the MPD rupture cannot be bridged, TM stents
should be left in place for as long as the disconnected
pancreatic tail secretes pancreatic juice (typically, for
years).426 In a retrospective series of 29 patients,
removal of TM stents after PPC resolution led to
PPC recurrence in half the cases.429 TM drainage in
the presence of an undetected rupture of the pancreatic
duct or a connection of the PPC with an obstructed
pancreatic duct is less promising with regard to a suc-
cessful long-term therapeutic outcome. The success rate
of attempted TP drainage reaches a maximum of
60%.402 Peri-interventional antibiotic prophylaxis
before ERCP is indispensable if PPC are suspected or
if they are the indication for ERCP or ERP. Without
antibiotic prophylaxis, the examination-related inci-
dence of infected pseudocysts and pancreatic abscesses
after ERCP increases.430
Q4-4.9: What are the roles of duct changes and pancreatic
duct stones in the presence of a PPC?
Statement 4-4.9. In the presence of pancreatic duct
stones, a pseudocyst should be treated as part of an
overall therapeutic concept. (GRADE 1B, moderate
agreement)
Comments. A relative indication for treating pancre-
atic cysts is the presence of CP with pancreatic duct
anomalies or pancreatic ductal stones, because in this
situation the rate of spontaneous resolution, even for
small cysts, is a maximum of 10–26% due to the con-
stant inflammatory stimulus.402
Q4-4.10: When should pancreatic stenting be performed?
Statement 4-4.10. ET of pancreatic duct obstruction
can be undertaken in patients with a PPC, prestenotic
duct dilatation or fistula formation. (GRADE 2C,
strong agreement)
Comments. PPCs are maintained by pancreatic duct
obstruction in the presence of prestenotic duct dilata-
tions or fistulae if these stenoses represent a blockage to
drainage. In such cases, treatment of the pancreatic
duct obstruction is recommended.
Q4-4.11a: Do vascular pseudoaneurysms warrant treatment?
Statement 4-4.11a. Vascular pseudoaneurysms that
develop secondary to CP should be treated. (GRADE
1C, strong agreement)
Comments. There are no comparative studies avail-
able that compare the active treatment of vascular
pseudoaneurysms with mere observation. Nor are
there studies examining the best moment for the
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treatment of vascular pseudoaneurysms at different
time points.
Q4-4.11b: What is the method of choice for the treatment of
vascular pseudoaneurysms?
Statement 4-4.11b. Angiographic embolisation is the
method of choice for haemorrhagic pseudoaneurysms.
(GRADE 1C, strong agreement)
Comments. If a pseudoaneurysm is detected in the
vicinity of the PPC, selective angiographic embolisation
prior to any attempt at PPC drainage should be con-
sidered because haemorrhages associated with a PPC
carry a high mortality.431,432 Surgery should be reserved
as a second-line treatment when embolisation does not
resolve the bleeding.433–435
There is a systematic review of case series and case
reports available on this issue.433 In this assessment, the
success rate of angiographic treatment was 66%. The
complication rate is less than that for surgical treatment
and was associated with a shorter hospital stay. Surgery
should remain reserved for patients not bleeding
acutely and in a good general condition, in whom an
operation is also indicated for other CP complications.
Q4-4.12: What is the minimal follow-up time before endo-
scopic intervention in PPC after an acute episode of CP?
Statement 4-4.12. In the presence of a recent episode
of acute pancreatitis or if the PPC was not detected on
prior examinations, the PPC should be observed for at
least six weeks to allow for either spontaneous reso-
lution or maturation of the cyst wall.416 (GRADE 1B,
strong agreement)
Comments. MRI and/or EUS should be performed to
distinguish an acute effusion or fluid collection, with or
without necrosis, from a previously undiagnosed
chronic fluid collection. Timing in the case of necrosis
due to acute-on-CP should be similar to what is advised
in acute pancreatitis: for patients with proven or sus-
pected infected necrotising pancreatitis, invasive inter-
vention should be delayed where possible until at least
four weeks after the initial presentation to allow the
collection to become ‘walled-off’.436 EUS and MRI
are the most useful techniques for assessing the presence
of debris within walled-off pancreatic necrosis.437,438
Pancreatic pain (WP9)
Q5-1: What is the natural history of pain in CP?
Statement 5-1.1. Pain is the first presentation of CP in
the majority of patients. (GRADE 1B, strong agreement)
Comments. Pain is the most disabling and dominant
symptom in patients with CP. Even though some stu-
dies have found that a substantial proportion (5–50%)
of patients do not report pain, most recent studies
reveal that intermittent or constant pain of varying
severity is present in most patients.439–442 In a recent
study exploring the pain pattern in 106 patients with
CP, only 6% were pain-free.443 The origin of the pain is
not fully understood but is likely to be multifactorial
and therefore the first appearance of pain can vary con-
siderably.444 Pain was previously believed to be a result
of structural changes in the gland such as duct strictures
and stones with local tissue hypertension.445,446
Although this may be true in selected patients and in
the early phase of the disease, the pain quickly becomes
more ‘neurogenic’ where there is evidence of massive
changes in the pancreatic nerves.447 As a consequence
of these peripheral changes, the central nervous system
becomes sensitised and a range of persistent neuroplas-
tic changes takes place. Hence, it has been suggested
that pain probably has a neuropathic origin in
CP.443,448,449 Thus there may be an evolution of the
pain pattern over time from the initial stages, which
are dominated by ‘true visceral pain’ to a neuro-
pathic-like pain with irreversible central sensitisation.
However, this hypothesis requires confirmation from
observational studies.
Statement 5-1.2. There is no evidence that pain symp-
toms ‘burn out’ in all patients with ongoing CP.
(GRADE 2C, moderate agreement)
Comments. It has been hypothesised that, due to
ongoing inflammation, pancreatic parenchymal
destruction will eventually lead to a decrease in pain
symptoms (‘burn-out’), especially in patients with alco-
holic CP.439 While some studies have reported a
decrease in pain symptoms after follow-up, others
have shown the opposite. For example, in patients
with alcoholic CP, a pain-free period of at least two
years was seen in 50% of CP patients within six
years, and in 80% of patients within 10 years after
the first documented episode of pancreatitis. In non-
alcoholic CP the pain-free period occurred in around
30% of patients within six years of the first documented
episode of pancreatitis.439,450 While in another study,
relief or improvement of pain in up to 73% of the
patients was seen in a follow-up of >5 years.440
In patients with idiopathic and alcoholic CP, pain
decreased or disappeared in 64–77% of patients over a
median follow-up period of 12–25 years.205 There is
little difference in subgroups of patients with (67–
74%) and without (56–79%) pancreatic surgery.205
However, other studies have reported an incidence of
relapsing pain attacks in 50% of alcoholic CP patients
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and 38% of non-alcoholic CP patients after a follow-up
of >10 years, with little difference in the course of pain
between the two groups.451 However, more recent stu-
dies have not reproduced these findings and have found
that pain does not resolve over time in most patients.442
Statement 5-1.3. There is no convincing evidence that
endocrine and exocrine pancreatic insufficiencies are
associated with pain relief. (GRADE 2C, moderate
agreement)
Comments. Endocrine and exocrine pancreatic insuf-
ficiencies have been associated with pain relief. Studies
have reported that patients who became pain-free had
greater pancreatic insufficiency than patients with pain.
One study reported that the incidence of endocrine and
exocrine insufficiency was approximately 20% and 55%
at six years and 50% and 80% at 10 years from onset,
respectively.450 Others have found differences in pan-
creatic insufficiency in patients with CP, for example,
31% painless vs 3% painful CP.452 However, other
studies have reported that the development of pancre-
atic insufficiency did not significantly influence the
course of pain, in which 54% (alcoholic CP) and 73%
(non-alcoholic CP) of patients still had pain attacks,
despite PEI.205,451
There are only a few studies relating to this topic,
often with different patient selection criteria, different
measurements of pancreatic function, and different def-
initions of pain and painlessness as well as mixed
groups of patients with, and without, intervention (sur-
gery and endoscopy).
Q5-2: Does pain influence quality of life in patients with CP?
Statement 5-2. Pain intensity and the pain pattern
over time (constant vs intermittent pain) have been
shown to reduce QoL in patients with CP. (GRADE
1A, strong agreement)
Comment. Both a high pain intensity and constant
pain, as compared to intermittent pain, have been
shown to reduce QoL in patients with CP and are asso-
ciated with greater rates of disability and health
resource utilisation.10,442,453
Q5-3: Which type(s) and causes of pain should be
investigated in CP?
Statement 5-3. Pancreatic and extra-pancreatic com-
plications may contribute to pain in the individual
patient and should be thoroughly investigated at the
time of diagnosis and if pain symptoms are worsening.
(GRADE 1B, strong agreement)
Comments. The mechanisms underlying pain in CP
are complex and highly variable between patients. A
number of pancreatic and extra-pancreatic causes of
pain should be thoroughly investigated and treated.
Peptic ulcers, gastrointestinal cancers and other comor-
bidities are reported to have an increased prevalence in
CP.74 In addition, pseudocysts and obstruction of the
duodenum or CBD are important sources of pain and
should be investigated with an appropriate radiological
work-up and then treated accordingly.444
The presence of pancreatic pathologies, such as pan-
creatic duct stones and strictures as well as inflamma-
tory masses of the pancreatic head are considered by
most clinicians as important sources of pain and com-
prise the basis for invasive treatments. These include
endoscopic stone removal, pancreatic duct dilatation
and stenting, as well as surgical resections and drainage
procedures.454 There is, however, no direct relationship
between pancreatic morphology and pain symptoms.455
In a large group of patients no clear source of pain is
identifiable and many of these patients, commonly
labelled as ‘minimal change CP’, may suffer from
neurogenic pain.446 Finally, adverse effects in response
to medical treatment such as opioid-induced bowel syn-
drome as well as endoscopic and surgical complications
may contribute to pain in a subset of patients.456
Q5-4: How should pain in CP be assessed?
Statement 5-4. Pain in CP should be assessed using a
multidimensional approach, including evaluation of
pain intensity, pain pattern and its impact on daily
function and QoL. (GRADE 1B, strong agreement)
Comments. Pain is complex, thus a multidimensional
approach is recommended for pain assessment and to
document treatment effects. In addition to pain inten-
sity, which is the only outcome reported in most previ-
ous studies, pain pattern over time, functional
impairment and QoL should also be documented to
capture the different aspects of pain.457
Pain intensity should be documented using a numer-
ical scale, such as the visual analogue scale (VAS).
Additionally, the pain pattern over time (constant vs
intermittent pain),) and the frequency of pain exacer-
bations should be characterised.442,453 Various ques-
tionnaires have been used to evaluate the impact of
pain on patients’ QoL, but only the European
Organisation for Research and Treatment of Cancer
(EORTC) QLQ-C30 questionnaire has been formally
validated for CP.458 The Izbicki pain score has been
developed to capture some of the aforementioned
dimensions of pain and provides a surrogate score
based on the pain attack frequency, pain intensity
score (VAS), analgesic use, and duration of
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disease-related inability to work.261 However, it has,
never been strictly validated in patients with CP.
Q5-5: Does cessation of smoking and alcohol influence pain
in CP?
Statement 5-5. Cessation of alcohol, and possibly
smoking, improves pain in CP. (GRADE 1B, moderate
agreement)
Comments. Cessation of alcohol has beneficial effects
on disease progression and pain in patients with alco-
holic CP.459,460 In addition, increasing evidence
suggests that tobacco use is an important and inde-
pendent risk factor for CP and that cigarette smoking
accelerates disease progression.28,461 Hence, tobacco
cessation is highly recommended, although an associ-
ation between smoking and CP pain has yet to be
determined.
Q5-6: Does pancreatic enzyme supplementation influence
pain in CP?
Statement 5-6. Pancreatic enzyme supplementation is
not recommended for pain treatment in CP. (GRADE
1B, moderate agreement)
Comments. Pancreatic enzyme therapy for pain con-
trol in CP has been the subject of several randomised
trials. Only non-enteric coated enzyme formulations
have documented improvement in pain, while enteric-
coated preparations have not shown any effects.462 A
meta-analysis combining all studies found no effect of
enzymes on pain relief in CP.463 Nevertheless, combin-
ing the two types of enzyme formulations in a meta-
analysis is probably not appropriate given their diverse
mechanisms of action.464 At present, pancreatic enzyme
supplementation is not recommended for pain relief in
CP, although it may have beneficial effects on abdom-
inal discomfort related to PEI (e.g. gas and bloating).
Q5-7: Does treatment with antioxidants influence pain in CP?
Statement 5-7. Antioxidants are not recommended
for pain treatment in CP. (GRADE 1B, moderate
agreement)
Comments. Antioxidant therapy was associated with
significant and prolonged pain relief in a randomised
placebo-controlled trial from India,465 but the findings
were not reproduced in a subsequent study from North
America.466 A possible explanation for this dichotomy
may relate to differences in study populations; while the
Indian study mostly included patients with trophic cal-
cifying pancreatitis and malnutrition (and hence
deficiency in antioxidants), the American study
included a more elderly population who had alcohol
as the leading aetiology of CP and a normal nutritional
condition. Hence, the efficacy of antioxidant therapy
may be related to the aetiology of CP and its associated
malnutrition.467 A recent Cochrane analysis concluded
that: ‘the current evidence shows that antioxidants can
reduce pain slightly in patients with CP. The clinical
relevance of this small reduction is uncertain, and
more evidence is needed’.468 Taken together, the evi-
dence is not sufficient to recommend that antioxidant
therapy be used routinely for the typical Western CP
patient with alcoholic pancreatitis.
Q5-8: Which analgesics are recommended for pain in CP?
Statement 5-8. The standard guideline for medical
analgesic therapy in CP follows the principles of the
‘pain relief ladder’ provided by the World Health
Organization (WHO). (GRADE 1B, strong agreement)
Comments. The WHO ‘pain relief ladder’ was intro-
duced for the treatment of cancer-related pain (not
chronic pain). The principle is based on the sequential
introduction of drugs with increasing analgesic
potency, titrated until pain relief is obtained.469
Paracetamol is the preferred level I analgesic due to
its limited side effects, while non-steroidal anti-inflam-
matory drugs (NSAIDs) should be avoided due to their
gastrointestinal toxicity.470 If necessary, PPIs should be
used in patients with CP who are at high risk of
developing peptic ulcers.
Tramadol is the preferred level II analgesic and was
shown to be superior to morphine in patients with CP,
with fewer gastrointestinal side effects for the same level
of analgesia.471 Although speculative, this may relate to
the many peripheral and central actions of this drug as
compared to traditional opioids.
Level III analgesia comprises the group of strong
opioids, such as morphine, which are widely used for
pain relief in CP. The potential for dependency and side
effects is high, but unfortunately no other strong anal-
gesics are available. Opioid treatment can be challen-
ging in this patient group, as the tendency to addiction
may be strong in the subset of patients with alcohol-
induced pancreatitis. Furthermore, the metabolism of
many opioids is dependent on a preserved liver and gut
function, which may not be the case in many
patients.472 Although not especially documented in
this patient group, there are major differences in the
positive and negative effects of opioids. However,
animal and human studies suggest that some drugs,
such as oxycodone, may be more efficacious for the
attenuation of visceral pain, including pain in
CP.473–475 This should also be taken into consideration,
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as some patients who may not tolerate one opioid find
effective pain relief with another. This rational for
opioid rotation may be advantageous in difficult
patients.472
The indication for opioid therapy follows the usual
guidelines and varies somewhat between countries; for
a comprehensive review the reader is referred to the
following website: http://americanpainsociety.org/
uploads/education/guidelines/chronic-opioid-therapy-
cncp.pdf. In general the lowest possible dose should be
used and the drug should always be taken orally to
avoid dose escalation and addiction. Note, in many
patients (up to 50% of chronic pain patients in gen-
eral) opioids do not alleviate pain and treatment
should be stopped. Transdermal administration of
opioids is not recommended as first-line opioid ther-
apy, and should be reserved for patients having trou-
ble with tablet ingestion and where malabsorption is
suspected.476 The clinician should also be aware that
opioid-induced bowel dysfunction may lead not only
to constipation, but to a variety of symptoms such as
reflux, gas and abdominal distension, which can them-
selves be painful.477 Hence, the tapering of opioids or
opioid antagonists with local effects on the gut may
improve pain and associated symptoms.444 Finally, it
has been estimated that up to 5% of patients undergo-
ing opioid therapy may develop ‘narcotic bowel syn-
drome,’ which is a paradoxical increase in abdominal
pain when the opioid dose is increased.478 This corres-
ponds to opioid-induced hyperalgesia of the somatic
tissues and the only treatment is tapering of the
opioids.
Adjuvant analgesics are a heterogeneous group of
drugs initially developed for indications other than
pain and include antidepressants, anticonvulsants
(including gabapentinoids) and anxiolytics. Although
adjuvant analgesics have been widely used in the
clinic to treat pain in CP, only the gabapentinoid,
pregabalin, has been investigated in a placebo-con-
trolled randomised trial and was found to induce
moderate pain relief with relatively limited side
effects.443 However, in selected patients anti-depres-
sive drugs in low doses may be recommended, and
in particular, drugs with serotonin–noradrenaline
reuptake inhibition may be preferred due to the
reduced adverse effect profile. In patients with a
severe and debilitating pain pattern, a more aggres-
sive top-down approach, using opioids combined with
adjuvant analgesics as first line therapy, is recom-
mended to control pain.462
Q5-9: Is endoscopic treatment effective for pain in CP?.
Statement 5-9.1. ET is effective in patients with an
obstructive type of pancreatic pain and in patients
with a pancreatic duct dilatation. (GRADE 2C, moder-
ate agreement)
Statement 5-9.2. ET could be useful as a bridge to
surgery. (GRADE 1B, moderate agreement)
Statement 5-9.3. Endoscopic drainage treatment is
less effective and has a shorter-term effect compared
with surgery. (GRADE 1B, moderate agreement)
Comments. Overall, surgical procedures may be more
effective in ameliorating pain in CP247–249
(Supplementary Material, Table S10). According to the
ESGE guidelines,345 the German S3 guidelines,4 Spanish
Pancreatic Club recommendations,8,9 the Belgian con-
sensus on CP,3 Italian consensus guidelines for CP6
and other publications, ET for painful CP is indicated
in patients with an obstructive form of CP due to stric-
tures and intraductal stones.325,353,479 The aim of this
therapy is decompression of an obstructed main pancre-
atic duct. However, as in surgery, all studies have used
historic controls, have compared different active treat-
ments, or have some other methodological draw-
backs.247,248 Hence, neither the natural history of the
disease nor the strong placebo effects associated with
invasive procedures are taken into consideration,480,481
which limits the generalisation of the studies.
With these limitations in mind, ET proved to be
effective after short-term follow-up in patients with
obstructive types of painful disease as it decreased the
numbers of hospitalisations for pancreatic pain and
reduced the intake of analgesics.249 Therefore, ET
could be recommended as a first choice therapy in
patients with obstructive CP and could serve as a
bridge in situations, when surgical therapy is indicated
and will follow eventually.
Q5-10: Is ESWL an effective approach for pain treatment in CP?
Statement 5-10.1. ESWL therapy is effective for dis-
integrating stones in the main pancreatic duct.
(GRADE 2C, weak agreement)
Statement 5-10.2. ESWL provides pain relief in
patients with CP. (GRADE 2B, no agreement)
Comments. ESWL therapy in painful CP is indicated
when the stone obstructs the main pancreatic duct,
when endoscopic extraction of the stone is limited by
the size and location of the stone and by the presence of
an MPD stricture.345 ESWL stone fragmentation has
the potential to clear the pancreatic duct and restore
pancreatic duct flow.344
ESWL therapy and its effects have been documented
in several studies.329 In one randomised study
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comparing ESWL alone versus ESWL combined with
endoscopy, no significant differences were found.325 In
other studies, ESWL þ endoscopy was found to be
better than ESWL alone for the prevention of pain482
(Supplementary Material, Table S10). However, the
long-term effects of ESWL therapy depend on the cor-
rect indications for stone dissolution: ESWL therapy
alone can be effective if the stone size is >5mm, the
stone is located in the head or pancreatic body, and
there are no strictures of the main pancreatic duct.343
However, for large stones with pancreatic duct stric-
ture, ESWL should be combined with endoscopic
therapy.
Q5-11: Are other treatments effective in selected cases of
painful CP?
Statement 5-11. Treatments such as EUS-guided
plexus block, splanchnic nerve block, spinal cord stimu-
lation, transcranial magnetic stimulation and acupunc-
ture may be effective in selected cases of painful CP.
(GRADE 1C, moderate agreement)
Comments. A percutaneous coeliac plexus block has
been successfully used for the treatment of pancreatic
cancer pain in patients with a short life expectancy, but
it has been disputed for CP. Compared to the posterior
blind approach used previously, EUS-guided, trans-
gastric coeliac plexus blocks are considered safer with
respect to serious complications like paraplegia and
pneumothorax.483 Local anaesthetics are used, as neu-
rodestructive methods with alcohol or phenol are con-
traindicated due to the high risk of severe
deafferentation syndromes. Studies have shown
improvements in pain and decreased opioid consump-
tion for a limited period of time. However, the use of
EUS-guided coeliac plexus blocks cannot be recom-
mended as routine therapy for pain in CP since only
one-half of the patients experience pain reduction.
Furthermore, the beneficial effect tends to be short-
lived, as <10% experience pain relief for >24
weeks.484 Typical adverse effects to EUS-guided ther-
apy are the transient worsening of pain, as well as diar-
rhoea and hypotension due to the unopposed
parasympathetic activity reported in about 40% of
the patients.485
Other methods for blocking pain transmission are
radiofrequency and transthoracic splanchnic block.
After a diagnostic block with a local anaesthetic, radio-
frequency lesions at the Th11 and Th12 level may result
in pain relief.486 Transthoracic splanchnicectomy is also
reported to decrease pain frequency and intensity as
well as opioid consumption. A recent review including
16 studies and 484 patients concluded that 62% of all
patients were responding (regarded as successful), and
opioid use dropped from 85% to 49% of patients at
follow-up after a mean of 21 months.487 However, most
patients were still suffering from pain, and no studies
included a sham group. With an expected placebo
response of 30%,488 the data do not support the general
use of splanchnicectomy in CP, but it may be indicated
in selected patients where conventional pain therapy is
not effective.
Intrathecal morphine therapy via continuous infu-
sion pumps has been described in case series with
good analgesic results.489 Radiation therapy to the pan-
creas has also been studied as a treatment for CP
pain.490 In the most recent study, a single dose of
8Gy resulted in a complete absence of symptoms in
13 out of 15 patients.491 However, the studies need to
be replicated in a controlled situation before the meth-
ods can be recommended in clinical practice.
Spinal cord stimulation via epidural lead placement
at the T6–T7 level has been shown to alleviate various
kinds of visceral pain including pain in CP.492
However, the effect in CP still needs to be documented
in controlled studies. Transcranial magnetic stimula-
tion is a non-invasive technique that has also been
used to treat chronic pain of various origins. In a
sham-controlled study it was shown to relieve pain
associated with CP.493 Although considered a phase
II study, the findings are interesting as there were
almost no adverse effects. Therefore, both spinal
cord stimulation and transcranial magnetic stimula-
tion may be used in selected centres with sufficient
expertise, but data are still preliminary and call for
further studies.
There are only a few studies available where ‘real’
acupuncture has been compared to ‘placebo acupunc-
ture’. An older study showed no effect of electro-acu-
puncture and transcutaneous electrical nerve
stimulation in CP, although pain relief, as measured
on a VAS, was significantly better in the active acu-
puncture arm.494 However, the study was flawed, as
the placebo arm was not sufficiently blinded. Recent
studies where an improved sham methodology was
used showed that electro-acupuncture was superior in
the treatment of postsurgical pain and therefore an
effect on painful CP should also be expected.495 As acu-
puncture is virtually harmless and without side effects it
may be an interesting topic for further research and
could be useful in selected patients.
Q5-12: What is the optimal surgical approach for alleviating
pain in CP?
Statement 5-12. Resection, decompression or mixed
surgical techniques achieve pain relief that is main-
tained over time in approximately 80% of patients.
However, as studies are not sham-controlled the effect
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of surgery is still debatable. (GRADE 1B, strong
agreement)
Comments. Surgery in patients with CP may be indi-
cated for relieving pain. The rationale being that pain
may be caused by increased intraductal and/or paren-
chymal pressure caused by decreased drainage of pan-
creatic juice into the duodenum, or by the release of
inflammatory mediators from masses usually located
in the head of the pancreas. However, recent literature
(Supplementary Material, Table S10) does not support
the contention that the micro/macrostructural changes
of the pancreas are exclusively related to the pain, and
in many patients other mechanisms, such as nerve
damage, seem to play a role.446,455,496,497
Furthermore, as for endoscopy, all surgical studies
have compared different procedures and have not been
sham-controlled. Hence, the natural course of the dis-
ease and any placebo effects have not been taken into
consideration. On the other hand, the very high efficacy
for pain relief in many series (up to 90%) points
towards an effect in selected patients. In many countries
invasive treatment is recommended in patients where
pain cannot be controlled without the use of strong
opioids, which carry a risk of adverse effects and addic-
tion. Although opioid treatment may result in bowel
dysfunction that may be painful per se, the rationale
for this surgical indication is not clear as the so-called
weak opioids and adjuvant therapies may also be
addictive and in some patients cause similar or even
worse adverse effects.498 Different studies have com-
pared surgical procedures vs ET for pain in CP and
most have documented substantial pain relief in
patients undergoing both derivative and resective oper-
ations.247,249,255,257,258,264,499 Moreover, two of these
studies showed a significant benefit of surgery over
ET for pain control in patients with pancreatic duct
obstruction.247,249 Along these lines, an observational
study documented that invasive-based treatments
(endotherapy and/or surgery) were superior to a con-
servative (medical) treatment approach.479 Taken
together, surgery may be an option for treatment of
painful CP, but the evidence for its indication and
timing is limited.
Surgical options for pain are classified into three
categories: (a) decompression (focusing on ductal
hypertension), (b) resection (focusing on inflammatory
masses in the pancreatic head), and (c) mixed tech-
niques (see section 4.1.7).
a. Decompression techniques have been recommended
in patients with a dilated MPD (>7–8mm)500 and
no inflammatory mass. This constitutes a rather
simple procedure with a low risk of postoperative
complications and of exocrine and endocrine
insufficiency. It provides pain relief in 66%–91%
of patients with a low morbidity (20%) and mortal-
ity (2%).247 However, the long-term results show
that up to 50% of patients experience a recurrence
of pain.501
b. Resection is indicated in patients with an inflamma-
tory mass or post-obstructive CP affecting the pan-
creatic body or tail502,503 and is partly based on the
belief that the pancreatic head is a ‘pacemaker’ for
the pain. Pancreaticoduodenectomy has demon-
strated long-term pain relief in about 75% of
patients,504 although long-term postoperative mor-
bidity is significant, involving up to 20% of cases,262
and most authors favour the more conservative
mixed techniques with resection and drainage
procedures.
c. Mixed techniques are based on the removal of the
inflammatory mass in the pancreatic head and
drainage of the obstructed pancreatic region
(body and tail). The most widely used techniques
are the duodenal preservation (Beger) technique or
the Frey method, which involves the coring out of
the pancreatic head associated with a longitudinal
pancreaticojejunostomy.505 Here, the duodenum
and intrapancreatic bile duct remain preserved,
with advantages for post-operative nutritional
status, pancreatic exocrine function, delayed gastric
emptying and QoL. In RCTs, mixed interventions
have shown short-term pain relief in 70–100% of
patients and long-term pain relief in 82–
100%.264,268
Other surgical procedures that may be useful in small
duct disease without an inflammatory mass include a
longitudinal V-shaped excision of the ventral aspect of
the pancreas combined with a longitudinal pancreatico-
jejunostomy.256 Total pancreatectomy with islet trans-
plantation is the most aggressive surgical approach, but
has poor evidence and obvious selection bias, and there
is no prospective randomised study comparing total
pancreatectomy with other surgical treatments. Insulin
independence rates are substantial (around 50%) at five
years, but case series have shown a reduction in mor-
phine requirements and improved QoL.506 However,
total pancreatectomy is seldom performed in Europe
mainly due to the long-term complications and a recur-
rence of pain in many cases. Other, less common indi-
cations for surgery are complications that unequivocally
require a surgical approach, such as pseudocysts and the
involvement of the biliary tree and duodenum.
In conclusion, resection, decompression or mixed
techniques achieve pain relief that is maintained over
time in approximately 80% of patients, but drainage
surgery in combination with limited duodenum-
preserving pancreatic head resection appears to be
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the best surgical strategy. Surgery is in most cases
superior to endoscopy but correct patient selection
in a multidisciplinary approach and appropriate
timing for referral to surgery are key to a successful
outcome.507
Nutrition and malnutrition (WP10)
Q6-1: What is the risk of developing malnutrition in CP and
what are the causes of malnutrition?
Statement 6-1.1. Malnutrition is common among
patients with CP. (GRADE 2B, strong agreement)
Statement 6-1.2. PEI, anorexia secondary to abdom-
inal pain, nausea and vomiting, alcohol and other sub-
stance abuse and diabetes mellitus may all contribute to
malnutrition in patients with CP. (GRADE 2C, strong
agreement)
Comments. Malnutrition can be defined as ‘a state
resulting from lack of uptake or intake of nutrition
leading to altered body composition (decreased fat-
free mass) and body cell mass leading to diminished
physical and mental function and impaired clinical out-
come from disease’.508,509 The European Society of
Clinical Nutrition and Metabolism (ESPEN) has
recently suggested that diagnostic criteria for malnutri-
tion should be a body mass index (BMI)< 18.5 kg/m2
or unintentional weight loss (>10% regardless of time
or >5% over three months), combined with either a
low BMI (<20 kg/m2 if <70 years of age or <22 kg/
m2 if >70 years of age) or a free-fat mass index
(FFMI) <15 kg/m2 in women and <17 kg/m2 in
men.508 However, malnutrition exists in many forms
and sarcopaenia and deficiencies of specific nutrients
frequently occur despite the absence of weight loss or
an abnormally low BMI.
Nutritional status based on anthropometric meas-
urements and biochemical analysis of different micro-
and macronutrients has been investigated in patients
with CP in several studies but definitions have been
inconsistent. Therefore, it is impossible to give a com-
pound estimate of the prevalence of malnutrition in CP.
It has been repeatedly demonstrated that patients with
CP have lower BMI than controls. The prevalence of
being underweight in CP patient series differs from
8–39%510–515 with a higher prevalence rate reported
in studies from India. Weight loss among patients
with CP appears to be common and has been observed
in 20%512 and 49%516 of cases. However, the number
of studies of the prevalence of low BMI and/or weight
loss in CP is low.
Studies investigating deficiencies of different lipid-
soluble vitamins have reported prevalence rates of
1–16% for vitamin A deficiency,517–521 33–87% for
vitamin D deficiency,518–521 2–27% for vitamin E defi-
ciency519–522 and 13–63% for vitamin K deficiency.
There is significant heterogeneity between studies,
which are of variable quality, as well as differences in
measurement techniques and ranges. Whilst biochem-
ical deficiency of the fat-soluble vitamins appears to be
reasonably common, clinical manifestations of defi-
ciency in CP are rare, take years to develop, and
occur when there is an additional co-morbidity such
as diabetes, celiac disease or after surgery.
Deficiencies of water-soluble vitamins in CP are less
frequent but studies are scarce;243 however, the risk of
thiamine deficiency secondary to concomitant alcohol-
ism has to be considered. Serum concentrations below
normal values of different plasma proteins is another
finding that has been used as a marker for malnutrition
and PEI in patients with CP. Low levels of plasma pro-
teins are an infrequent finding in patients on PERT
treatment included in RCTs,296,511 but higher preva-
lence rates have been reported from observational stu-
dies with low levels of albumin, prealbumin/
transthyretin and retinol-binding protein in the ranges
of 6–30%,244,523,524 12–37%244,288,523 and 12–68%,244,288
respectively. Minerals and trace elements have also been
investigated in CP in case-control studies with partially
conflicting results.243 Lower levels of zinc, selenium525
and magnesium244 have been observed in some,244,525
but not all, studies comparing CP patients with controls.
However, despite differences demonstrated at group
level, most patients with CP still present within normal
range values of these parameters and the prevalence of
clinically overt deficiencies is low.243,244
In general, studies on the nutritional status of CP
patients are hampered by patient selection, small
patient numbers, varying rates of concomitant PEI
and the use of PERT, thus the generalisability of
reported rates of deficiencies can be questioned.
No studies have specifically addressed the relative
importance of the different causes of malnutrition in
patients with CP. PEI is the most important cause of
malnutrition in CP and should always be considered
when malnutrition is suspected in these patients.8
Q6-2: How is malnutrition detected in patients with CP?
Statement 6-2.1. Patients with CP should undergo
initial screening for BMI either with the community
malnutrition universal screening tool (MUST) or hos-
pital nutritional risk screening (NRS-2002). More spe-
cifically, dietary intake should be documented as well as
symptoms consistent with malnutrition and those
symptoms that have an increased risk of secondary
anorexia (pain, nausea and vomiting). (GRADE 1B,
moderate agreement)
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Statement 6-2.2. A physical examination should be
performed, if ascites or oedema are present and
should include anthropometric measurements of mid-
arm circumference, triceps skin-fold and hand-grip
strength. (GRADE 2B, moderate agreement)
Statement 6-2.3. Screening for a deficiency of fat-
soluble vitamins (A, D, E and K), zinc, magnesium
and glycated haemoglobin (HbA1c) should be con-
sidered. (GRADE 2A, moderate agreement)
Comments. Nutritional screening should be a simple
and rapid process using the community MUST, which
can be extended to the NRS-2002 tool in hospitals, and
is recommended by ESPEN.526 Although not specific-
ally designed or tested in CP, both tools have a high
degree of inter-rated reliability (k¼ 0.88–1.00) for iden-
tifying patients that will benefit from nutritional inter-
vention. These tools have been retrospectively validated
and subsequently prospectively validated in an RCT of
212 patients.527–529 A previous RCT showed that diet-
ary counselling for a balanced diet is as good as com-
mercial food supplements and that dietary intake
should be addressed early.530
Two prospective studies of 58 and 62 patients with
CP have shown a significant decrease in the lean muscle
mass and body fat compared to controls.170,510
Deficiency of fat-soluble vitamins, magnesium, haemo-
globin, albumin, prealbumin, retinol-binding protein
and HbA1c levels above the upper limit of normal have
been associated with pancreatic insufficiency.173,244,520,522
Q6.3: What recommendations regarding diet and intake of
proteins, fat and carbohydrates can be given to patients
with CP?
Statement 6-3.1. Patients who are well nourished
should be encouraged to follow normal healthy eating
advice. PEI should be corrected in those patients who
are nutritionally compromised. Improved nutritional
status can be achieved with nutritional assessment
and individualised dietary counselling by an experi-
enced dietician. (GRADE 1B, strong agreement)
Statement 6-3.2. Dietary fat restriction and very high
fibre diets should be avoided. (GRADE 1C strong
agreement)
Statement 6-3.3. Small, frequent, high-energy meals
should be recommended for those with malnutrition.
(GRADE 2C strong agreement)
Statement 6-3.4. Nutritional intervention should be
carried out alongside PERT. (GRADE 2C, strong
agreement)
Comments. Professional dieticians or nutritionists
should be involved.2,175 Sixty CP patients, defined as
malnourished (>10% weight loss within six months
and/or a BMI< 18.5 kg/m2), were randomised to
receive individualised dietary counselling by an experi-
enced dietician or a polymeric medium chain triglycer-
ide (MCT) oral nutritional supplement. There was a
significant improvement in anthropometric measure-
ments (p¼ 0.001), a reduction in pain (p¼ 0.001) and
fat malabsorption (p< 0.007) in both groups. However,
there was no significant difference between the two
arms of the study, leading to the conclusion that dietary
intervention by a specialist dietician was as effective as
oral nutritional supplements in patients with CP.530
An observational study of 40 male patients with CP
identified higher energy intakes than healthy male con-
trols (p< 0.01). Despite this, nutritional markers were
lower in the CP group (p< 0.001), even though PERT
had been used in 32/40 patients.531 Nutritional require-
ments are estimated at 25–35 kcal/kg and 1.2–1.5 g
nitrogen/kg532,533 and this study serves as a useful
reminder that malabsorption will render these estimates
inaccurate for oral and enteral nutrition in the presence
of malabsorption.
Whilst low fat diets remain commonplace, studies
show that 30–33% of energy from dietary fat is well
tolerated by patients with PEI.530 Carbohydrate and
protein malabsorption is significant, and can account
for between 10–30% of dietary carbohydrate malab-
sorption,534 and >7 g nitrogen malabsorption535 per
day. In energy terms, 7 g nitrogen equates to 44 g pro-
tein, resulting in a 175 kcal loss from nitrogen malab-
sorption. Assuming a 50% carbohydrate, 2000 kcal/day
diet, carbohydrate malabsorption may account for up
to 300 kcal per day. Consequently, dietary fat restric-
tion is only recommended as a last resort for control-
ling symptomatic steatorrhoea in patients where dose
adjustments in pancreatic replacement therapy and the
addition of PPIs have not resulted in satisfactory symp-
tom relief.175,536,537 The inappropriate use of low fat
diets can mask clinical symptoms of malabsorption;
however, some patients avoid fat unconsciously.
Dietary fibre has been associated with a reduction in
enzyme availability in a trial with 12 CP patients com-
paring a normal diet and a diet supplemented with 75–
80 g dietary fibre. Fat intake was controlled at 100 g fat
per day.538 Significant increases in faecal fat (p< 0.005)
were observed in the fibre-supplemented group; there-
fore, very high fibre diets are not recommended.532
Q6-4: Are oral nutritional supplements, with or without MCTs,
indicated in CP?
Statement 6-4.1. For most patients with CP, oral
nutritional supplements are not required. For those
188 United European Gastroenterology Journal 5(2)
who are undernourished and cannot meet their nutri-
tional requirements orally despite dietary intervention,
oral nutritional supplements may be useful.
Statement 6-4.2. MCT supplements are not recom-
mended. (GRADE 2C, strong agreement)
Comments. For most patients with CP, oral nutri-
tional supplements are not required to maintain nutri-
tional status. In CP patients, 10–15% are estimated to
require oral nutritional supplements, whilst >80% can
be managed by diet and PERT when necessary.289 The
theoretical advantage of MCTs is that they are less
dependent on lipase activity for their absorption.535
However, initial studies have not shown any clear bene-
fit of MCTs over standard long-chain triglycerides
when used in combination with PERT.535,539
Therefore, the use of MCTs has either not been recom-
mended at all3,4,6 or only as a last resort289,540 in
recently published guidelines.
One RCT investigated the efficacy of oral nutritional
supplements in patients with CP and severe malnutri-
tion (with a BMI< 18.5, or >10% weight loss over six
months).530 Dietary counselling achieved equal gains in
BMI, mid-upper-arm circumference and triceps skin-
fold thickness compared to the use of a commercial
supplement enriched with MCTs. However, both
groups also received PERT and it is not possible to
conclude from this study what the additional gain
from dietary intervention was over PERT treatment.
Furthermore, the study was performed in India on
very malnourished subjects who consumed a mainly
vegetarian diet, limiting the generalisability to CP
patients in the western world.
To date, no other study has investigated the effect-
iveness of oral nutritional supplements in CP, which
constitutes an important gap in research. For under-
nourished patients with CP, as with all undernourished
patients, it is more desirable to implement dietary stra-
tegies to improve oral intake (rather than using supple-
ments or nutritional support), not least for economic
reasons. For those who are unable to meet their
requirements with dietary intervention alone, oral
nutritional supplements are a simple way to improve
oral intake, and might delay or reduce the need for
enteral tube feeding.
Q6-5.1: When is micronutrient supplementation indicated
in CP?
Statement 6-5.1. Specific recommendations on the
supplementation of vitamins A, E and K are not pos-
sible, as there are few studies. Clinical evaluation is
advised, along with adequate PERT and dietary inter-
vention. (GRADE 1B, strong agreement)
Q6-5.2: How should it be administered?
Statement 6-5.2. Vitamin D deficiency may be treated
with oral supplementation or by a single intramuscular
(IM) injection. (GRADE 2C, strong agreement)
Comments. There is a dearth of studies on the man-
agement of nutrient deficiency in CP, with the exception
of vitamin D. One study541 found that oral vitamin D
(1520 IU/day) was significantly more effective at
increasing serum 25 hydroxyvitamin D (25[OH]D)
than UVB radiation in patients with CP. This level of
oral supplementation achieved an increase of
32.3 nmol/l (95% CI 15–50) over the 10-week trial.
Another study542 supplemented 40 patients with trop-
ical CP with either 600,000 IU or 300,000 IU (single IM
injection) or IM saline. All three groups received daily
calcium and oral vitamin D3 (500 IU). After nine
months, the higher dose was more effective at increas-
ing serum vitamin D levels. There were no reports of
hypervitaminosis or hypercalcaemia, despite the high
doses.
It seems practical to replace fat-soluble vitamins in
those patients with low serum levels along with docu-
mented malabsorption and poor dietary intakes; how-
ever, few, if any studies have examined the efficacy or
safety of supplementing vitamin E, vitamin A or vita-
min K in patients with biochemical deficiencies. This
constitutes a significant research gap. In addition, at
least one study518 has reported excess levels of vitamin
A in patients with CP. Therefore, blanket supplemen-
tation for all CP patients is not advised, nor is it pos-
sible to provide specific guidelines on dosage,
administration methods or specific patient types that
will benefit from supplementation. Therefore, for
these nutrients, a case-by-case clinical judgment
approach is advised. Where possible, fat-soluble vita-
min levels should be measured as part of the overall
nutritional work-up. In all cases, appropriate and ade-
quate PERT should be established, and priority should
be given to optimising nutrient intake, including
detailed dietary assessment and monitoring.532,543
Q6-6. When is parenteral nutrition indicated in CP and by
what means should it be provided?
Statement 6-6. Parenteral nutrition is indicated in
patients with gastric outlet obstruction secondary to
duodenal stenosis, in patients with complex fistulating
disease and in patients with apparent severe malnutri-
tion prior to pancreatic surgery if enteral feeding is not
possible. (Level 1C, strong agreement)
Comments. More than 80% of patients suffering
from CP can be treated adequately with normal food
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supplemented by pancreatic enzymes and only about
10–15% of all patients will require oral nutritional sup-
plements.526 Enteral nutrition preserves immune func-
tion and mucosal architecture and decreases the
possibility of hyperglycaemia while parenteral nutrition
increases the risk of catheter infections and sepsis com-
plications.289 Tube feeding is indicated in approxi-
mately 5% of patients with CP.526 Therefore,
parenteral nutrition is only indicated if the patients
do not reach their requirements because gastric empty-
ing is blocked, the patient needs gastric decompression,
it is impossible to introduce a tube into the jejunum, or
a complicated fistula is present.8,289,526,533 Parenteral
nutrition is mainly performed over a short-term
period and long-term studies are lacking.
Q6-7. When is enteral nutrition indicated in CP and by what
means should it be provided?
Statement 6-7.1. Enteral nutrition is indicated in
patients with malnutrition who are not responding to
oral nutritional support. (GRADE 2C, strong
agreement)
Statement 6-7.2. It is recommended that enteral
nutrition be administered via the naso-jejunal route in
patients with pain, delayed gastric emptying, persistent
nausea or vomiting. (GRADE 2C, strong agreement)
Jejunostomy feeding tube insertion should be con-
sidered in those requiring enteral nutrition for longer
than 30 days. Peptide, medium chain triglyceride-based
enteral feeds may be used in patients with PEI.
(GRADE 2C, strong agreement)
Statement 6-7.3. Enteral nutrition is indicated with
PERT administered alongside where necessary.
(GRADE 2C, strong agreement)
Comments 6-7.1-3. Oral nutritional support is ade-
quate for improving nutritional status in the majority
of patients with CP.530 RCTs that specifically investi-
gate indications for, as well as optimal administration
of, enteral nutrition in CP are generally lacking and
current guidelines are based on observational studies,
expert opinion and clinical experience. ESPEN states
that enteral nutrition is indicated if the patients
cannot ingest sufficient calories or prior to surgery.544
A retrospective review of 58 patients545 and a case
series of three patients544 demonstrated the benefits of
naso-jejunal feeding, which was associated with an
improvement in nutritional status, and a reduction in
pain, pseudocysts and inflammation.544,545
Enteral nutrition should be used alongside an oral
diet in those with poor oral intake, and parenteral
nutrition should be used when enteral nutrition is not
tolerated.289,526 Enteral nutrition by the naso-jejunal
route may be beneficial in those patients with post-
prandial pain, persistent nausea, vomiting, obstructed
pancreatic ducts, or are unable to tolerate gastric feed-
ing. Surgical jejunostomy should be considered in those
requiring enteral nutrition for longer than 30
days.289,533 The successful use of naso-jejunal feeding
alongside naso-gastric drainage has been reported in
CP patients with gastric outflow obstruction.546
There is limited high quality evidence for the com-
position of enteral feeds in CP. However, most clin-
icians support the use of small peptide/MCT feeds,547
and improvements in nutritional status have been
reported in over 70 CP patients receiving this compos-
ition of feed.544–546 Pancreatic enzymes can be admin-
istered alongside the feed539,548 in those patients whose
nutritional status does not improve with peptide/MCT-
based feeds.
Q6-8.1: What is the risk of developing osteoporosis/
osteopaenia in CP?
Statement 6-8.1. Patients with CP are at high risk of
developing osteoporosis and osteopaenia (Grade 1A),
and are at high risk of suffering a low trauma fracture
(Grade 1B). (GRADE 1B, strong agreement)
Q6-8.2: How can those at risk of developing osteoporosis/
osteopaenia be identified?
Statement 6-8.2. To identify those at risk, regular
assessment of bone density by dual-energy X-ray
absorptiometry (DXA), along with regular measure-
ment of serum 25(OH)D should be undertaken.
(GRADE 1C, strong agreement)
Q6-8.3: What is the recommended management for the
prevention and treatment of these conditions?
Statement 6-8.3. Basic preventative measures (ade-
quate diet, particularly calcium and vitamin D intake,
regular weight-bearing exercise, and smoking/alcohol
avoidance) should be encouraged for all CP patients
(Grade 1C). For those with osteopaenia, basic pre-
ventative measures should be implemented and DXA
should be repeated every two years (Grade 1C).
Patients with osteoporosis (or vertebral fractures)
should receive appropriate medication, screening for
other causes, and/or referral to a bone specialist,
along with basic preventative measures. (GRADE 1C,
strong agreement)
Comments 6-8.1-3. A systematic review and meta-
analysis510 found that, in a pooled sample of 513
patients from 10 studies, almost a quarter (23.4%) of
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patients with CP had osteoporosis and 39.8% had
osteopaenia, with a combined osteoporosis/osteopaenia
rate of 65% (95% CI 54.7–74). The corresponding
osteoporosis rate for controls was 8.6–10.2%, based
on only two studies with usable data.549 In general
the studies were heterogeneous and not amenable to
subgroup analysis, however five studies172,511,520,550,551
found an association between bone mineral density
(BMD) and fat malabsorption, while there was no
clear relationship overall between serum 25(OH)D
and BMD. A study of bone histomorphometry in CP
found that patients exhibited loss of cortical thickness
and trabecular bone volume with micro-architectural
deterioration compared to controls.552
The high prevalence of osteoporosis and osteopaenia
appears to correlate with clinically relevant outcomes.
A higher-than-average fracture rate was noted among
CP patients compared to population-based controls in
a study from Denmark (adjusted hazard ratio (HR) 1.7,
95% CI 1.6–1.8).553 Likewise, in a US American
study,554 the rate of low-trauma fracture was similar,
or higher, in patients with CP compared to other ‘high-
risk’ gastrointestinal diseases. In the latter study, the
risk of fracture for CP was 4.8%, compared to coeliac
disease (5%), Crohn’s disease (3%), gastrectomy
(5.4%), cirrhosis (4.8%) and controls (1.1%). Several
factors contribute to low BMD in CP, serum 25(OH)D
insufficiency, poor diet, smoking, malabsorption and
poor physical activity levels. More recently, an associ-
ation between chronic systemic inflammation and ele-
vated bone turnover in CP was reported. While DXA
remains the primary diagnostic tool, bone turnover
markers173,522 could act as useful complementary mar-
kers where the mechanisms of bone turnover are
unclear, or to evaluate the use of therapeutic agents,
thereby reducing the necessity for repeated BMD
assessments.
Interventional studies on bone health in CP are lack-
ing. One study of 30 patients found that enteral vitamin
D supplementation at a relatively modest dose (1520 IU
daily) was effective in increasing serum 25(OH)D in CP
patients with confirmed fat malabsorption (change in
25(OH)D levels: 32.3 nmol/l, 95% CI 15–50).541
Unfortunately, there is a dearth of studies investigating
the efficacy of therapeutic agents for osteoporosis in
patients with CP, which constitutes a significant
research gap. Direction may be sought from existing
bone management guidelines for other malabsorptive/
gastrointestinal diseases.
The American Gastroenterological Association
(AGA) recommends that patients with inflammatory
bowel disease, coeliac disease and post-gastrectomy
should undergo DXA if they have at least one other
additional osteoporosis risk factor.555 Similar select-
ive testing in CP would mandate DXA for
post-menopausal women, those with previous low-
trauma fractures, men >50 years, and those with mal-
absorption. However, given the high risk for osteopor-
osis and fracture (and associated morbidity and cost), it
may be prudent to extend a baseline bone density
assessment to all patients with CP, as well as ensuring
that basic preventative measures are implemented in
standard clinical practice.543 For those with osteopae-
nia, basic preventative measures should be imple-
mented in line with the AGA recommendations for
other gastrointestinal conditions, and DXA should be
repeated every two years.
Diabetes mellitus (WP11)
Introduction. Diabetes mellitus is defined as a regulatory
dysfunction of the metabolism mainly characterised by
chronic hyperglycaemia. The underlying causes may be
impaired insulin secretion or insulin resistance or a
combination of both. Due to this causal heterogeneity,
diabetes mellitus is currently classified as four different
types, comprising types I–IV.556,557
Diabetes mellitus secondary to pancreatic diseases
(such as CP) is classified as pancreatogenic diabetes
or Type IIIc diabetes mellitus (T3cDM) according to
the current classification of diabetes mellitus.556,557
Exocrine pancreatic diseases underlying T3cDM
include both benign and malign conditions such as
acute, relapsing and CP of any aetiology, haemo-
chromatosis, cystic fibrosis, fibrocalculous pancreato-
pathy, pancreatic trauma, pancreatectomy, pancreatic
agenesis and pancreatic cancer. Even within this
T3cDM group, there may be different diabetes subtypes
relating to different pathophysiologies of the underlying
pancreatic diseases.558 Therefore, it is important to
stress that the following suggestions focus solely on
T3cDM due to CP. A summary diagram is provided
(Supplementary Material, Figure S1).
Q7-1: What is the risk of developing T3cDM diabetes in CP?
Statement 7-1. Diabetes is a common complication
of CP, although its occurrence varies widely from 5%
to >80%, depending largely on aetiology, geographical
location and duration of follow-up. It appears to be a
common complication of both idiopathic/tropical CP
and alcoholic CP. (GRADE 1B, strong agreement)
Comments. Type of diabetes: T3cDMmay be misclas-
sified (usually as type 2 diabetes); however, most studies
on the risk of diabetes in CP do not specify the type of
diabetes.559 Factors that influence the risk of developing
type 2 diabetes (such as family history and BMI) are
certain to impact the occurrence of T3cDM in CP, as
both type 2 and T3cDM can co-exist.560
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Aetiology and geography: Several studies noted that
an alcohol aetiology increased the risk of developing
diabetes compared to other aetiologies.561–564
However, diabetes was diagnosed in as few as 5%
(Australia) and 7% (South Korea) of CP patients,565
where alcohol-induced pancreatitis patients were in the
majority. Meanwhile, the occurrence of diabetes in
Malaysia and Southern India was reportedly 50%
and 55% respectively565 with a majority of tropical or
idiopathic pancreatitis diagnoses. There is regional
variation even within India, with patients in Northern
India566 having a lower occurrence of diabetes (31%)
than in the South (65%),565 along with a lower percent-
age of tropical pancreatitis aetiology. In Indian idio-
pathic CP, those with late-onset disease tend to
develop diabetes more frequently.562,566 In Japan,
three studies identified that 30%,565 39.7%564 and
46.3%563 of CP patients had a diagnosis of diabetes,
with the latter identifying the diabetes as a ‘true’
T3cDM, that is, being diagnosed following a CP diag-
nosis. For autoimmune CP, the pre-steroid therapy
occurrence was 24%, doubling post-steroid therapy to
48% in one small study of 21 patients.305 Over a quar-
ter (26%) of subjects developed diabetes in a French
study of 200 hereditary CP patients.567
Q7-2: What factors affect the risk of developing diabetes in CP?
Statement 7-2.1. The risk of developing diabetes
increases with surgical intervention (especially distal
pancreatectomy) and with increasing age. (GRADE
1B, strong agreement)
Statement 7-2.2. The evidence appears to support
an association between (heavy) smoking and the
development of diabetes. Most studies support a
link between the presence of calcifications and the
risk of developing diabetes. (GRADE 1C, strong
agreement)
Statement 7-2.3. Most studies show that the risk of
diabetes increases with the duration of disease.
(GRADE 1B, strong agreement)
Statement 7-2.4. There is some evidence of an asso-
ciation with gender and family history. (GRADE 2A,
strong agreement)
Statement 7-2.5. There is insufficient evidence of a
relationship between diabetes and BMI or zinc status.
(GRADE 2C, strong agreement)
Statement 7-2.6. There is no evidence that a higher
dietary fat intake influences the development of dia-
betes in CP. (GRADE 2C, strong agreement)
Statement 7-2.7. The development of diabetes does
not appear to be influenced by the presence of various
genetic mutations. (GRADE 1B, strong agreement)
Comments. Surgery: Those who undergo pancreatic
resection have an increased risk of diabetes, with 37%
of previously non-diabetic patients developing de novo
diabetes following surgery.253 The type of surgery may
impact the likelihood of developing diabetes; those
undergoing distal pancreatectomy had a risk ratio of
2.4 for the development of diabetes (57% of distal pan-
createctomy patients had diabetes after five years, com-
pared to 36% of pancreaticoduodenectomy patients,
and in fact there was no increased risk for diabetes
associated with pancreaticoduodenectomy compared
to the natural history of CP).568 A study of Chinese
patients also identified distal pancreatectomy as being
an independent risk factor for developing diabetes (HR
of 5.4).569 Other risk factors for developing diabetes
following surgery for CP include an increased BMI,
and higher pre-operative fasting glucose/glycosylated
haemoglobin (HbA1c) levels (570) (Supplementary
Material, Figure S1).
Smoking: In a five-country study of smoking in alco-
holic CP, smoking was shown to increase the risk of
developing diabetes after the diagnosis of CP by an HR
of 2.3.28 In an Italian cohort of idiopathic CP patients,
heavy smoking was associated with the development of
diabetes (HR 3.9).571 A second study on early-onset
idiopathic CP found that smoking was a strong inde-
pendent risk factor (odds ration (OR) 4.252) for
developing diabetes (and that alcohol was of lesser
importance).562 In a study of 445 patients from
China, smoking was an independent risk factor for
developing diabetes both before and after invasive ther-
apy (endoscopy and surgery).569 In patients with AIP,
high tobacco usage was associated with the occurrence
of diabetes, with those with a >10-pack year history of
smoking developing diabetes more frequently than
‘low’ smokers (including never- and ex-smokers), 50%
vs 27% respectively.572 Conversely, a study of 241
patients with CP found that smoking was not asso-
ciated with the development of diabetes,573 and
Malka and colleagues568 found that smoking was not
a risk factor for the development of diabetes in a multi-
variate analysis of 500 patients. However, the latter
study compared the percentage of smokers between
diabetes and non-diabetes groups, without examining
the degree of smoking.
Calcifications: Diabetes tends to develop more fre-
quently in those with calcific CP566 with the relative risk
varying from 3.2 (in surgical patients)568 to 7.7 (in idio-
pathic CP).562 The presence of calcifications was an
independent risk factor for developing diabetes (prior
to invasive therapy) in a study of Chinese patients
192 United European Gastroenterology Journal 5(2)
with CP.569 Conversely, no association was found
between the presence of calcifications and the risk of
developing diabetes in a surgical group.253
Duration of disease: The diabetes risk was 50% after
10 years, increasing to 83% after 25 years.568 Insulin
requirement increased from 26% to 53% during the
same time-frame. Ito and colleagues563 also reported
that the prevalence of diabetes increases with time. In
a cohort of 418 patients with hereditary pancreatitis in
14 countries, there was a clear, linear, cumulative risk
of endocrine failure from 1.3% at age 10 years, to
79.1% at age 80 years.68 However, in a surgical
group, there was no association between the develop-
ment of diabetes and the length of post-operative
follow-up, pre-operative duration of CP, or the total
duration of CP (median follow-up, 56 months).253
Age: In hereditary CP, the mean age of diabetes
occurrence in France was 38 years, according to a
study published in 2009.567 The risk of diabetes
increases considerably with age, and patients over the
age of 40 years carried an OR of 9.2 for the develop-
ment of diabetes.562
BMI/lean body mass: Aside from pre-operative BMI,
there are few studies examining the effect of lean body
mass, fat mass, or obesity on the risk of developing dia-
betes in patients with CP. One study (idiopathic patients
from India) found that BMI was not an independent
risk factor for diabetes on univariate analysis.562
However, as type 2 diabetes may be superimposed
onto T3cDM in CP, it must be supposed that increasing
BMI also increases the risk of diabetes in CP.
Gender: A strong gender variation was noted in one
study564 in which 42.4% of males developed diabetes
versus 27.8% of females. However in an all-India
study,561 the reverse was noted, with non-alcoholic
females (44%) being more likely to develop diabetes
than non-alcoholic males (31%).
Family history: In idiopathic CP, a positive family
history resulted in an OR of 3.5 for developing dia-
betes.562 As with BMI, since type 2 diabetes and
T3cDM may co-exist, a family history of type 2 dia-
betes is likely to impact the development of diabetes in
patients with CP.
Genetic mutations: In a small study of 79 patients,
there was no significant difference in the risk of
developing diabetes for those with both the secretory
trypsin inhibitor (SPINK 1) and PiZ mutations vs no
mutations.574 In a cohort of 200 patients with heredi-
tary CP, the presence, or absence, of a PRSS1 gene
mutation did not influence the diabetes risk.567 In
another cohort study of hereditary pancreatitis, specific
gene mutations had no influence on the age of onset of
diabetes.68
Diet and nutrition: In a study from Spain575 on the
effect of a high-fat diet (defined as >30% of total daily
calorie intake from fat) on complications in CP, there
was no evidence that a high-fat diet resulted in a higher
risk of developing diabetes. One study of 101 CP
patients (34 alcoholic and 67 tropical aetiologies)
showed that erythrocyte zinc levels were lower in
those with diabetes than in non-diabetics.524
Q7-3: How should T3cDM be diagnosed in CP?
Statement 7-3.1. The initial evaluation of a patient
with CP should include fasting plasma glucose (FPG)
and HbA1c. Criteria for a diagnosis of T3cDM are
FPG 126mg/dl (7.0mmol/l) or HbA1c 6.5%
(48mmol/mol). (GRADE 1A, strong agreement)
Statement 7-3.2. An HbA1c< 6.5% does not rule out
T3cDM due to the limitations of this test in this patient
population. Therefore, normal HbA1c (<6.5%) should
always be confirmed by FPG. (GRADE 1B, strong
agreement)
Statement 7-3.3. In the absence of unequivocal
hyperglycaemia (random plasma glucose 200mg/dl
(11.1mmol/l)) or in cases of doubt, results should be
confirmed by repeat testing or by the evaluation by a
standard 75 g oral glucose tolerance test (OGTT, 2 h
fasting glucose 200mg/dl (11.1mmol/l)). (GRADE
1A, strong agreement)
Statement 7-3.4. These tests should be performed
annually, even in the absence of typical clinical symp-
toms of diabetes mellitus. (GRADE 1C, strong
agreement)
Comments 7-3.1-4. Current clinical criteria issued by
the WHO, many national European diabetes associ-
ations and the American Diabetes Association (ADA)
are based on FPG and 2 h plasma glucose (2hPG) fol-
lowing an OGTT (Supplementary Material, Figure S1).
FPG 126 mg/dl and/or HbA1c 6,5% and/or plasma
glucose 200mg/dl confirmed by a 2 h glucose meas-
urement after ingestion of 75 g oral glucose (OGTT) are
cut-off points for diagnosing diabetes mellitus.557,576
Although there are several other methods of assessing
the insulin reserve in CP (serum/urinary insulin, serum/
urinary C-peptide, beta-cell stimulation with arginine,
glucagon or tolbutamide), there is little evidence that
these have any effect on clinical decision-making.577–579
The argument for FPG and/or HbA1c over 2hPG is
primarily related to feasibility. HbA1c is known to
have limitations in CP patients suffering from multiple
conditions;580 therefore, a negative HbA1c (<6.5%)
does not rule out diabetes in this population.
In summary, since there is a high prevalence of dia-
betes mellitus in CP as described above and the
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deterioration of glucose metabolism is well known to be
associated with multiple serious health risks, an early
diagnosis of diabetes mellitus is crucial and annual
screening is suggested.
Q7-4: How to distinguish T3cDM from type 1 and type 2 dia-
betes mellitus?
Statement 7-4.1. An absent pancreatic polypeptide
response to mixed-nutrient ingestion seems to be a spe-
cific indicator of T3cDM as compared to the other
types of diabetes. (GRADE 1C, strong agreement)
Comments. Due to feasibility, this test is only recom-
mended in cases of doubt. As differentiating between
the two types of diabetes is not easy, the criteria
below might be helpful (Supplementary Material,
Figure S1):
Major criteria (must be present):
. Established diagnosis of CP
. Absence of type 1 diabetes mellitus-associated auto-
immune markers
Minor criteria (two of four must be present):
. Impaired beta cell function (e.g. homeostatic model
assessment for beta-cell dysfunction (HOMA-B),
C-peptide/glucose ratio)
. No excessive insulin resistance
. Impaired incretin secretion (e.g. glucagon-like pep-
tide-1 (GLP-1), pancreatic polypeptide)
. Deficiencies of fat-soluble vitamins and/or presence
of micronutrient deficiency/insufficiency (in the
absence of enzyme therapy and/or nutrient
supplementation)
Statement 7-4.2. Laboratory tests to classify the
patient as accurately as possible should be performed
at least once. They should include diabetes-associated
antibodies, C-peptide/glucose ratio, and assessment of
exocrine pancreatic function, as well as pancreatic ima-
ging. (GRADE 1C, strong agreement)
Comments. One of the most problematic issues with
T3cDM is defining it precisely and differentiating it
from the other types of diabetes as different types
might precede each other or might be superimposed
on each other. To date, certain diagnostic criteria,
which have been proposed by two research groups,
appear helpful.560,581 However, probably due to the
potential overlap of the different diabetes types, they
all fall short to a certain degree. An absent pancreatic
polypeptide response to mixed-nutrient ingestion seems
to be a specific indicator of pancreatogenic diabetes.560
Q7-5.1: What is the prevalence of acute diabetes complications
for patients with T3cDM?
Statement 7-5.1. Patients with T3cDM are generally
considered difficult to manage, with potential life-threa-
tening acute complications (hypoglycaemia and ketoa-
cidosis). Up to 25% of the patients with T3cDM have
‘brittle diabetes’ with rapid swings in glucose levels.
(GRADE 1C, strong agreement)
Comments 7-5.1. Patients with T3cDM can develop
potential life-threatening acute complications578,582–586
may develop ‘brittle diabetes’587–593 with rapid swings
of glucose levels from hyperglycaemia (due to unsup-
pressed hepatic glucose production) to severe hypogly-
caemia after administration of exogenous insulin (due
to the lack of a contra-regulatory hormone
response).594–600 Repeated hypoglycaemic events may
result in hypoglycaemia unawareness because of the
progressive decrease in the glucose threshold for trig-
gering symptoms.601
Total or partial pancreatectomy is often associated
with the resection of the duodenum, gallbladder, distal
common bile duct and, often, distal stomach. The con-
sequences of such extensive ablative surgery result, not
only in pancreatic hormone deficiency, but also in the
deterioration of gut hormones.257,602 However, several
authors have recently reported that the glycaemic con-
trol of patients with T3cDM has improved compared to
that reported in earlier studies.603–608 Several factors
may explain these changes: nowadays insulin-depen-
dent diabetes and malabsorption can be controlled
more effectively than in the past with new drugs, includ-
ing insulin analogues. Moreover, the rate and severity
of hypoglycaemia are affected by the underlying pan-
creatic disease. For example, in patients undergoing
total pancreatectomy for alcoholic CP, hypoglycaemic
events are more frequent and severe if alcohol abuse
persists.
Finally, improving patient awareness and compli-
ance irrespective of socio-economic class, increasing
referrals to a diabetes centre, and the widespread use
of glucose meters may have contributed to the improve-
ment of glycaemic control and stability over time.
However, although there are no large, prospective con-
trolled clinical trials estimating the true incidence of
brittle diabetes after total pancreatectomy, in clinical
practice the diabetes management of these patients is
often problematic, especially in relatively young indi-
viduals where the risk of developing chronic
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complications later in life has to be carefully balanced
against the risks of repeated life-threatening severe
hypoglycaemia.
Q7-5.2: What is the prevalence of chronic diabetic
complications for a patient with T3cDM?
Statement 7-5.2a. Chronic microangiopathic compli-
cations are as frequent in T3cDM patients as in other
diabetic patients. The incidence of retinopathy is
reportedly similar to that observed in type 1 diabetes
and its prevalence increases with diabetes duration.
(GRADE 1B, strong agreement)
Statement 7-5.2b. Early signs of renal dysfunction,
such as microalbuminuria or glomerular hyperfiltra-
tion, are similar to that reported in type 1 dia-
betes mellitus, while macroalbuminuria and overt
renal disease are unusual. (GRADE 1B, strong
agreement)
Statement 7-5.2c. Neuropathy is also described as a
common complication of T3cDM. (GRADE 1B, strong
agreement)
Statement 7-5.2d. There is a general acceptance that
T3cDM is not associated with macrovascular compli-
cations. (GRADE 2B, strong agreement)
Comments 7-5.2a-d. Chronic diabetic complications
(microangiopathy and macroangiopathy): The underly-
ing pancreatic disease and the relatively short duration
of follow-up make it difficult to estimate the incidence
and prevalence of diabetes complications in these
patients.609–619 The incidence of retinopathy is similar
to that in type 1 diabetes mellitus and its prevalence
increases with diabetes duration.611,613,620–624
Early signs of renal dysfunction, such as microalbu-
minuria or glomerular hyperfiltration, are similar to
that reported in type 1 diabetes mellitus,613,625,626
while macroalbuminuria and overt renal disease are
unusual.627–630 Neuropathy is also described as a
common complication of T3cDM.563,630 It is generally
accepted that T3cDM is not associated with macrovas-
cular complications since concomitant PEI, lower chol-
esterol levels and lower caloric intake may all reduce
cardiovascular risk. However, with increasing life
expectancy, cases of diabetic macrovascular complica-
tions have been reported in patients after pancreatic
surgery.609,612,631 These data support the need to treat
patients with diabetes after pancreatic surgery with the
goal of preventing long-term complications while mini-
mising the risk of life-threatening severe
hypoglycaemia.632–639
Q7-6: What is the optimal pharmacological treatment
for T3cDM
Statement 7-6.1. No evidence-based study relating to
treatment practice in T3cDM has been reported to
date. Treatment should include efforts to promote life-
style changes, which may improve glycaemic control
and minimise the risk of hypoglycaemia. In patients
with severe malnutrition, insulin therapy is commonly
used as a first choice due to the desired anabolic effects
of insulin in this special subset of patients. (GRADE
1C, strong agreement)
Statement 7-6.2. If hyperglycaemia is mild and con-
comitant insulin resistance is additionally diagnosed or
suspected, therapy with metformin may be a choice in
the absence of contraindications. (GRADE 1C, strong
agreement)
Statement 7-6.3. Ensuring adequate and appropriate
PERT is essential. (GRADE 1C, strong agreement)
Comments 7-6.1-3. No evidence-based study relating
to treatment practice in T3cDM has been reported to
date and all the large clinical diabetes trials have spe-
cifically excluded patients with T3cDM. The commonly
prescribed agents are the same as for type 2 diabetes
(Supplementary Material, Figure S1). The maldigestion
of carbohydrates due to coexisting PEI, concomitant
alcohol consumption and hepatic disease, a lack of
compliance with the prescribed diet and/or med-
ical therapy, and enhanced intestinal transit ham-
per the appropriate glycaemic treatment of these
patients.
Treatment should include efforts to promote lifestyle
changes (minimise high glycaemic-index foods, healthy
diet, physical activity, abstinence from alcohol and
smoking cessation, etc.), which may improve glycaemic
control and minimise the risk of hypoglycaemia. Some
authors suggest a trial of oral antidiabetic agents fol-
lowed by insulin therapy when the need arises.640,641 In
patients with severe malnutrition, insulin therapy is
commonly used as a first choice therapy due to the
desired anabolic effects of insulin in this distinctive
subset of patients. If hyperglycaemia is mild and con-
comitant insulin resistance is additionally diagnosed or
suspected, therapy with metformin may be a choice in
the absence of contraindications. However, metformin
treatment might not be tolerated by a majority of
patients since its main side effects include nausea,
abdominal complaints, diarrhoea and weight reduc-
tion.642 Metformin should be avoided in patients with
ongoing alcohol abuse because of the risk of lactic
acidosis.
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Regarding the prescription of other oral agents for
the treatment of diabetes:
Sulfonylureas are associated with an increased risk of
severe and prolonged hypoglycaemia, are often contra-
indicated due to the accompanying liver disease643 and
should not be prescribed.
Glinides are also associated with an increased risk of
hypoglycaemia; however, their half-life is much shorter
than that of sulfonylureas and glinides at low doses
may be considered before switching the patient to insu-
lin therapy.
Thiazolidines should be avoided due to prominent side
effects (bone fractures, fluid retention, congestive heart
disease).
Alpha-glycosidase inhibitors can aggravate existing exo-
crine insufficiency and should not be prescribed.
Incretin-based therapies are reported to have a high fre-
quency of prominent gastrointestinal side effects.
Additionally, they are currently under discussion
because of a potential association with an increased
risk of pancreatitis.644–647
Sodium glucose co-transporter-2 (SGLT-2) inhibitors
have been described as being able to induce euglycae-
mic diabetic ketoacidosis in insulin-deficient patients
(both type 1 diabetes and T3cDM)648,649 and should
not be prescribed until they are proven safe in these
patients.
Most patients do not respond satisfactorily to oral
agents and should be switched to insulin treatment, for
example, twice-daily pre-mixed insulin or multiple daily
injections.650 Patients should be treated using general
insulin dosage guidelines as established for type 1 dia-
betes mellitus. Insulin pump therapy may also be con-
sidered for patients who experience a brittle form of
diabetes mellitus despite being sufficiently motivated.
A helpful algorithm for diabetes therapy in T3cDM
was suggested.640
Establishing adequate oral PERT is very important
in T3cDM651 since patients are likely to develop mal-
nutrition-related problems due to the lack of exocrine
pancreatic enzymes. Thus ensuring adequate and
appropriate PERT should be instituted early on to pre-
vent qualitative malnutrition and metabolic complica-
tions.520,521,652 Malnutrition may also affect glucose
management, increasing the susceptibility of patients
to swings in glucose levels.653,654
Assessments and quality of life (WP12)
Life-style factors influencing the natural course
of CP as well as the outcome in terms of QoL
have been brought more into focus during recent
years.453,655
Q8-1: How should smoking be assessed in patients with newly
diagnosed or suspected CP?
Statement 8-1. There is no specific, widely accepted
questionnaire for assessing smoking status. Several stu-
dies have reported positive findings regarding the rela-
tionship between smoking and CP using different
questionnaires. (GRADE 2C, strong agreement)
Comments. The studies addressing the role of smok-
ing on the aetiology and clinical course of CP have
categorised the patients in different
ways.27,28,461,573,656–662
The NAPS2460,659,663 classified smoking status as
‘never smoked’ (<100 cigarettes in lifetime), or ‘ever
smoked’ (>100 cigarettes). ‘Ever smokers’ were then
categorised as ‘past’ or ‘current’ smokers. The
amount of smoking was classified as <1 or 1 or more
packs per day (ppd). The number of pack-years of
smoking was calculated from the self-reported
amount of smoking (average number of cigarettes
smoked per day and the duration of smoking) and stra-
tified as <12, 12–35, and >35 pack-years.
A Danish group461 calculated grams of tobacco con-
sumed, assuming one cigarette to be equivalent to 1 g of
tobacco, one cheroot or one pipe to 3 g of tobacco, and
one cigar to 5 g of tobacco, and separated the patients
into five groups (‘never-smokers’, ‘ex-smokers’, and
smokers of 1–14, 15–24, and >24 g/d of tobacco).
Pack-years of smoking were calculated as (years of
smoking daily grams of tobacco)/20.
The European Smoking Cessation Guidelines,664
issued in 2012, recommend that smoking status be
defined using the following questionnaire:
1. Have you ever smoked?
2. How many cigarettes have you smoked in your life?
Is it more or less than 100? (80 cigarettes¼ 100 g of
tobacco as one cigarette contains 0.8 g of tobacco).
3. Do you smoke every day/on certain days/in specific
situations? Which situations?
4. How many years have you been smoking?
5. How many cigarettes (or other tobacco products,
e.g. pipes, cigars etc.) do you usually smoke per day?
6. For how many years/months have you quit
smoking?
Definitions: a ‘daily smoker’ is a person who has
smoked on a daily basis for at least three months; an
‘occasional smoker’ is a person who has smoked, but
not on a daily basis; a ‘non-smoker’ is a person who has
not smoked more than 100 cigarettes in his/her life-time
(or <100 g of tobacco, in the case of pipes, cigars or
other tobacco products); an ‘ex-smoker’ is a person
who has quit smoking for at least six months.
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Q8-2: What are the most efficacious methods for treating
nicotine dependence in patients with CP?
Statement 8-2. The key components for the treat-
ment of smoking dependence are combinations of
therapeutic education, behavioural support and medi-
cation. (GRADE 1A, strong agreement)
Comments. Smoking is the leading preventable cause
of death worldwide. There are no specific studies com-
paring different methods for treating nicotine depend-
ence/smoking cessation in CP. Furthermore, the
treatment of smoking dependence should not depend
on a single method: according to the European
Smoking Cessation Guidelines, issued by the
European Network for Smoking and Tobacco
Prevention (ENSP), the key components of successful
cessation (remission) are combinations of therapeutic
education, behavioural support and medication; how-
ever, the preparation and motivation to quit, age,
comorbidity and numerous personal factors affect the
chances of success.665 About 90–95% of unaided
attempts to quit smoking end in failure. A detailed
protocol for smoking cessation is beyond the scope of
this document. Trained personnel should manage the
treatment of smoking dependence.
In the setting of primary care, the classic steps known
as the ‘5 As’ are helpful for planning the treatment:666
Ask: Systematically identify all tobacco users at every
visit.
Advise: Strongly urge all tobacco users to quit.
Assess: Determine willingness to make a quit attempt.
Assist: Aid the patient in quitting (provide counselling-
style support and medication).
Arrange: Ensure follow-up contact.
Systematic reviews have shown that a combination
of counselling and pharmacotherapy for treating nico-
tine dependence is more effective for smoking cessation
than each of the two methods taken separately.667,668
Nicotine replacement therapy, bupropion and vareni-
cline are efficiently proven first-line pharmacologic
therapies for smoking cessation according to the
ENSP guidelines.665 Second-line medications include
clonidine and nortriptyline.665 In addition to pharma-
cological therapy, patients benefit from individual cog-
nitive-behavioural counselling, telephone support,
group counselling and educational materials.665
Q8-3.1: What are the effects of smoking on the
progression of CP?
Statement 8-3.1. There is some evidence to suggest
that cessation of smoking and/or drinking may improve
the course of CP; however, the global benefits of stop-
ping smoking and/or abusive alcohol consumption are
unquestionable. (GRADE 1C, strong agreement)
Comments. Smoking seems to be an independent
aetiologic factor for the development of CP; with evi-
dence from case-control studies,27,656,657 cross-sectional
studies658 and cohort studies.460,461,659 Smoking is asso-
ciated with progression from acute to CP,669 to a more
frequent and earlier development of calcifica-
tions28,573,660–662 and also to increased mortality670
although there are conflicting reports.671 In some stu-
dies, an association between smoking and the develop-
ment of diabetes mellitus28,662 and PEI573 has been
described, but there are conflicting reports regarding
both diabetes573,661 and PEI.661
It has been reported that patients in constant pain
are more likely to be ‘current’ (rather than ‘past’ or
‘never’) smokers compared to patients with an intermit-
tent pattern of pain.442 An absence of smoking at the
last follow-up evaluation has been associated with long-
term clinical success of ET for pain.328 Smoking is an
established risk factor for pancreatic adenocarcinoma
in the general population, and it is reported to increase
the risk of this serious complication in patients with
hereditary pancreatitis.672
Q8-3.2: Once the disease has been diagnosed, what impact
does stopping drinking and/or smoking have on the course of
the disease?
Statement 8-3.2. Smoking seems to be an independ-
ent aetiologic factor for the development of CP.
(GRADE 1C, strong agreement)
Comments. There are few studies that focus specific-
ally on the effects of smoking and/or alcohol cessation
in the natural course of established CP. However, there
is evidence from observational studies that early smok-
ing cessation after the diagnosis of the disease reduces
the risk of developing pancreatic calcifications.673 In
addition, alcohol abstinence seems to slow the progres-
sion of the illness674 and may result in better pain
control.675
Q8-4: How do we assess quality of life in patients with CP?
Statement 8-4. Validated questionnaires should be
applied for the assessment of QoL in patients with
CP. (GRADE 1A, strong agreement)
Comment. Different validated questionnaires have
been applied to assess QoL in CP patients. The use of
questionnaires enables a standardised multidimensional
evaluation of QoL. The following questionnaires are
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most frequently used in CP patients: Short-Form
Health Survey 36 (SF-36) and its shorter version, SF-
12; EORTC QLQ-C30 with, and without, the supple-
mentary QLQ-PAN26 questionnaire; the
Gastrointestinal Quality of Life Index (GIQLI) was
specifically developed for patients with gastrointestinal
diseases.676 The pain dimension can be assessed either
using a VAS677 or the Izbicki pain score261 (see Q5-4:
‘How should pain in CP be assessed?’). GIQLI was first
introduced in 1995, comprises 36 questions and is
intended for use in patients with a range of different
gastrointestinal diseases, including CP.676,678 No ques-
tionnaire has been designed specifically for patients
with CP.
The EORTC QLQ-C30 was originally designed to
assess QoL in patients with all types of cancer and con-
sists of 30 questions.458 It has been used frequently in
CP patients and most items of the QLQ-C30 question-
naire are highly relevant for CP patients (for example,
questions relating to pain and diarrhoea). This tool
comprises one global item (global health), five func-
tional domains evaluating physical, cognitive, emo-
tional and social domains, three symptom scales
(fatigue, pain, and nausea/vomiting), five single items
for symptoms (dyspnoea, loss of appetite, insomnia,
constipation, diarrhoea), and one item for the financial
impact of the disease. Changes in the mean QoL score
of 5–10%, 10–20% and >20% represent small, moder-
ate and large changes in QoL, respectively.679
As a supplement to the QLQ-C30 form, a question-
naire was developed that specifically addresses patients
with pancreatic cancer (QLQ-PAN26) and includes 26
questions.458 The module was intended particularly for
patients with pancreatic cancer undergoing surgical
resection, palliative surgical intervention, endoscopic
palliation or palliative chemotherapy. Both QLQ-C30
and QLQ-PAN26 have also been validated in patients
with CP.680 The QLQ-PAN26 modification includes
two extra questions having significance for patients
with alcoholic CP (guilt about alcohol consumption
and the burden of abstinence).
The SF-36 was initially designed for non-disease-spe-
cific population studies but proved to be a reliable and
valid tool for assessing QoL in patients with CP.681 The
test includes eight different domains (including phys-
ical, emotional, mental, social and general health sec-
tions) with 36 questions for measuring physical,
emotional and social role functioning and symptoms
such as bodily pain.
A study using a shorter version of the survey with
only 12 items (SF-12) demonstrated that the loss of
information in applying the SF-12 rather than the
longer survey was very low and that the SF-12 was a
viable alternative to the SF-36.515 The scores for each
version range from 0–100.515
Q8-5: When do we assess quality of life in patients with CP?
Statement 8-5.1. Health-related QoL should be
assessed in both in- and out-patients and during their
follow-up. (GRADE 2C, strong agreement)
Statement 8-5.2. Assessment of QoL should be
included as an endpoint in clinical treatment studies
of CP. (GRADE 2B, strong agreement)
Comments. Assessing QoL in both in- and out-
patients with CP is rarely done nowadays in routine
clinical practice and is mostly limited to clinical studies.
In a modern, patient-centred healthcare system
patients should be assessed with regard to their
health-related QoL, which is the perceived QoL of a
patient represented by social, mental and physical
well-being in relation to health and disease. This is par-
ticularly important in patients with chronic diseases
such as CP, which is a chronic and still incurable dis-
ease that frequently affects all dimensions of a patient’s
well-being. Multidimensional QoL questionnaires
facilitate a multidimensional approach to the patient
and problematic issues can be met by a multidisciplin-
ary team of general practitioners, gastroenterologists,
surgeons, psychologists, pain specialists, dieticians,
social workers and others.
QoL questionnaires have shown that the following
factors (amongst others) contribute to lower QoL in
CP: pain, a low BMI, early retirement, unemployment,
depression, fatigue, fear of the future. These question-
naires can be used in the follow-up of patients with CP
for investigating changes in QoL over time,682 and the
results can be used in the modification and adjustment
of treatment decisions.
QoL questionnaires have been used extensively as an
endpoint in evaluating treatment outcomes in patients
with CP. Accordingly, QoL is assessed prior to and
after endoscopic and surgical procedures, EUS-guided
coeliac plexus blockade,683 thoracosopic splanchnicect-
omy,684 ESWL,343,685 ERCP322 enzyme replacement
therapy and medical management of pain.
Q8-6: Which questionnaire should be used to assess QOL in
patients with CP?
Statement 8-6. SF-36, its shorter version SF-12,
EORTC QLQ-C30 with, and without the supplemen-
tary QLQ-PAD26 questionnaire, and GIQLI can be
used for assessing QOL in patients with CP. It takes
12min to complete the SF-36 form but only 2min to fill
out the SF-12 questionnaire – making this test suitable
as a screening tool even for the daily busy clinical prac-
tice. (GRADE 1C, strong agreement)
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Comments. In the setting of clinical studies, the
QLQ-C30 and SF-36 are the most widely used ques-
tionnaires studying QOL in patients with CP. No stu-
dies have been performed to compare the validity and
reliability of both tests in patients with CP in order to
determine whether one test is superior to the other.
Even in a busy outpatient clinic, CP patients can use
the waiting time before consultation to fill out the SF-12
questionnaire. The less time-consuming questionnaire
may even increase the motivation and participation of
patients in clinical studies to complete QoL question-
naires. The SF-12 showed excellent correlation with the
longer SF-36 questionnaire (r¼ 0.960, p< 0.001).515 In
one study, SF-12 was compared to QLQ-C30 in 163
patients with CP and the SF-12 was found to be more
reliable and easier to use in routine clinical practice.686
Conclusions
The HaPanEU/UEG guidelines on the management of
CP are the result of an international, multidisciplinary,
evidence-based approach. These guidelines provide rec-
ommendations for key aspects of the medical and sur-
gical management of CP combined with comments
based on the available literature and the opinions of
leading pancreatologists from Europe.
The focus should now shift towards the optimal dis-
semination and implementation of these guidelines,
which is not a given likelihood.687 Several studies
have indicated that guideline implementation is fre-
quently suboptimal, at least in acute pancreatitis,688,689
and hence a structured, ongoing effort is required, espe-
cially since guidelines in gastroenterology tend to fall
short of other disciplines.690 To overcome these short-
comings, guideline dissemination will be facilitated by
free online access. There will also be a Smartphone
application (HaPanEU) available to allow easy access
and facilitate guideline use in daily practice as such
apps are becoming increasingly popular.691–693
Although there is no optimal strategy for ensuring
good implementation of any set of guidelines,694 there
is clearly a role for pancreatologists in this process. By
informing specialist and non-specialist colleagues and
encouraging them to use these guidelines, by presenting
the guidelines at local or national meetings, and by writ-
ing about and referring to these guidelines in national
and international journals, pancreatologists can opti-
mise their implementation. Some evidence also suggests
that instituting aprocess of audit feedback could increase
awareness and improve guideline implementation,695
These guidelines will also be useful when designing
future studies as they reflect the current ‘benchmark’
for diagnosing and treating CP. This holds particularly
true for imaging techniques. The existence of evidence-
based guidelines obviously does not relieve clinicians
from their professional obligation to keep up-to-date
with new developments in CP. In particular, the results
of ongoing RCTs (www.clinicaltrials.gov) should be
taking into account. How then to decide when to
update these guidelines? Some have argued that clinical
guidelines should be updated continuously. Although
appealing, this is clearly impractical and the HaPanEU
working groupwill use a published framework on how to
decide when to initiate an update.15
The HaPanEU/UEG evidence-based guidelines on
themanagement of CP should result in reduced variation
in practice and an improvement in patient outcome
across Europe. The challenge now is to ensure high com-
pliance in clinical practice and future trial design.453
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